



(86) **Date de dépôt PCT/PCT Filing Date:** 2014/04/23
(87) **Date publication PCT/PCT Publication Date:** 2014/10/30
(85) **Entrée phase nationale/National Entry:** 2015/09/25
(86) **N° demande PCT/PCT Application No.:** US 2014/035201
(87) **N° publication PCT/PCT Publication No.:** 2014/176373
(30) **Priorité/Priority:** 2013/04/24 (US61/815,657)

(51) **Cl.Int./Int.Cl.** **C07K 14/54** (2006.01),
A61K 38/20 (2006.01), **A61K 39/395** (2006.01),
C07K 16/24 (2006.01), **C07K 17/08** (2006.01),
C07K 19/00 (2006.01), **C12N 15/24** (2006.01)

(71) **Demandeur/Applicant:**
ARMO BIOSCIENCES, INC., US

(72) **Inventeurs/Inventors:**
MCCAULEY, SCOTT, US;
VAN VLASSELAER, PETER, US

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

(54) **Titre : COMPOSITIONS D'INTERLEUKINE-10 ET LEURS UTILISATIONS**
(54) **Title: INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF**

(57) **Abrégé/Abstract:**

Interleukin-10 muteins and other interleukin-10 - related molecules are described, as well as methods of identifying interleukin-10 muteins and other interleukin-10 - related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-10. Particular interleukin-10 muteins and related molecules have comparable immunogenicity to human interleukin-10 and/or bioactivity at least comparable to human interleukin-10. Pharmaceutical compositions and methods of use are also described herein.



(51) International Patent Classification:
C40B 40/10 (2006.01) A61K 38/00 (2006.01)
G01N 33/00 (2006.01)

(21) International Application Number:
PCT/US2014/035201

(22) International Filing Date:
23 April 2014 (23.04.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/815,657 24 April 2013 (24.04.2013) US

(71) Applicant: ARMO BIOSCIENCES, INC. [US/US]; 575 Chesapeake Drive, Redwood City, California 94603 (US).

(72) Inventors: MCCAULEY, Scott; 660 Teresita Blvd., San Francisco, California 94127 (US). VAN VLASSELAER, Peter; 108 Crescent Ave., Portola Valley, California 94028 (US).

(74) Agent: FRANCIS, Carol L.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, California 94303 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
18 December 2014

(54) Title: INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF

(57) Abstract: Interleukin-10 muteins and other interleukin-10 - related molecules are described, as well as methods of identifying interleukin-10 muteins and other interleukin-10 - related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-10. Particular interleukin-10 muteins and related molecules have comparable immunogenicity to human interleukin-10 and/or bioactivity at least comparable to human interleukin-10. Pharmaceutical compositions and methods of use are also described herein.

WO 2014/176373 A3

INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF

Cross-Reference to Related Application

[0001] This application claims priority benefit of US provisional application serial no. 61/815,657, filed April 24, 2013, which application is incorporated herein in its entirety.

Field of the Invention

[0002] The present invention relates to, among other things, interleukin-10 muteins and other interleukin-10 – related molecules, modifications of the foregoing, and associated uses thereof.

Introduction

[0003] The cytokine interleukin-10 (IL-10) is a pleiotropic cytokine that regulates multiple immune responses through actions on T cells, B cells, macrophages, and antigen presenting cells (APC). IL-10 may suppress immune responses by inhibiting expression of IL-1 α , IL-1 β , IL-6, IL-8, TNF- α , GM-CSF and G-CSF in activated monocytes and activated macrophages, and it also suppresses IFN- γ production by NK cells. Although IL-10 is predominantly expressed in macrophages, expression has also been detected in activated T cells, B cells, mast cells, and monocytes. In addition to suppressing immune responses, IL-10 exhibits immuno-stimulatory properties, including stimulating the proliferation of IL-2 – and IL-4 – treated thymocytes, enhancing the viability of B cells, and stimulating the expression of MHC class II.

[0004] As a result of its pleiotropic activity, IL-10 has been linked to a broad range of diseases, disorders and conditions, including inflammatory conditions, immune-related disorders, fibrotic disorders and cancer. Clinical and pre-clinical evaluations with IL-10 for a number of such diseases, disorders and conditions have solidified its therapeutic potential. Moreover, pegylated IL-10 has been shown to be more efficacious than non-pegylated IL-10 in certain therapeutic settings.

[0005] In view of the prevalence and severity of IL-10 – associated diseases, disorders and conditions, novel IL-10 agents and modifications thereof would be of tremendous value in the treatment and prevention of IL-10 – associated diseases, disorders and conditions.

SUMMARY

[0006] The present disclosure relates to IL-10 compositions and uses thereof. The terms “IL-10”, “IL-10 polypeptide(s)”, “IL-10-agent(s)”, “IL-10 molecule(s)” and the like are intended to be construed broadly and include, for example, human and non-human IL-10 – related polypeptides, including homologs, variants (including muteins), and fragments thereof, as well as IL-10 polypeptides having, for example, a leader sequence (e.g., a signal peptide). Particular embodiments relate to modifications of the foregoing. In particular embodiments, the modification(s) improves at least one property or other characteristic (e.g., efficacy) of the peptides compared to unmodified versions of the peptides thereof. Further embodiments of the present disclosure pertain to methods and other technologies for identifying specific amino acid residues or domains of IL-10 that may be modified according to the methods described herein. Methods of using (e.g., in the treatment or prevention of a disorder or a symptom thereof), identifying and/or generating the peptides described herein are also aspects of the present disclosure. Other aspects include, for example, pharmaceutical compositions comprising the peptides.

[0007] Human IL-10 (and IL-10 from other species) exists as a homodimer. Each monomer of wild-type human IL-10 comprises 178 amino acids, the first 18 of which comprise a signal peptide. As set forth in detail hereafter, each 160 amino acid monomer of mature human IL-10 (hIL-10) comprises six helices (A-F) linked by short loops, which are also referred to herein as inter-helix junctions. For the sake of clarity, inter-helix junctions can comprise one or more amino acid residues (generally fewer than 10 residues).

[0008] Amino acid residues and regions of the IL-10 helices, inter-helices junctions and kinks (described hereafter) that can or cannot be mutated and/or modied are discussed hereafter. By way of example, amino acid residues and regions that are buried within the three-dimensional core of IL-10 or that are involved with receptor binding are generally not candidates for modification.

[0009] The present disclosure contemplates peptides comprising a substitution that would facilitate the attachment of a PEG or other moiety to at least one amino acid residue. Examples of such peptides are described in detail hereafter.

[0010] In particular embodiments of the present disclosure, a mutant IL-10 or a modified IL-10 peptide is less immunogenic (i.e., stimulates less of an immune response) than the corresponding unmodified IL-10 peptide. In other embodiments, a modified IL-10 peptide is

immunogenic-neutral (i.e., immunogenicity is not altered in a therapeutically relevant way) than the corresponding unmodified IL-10 peptide. Methods are described herein for evaluating the immunogenicity of the IL-10 peptides described herein. In still further embodiments, a modified peptide has an improvement in at least one property (e.g., a physical property, including solubility, bioavailability, serum half-life, and circulation time). Such properties are described further hereafter.

[0011] The present disclosure contemplates peptides comprising the amino acid sequence of SEQ ID NO:2, wherein the peptides comprise at least one amino acid substitution, deletion or addition, and wherein the substitution(s), deletion(s) or addition(s) does not, for example, adversely affect immunogenicity. The present disclosure also contemplates peptides having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NO:2, wherein the peptides a) are not more immunogenic than the peptide of SEQ ID NO:2, and/or b) have a bioactivity at least equal to the bioactivity of the peptide of SEQ ID NO:2, and/or c) have at least one property (e.g., a physical property, including solubility, bioavailability, serum half-life, and circulation time) that is improved compared to the peptide of SEQ ID NO:2. It will be apparent to the skilled artisan that utilization of different methodologies (e.g., different methods of quantifying the exact concentration of IL-10 and/or different methods of producing IL-10) may result in IL-10 that is more or less active – either in apparent activity due to differences in calculating protein concentration or in actual activity – than this reference standard. By leveraging their skill and experience, the skilled artisan will be able to factor in these differences in determining the relative bioactivities of an IL-10 molecule versus hIL-10. In some embodiments, each monomer of such peptides has at least 100, at least 110, at least 125, at least 140, at least 145, at least 150, at least 151, at least 152, at least 153, at least 154, at least 155, at least 156, at least 157, at least 158, or at least 159 amino acid residues.

[0012] In some embodiments, the amino acid residue addition(s), deletion(s), or substitution(s) of the aforementioned peptides does not disrupt the intramolecular disulfide bonds of the peptides or the non-covalent interactions between the two monomer subunits of the peptides. However, it should be noted that such an addition(s), deletion(s), or substitution(s) might possibly disrupt one or more of the intra-monomeric non-covalent bonds (e.g., hydrogen bonds), but that such disruption should not have a therapeutically relevant effect on protein

function. According to the teachings of the present disclosure, an amino acid substitution may be a conservative substitution, and/or an amino acid substitution is not a substitution at one or more of amino acid residues 12, 62, 108 and 114.

[0013] In particular embodiments, the present disclosure contemplates peptides having a bioactivity at least equal to the bioactivity of SEQ ID NO:2. Bioactivity may be determined by any method known in the art, including a chemokine release assay, a TNF α inhibition assay or an MC/9 cell proliferation assay. Exemplary protocols for such assays are described herein. Likewise, the immunogenicity of the peptides may be predicted or determined by any method known to the skilled artisan, including prediction by screening for at least one of T-cell epitopes or B-cell epitopes. In one aspect, immunogenicity is predicted by an in silico system and/or in an ex vivo assay system.

[0014] The instant disclosure also contemplates peptides comprising the amino acid sequence of SEQ ID NO:2, wherein the peptides comprise at least one amino acid substitution of a surface-exposed amino acid residue, and wherein the substitution does not adversely affect immunogenicity and/or another property or characteristic. In certain embodiments, these peptides also do not comprise substitution of any amino acid residues involved with receptor binding. However, it is to be understood that substitution, deletion, and/or addition of one or more amino acid residues within the IL-10 receptor binding region, or in close proximity thereto, that may be tolerated are contemplated by the present disclosure.

[0015] In further embodiments, the peptides described in the preceding paragraph comprise a) a Pre-helix A; b) a Helix A; c) an A/B Inter-helix Junction; d) a Helix B; e) a B/C Inter-helix Junction; f) a Helix C; g) a C/D Inter-helix Junction; h) a Helix D; i) a D/E Inter-helix Junction; j) a Helix E; k) an E/F Inter-helix Junction; l) a Helix F; and m) a Post-helix F; wherein such peptides further comprise at least one of: i) substitution of at least one amino acid residue of Pre-helix A other than amino acid residues 12 (C), 15 (F) or 16 (P); or ii) substitution of at least one amino acid residue of Helix A other than amino acid residues 19-24 (LPNMLR (SEQ ID NO:33)), 26-30 (LRDAF (SEQ ID NO:34)), 33-39 17 (VKTFFQM (SEQ ID NO:35)), or 41 (D); or iii) substitution of at least one amino acid residue of Helix B other than amino acid residues 52 (L), 53 (L), or 56 (F); or iv) substitution of the amino acid residue of the B/C Inter-helix Junction; or v) substitution of at least one amino acid residue of Helix C other than amino acid residues 62 (C), 64 (A), 65 (L), 68 (M), 69 (I), 71-73 (FYL), 76 (V), 77 (M), or 80 (A); or vi) substitution of at least one amino acid residue of the C/D Inter-helix Junction; or vii)

substitution of at least one amino acid residue of Helix D other than amino acid residues 87 (I), 91 (V), 94 (L), 98 (L), 101 (L), 105 (L), or 108 (C); or viii) substitution of at least one amino acid residue of the D/E Inter-helix Junction other than amino acid residues 111 (F), 112 (L), or 114 (C); or ix) substitution of at least one amino acid residue of Helix E other than amino acid residues 120 (A), 121 (V), 124 (V), 127 (A), 128 (F) or 131 (L); or x) substitution of the amino acid residue of the E/F Inter-helix Junction; or xi) substitution of at least one amino acid residue of Helix F other than amino acid residues 136-156 (IYKAMSEFDIFINYIEAYMTM (SEQ ID NO:36)), 158 (I) or 159 (R); or xii) substitution of the amino acid residue of Post-helix F. The boundaries of these regions are set forth in FIG. 3C. The tyrosine at amino acid residue 59 is a candidate for modification (e.g., pegylation).

[0016] In some embodiments the amino acid residue addition(s), deletion(s), or substitution(s) of the peptides described in the preceding paragraph does not disrupt the intramolecular disulfide bonds of the peptides or the non-covalent interactions between the two monomer subunits of the peptides. It should be noted, however, that such an addition(s), deletion(s), or substitution(s) might possibly disrupt one or more of the intra-monomeric non-covalent bonds (e.g., hydrogen bonds), but that such disruption should not have a therapeutically relevant effect on protein function. In other embodiments the amino acid substitution may be a conservative substitution, and/or the amino acid substitution is not a substitution at one or more of amino acid residues 12, 62, 108 and 114. The bioactivity and immunogenicity of these peptides may be assessed according to the teachings set forth herein.

[0017] Particular embodiments of the present disclosure contemplate modification(s) of the peptides described herein, wherein the modification(s) does not alter the amino acid sequence of the peptides (i.e., no amino acid substitutions, additions or deletions are introduced into the IL-10 primary amino acid sequence), and wherein the modification(s) improves or otherwise enhances at least one property or other characteristic (e.g., a pharmacokinetic parameter or efficacy) of the peptides compared to unmodified versions of the peptides.

[0018] In some embodiments, modification of the IL-10 peptides does not cause a detrimental effect on immunogenicity of a level that is therapeutically relevant, and in still further embodiments the modified IL-10 is less immunogenic than unmodified IL-10.

[0019] The present disclosure contemplates the introduction of any modification that may be advantageous. Thus, in particular embodiments, the modification improves at least one physical property of the peptide (e.g., solubility, bioavailability, serum half-life, and circulation

time). Other modifications include introducing means for blocking receptor cleavage and increasing affinity for the IL-10 receptor(s) (or modifying the off-rate so that the IL-10 molecule will be docked with the receptor(s) for a longer duration).

[0020] In some embodiments, the modification is pegylation and the modified peptide is PEG-IL-10. The pegylated peptides may comprise at least one PEG molecule covalently attached to at least one amino acid residue of at least one monomer of IL-10. The PEG molecule may be conjugated to IL-10 through a linker; linkers are described in detail hereafter. Such pegylated peptides may comprise a mixture of mono-pegylated and di-pegylated IL-10. References herein to “mono-pegylated” or “di-pegylated”, or equivalents thereof, are meant to be construed more broadly than to just mono-pegylated and di-pegylated IL-10. To illustrate, two or more different sites on each IL10 monomer might be modified by introducing more than one mutation and then modifying each of them; tyrosine 59 might be pegylated in combination with one or more modified mutant; or tyrosine 59 might be pegylated in combination with pegylation of the N-terminus. Exemplary pegylation conditions are described herein. The PEG component may be any PEG tolerated by the peptides. By way of example, the PEG component of the modified peptide has a molecular mass from 5kDa to 20kD in some embodiments, a molecular mass greater than 20kDa in other embodiments, or a molecular mass of at least 30kD in still other embodiments. PEGs having other molecular mass values are described herein.

[0021] The present disclosure contemplates any modification to the peptides that imparts a desired property, including improvement (e.g., masking) of a property of the unmodified peptides. In some embodiments the modified peptides comprise an Fc fusion molecule; a serum albumin (e.g., HSA or BSA), which may be in the form of an HSA fusion molecule or an albumin conjugate; or an albumin binding domain. The modified peptides may be glycosylated or hesylated. Detailed descriptions of the foregoing are described elsewhere within the present disclosure.

[0022] In particular embodiments, the modification is site-specific. In further embodiments, the modification comprises a linker. Some modified IL-10 molecules may comprise more than one type of modification. The types of modifications and the methods of introducing such modifications to the IL-10 peptides described herein are not limiting, and the skilled artisan can envisage other such modifications and methods.

[0023] The peptides described herein may be produced recombinantly. The present disclosure contemplates nucleic acid molecules encoding the peptides, wherein the nucleic acid

molecules may be operably linked to an expression control element that confers expression of the nucleic acid molecule encoding the peptide in vitro, in a cell or in vivo. Vectors (e.g., a viral vector) may comprise such nucleic acid molecules. Further embodiments entail transformed or host cells that express the peptides described herein.

[0024] The present disclosure also contemplates the use of gene therapy in conjunction with the teachings herein. For gene therapy uses and methods, a cell in a subject can be transformed with a nucleic acid that encodes an IL-10 – related polypeptide as set forth herein in vivo. Alternatively, a cell can be transformed in vitro with a transgene or polynucleotide, and then transplanted into a tissue of subject in order to effect treatment. In addition, a primary cell isolate or an established cell line can be transformed with a transgene or polynucleotide that encodes an IL-10 – related polypeptide, and then optionally transplanted into a tissue of a subject.

[0025] The peptides of the present disclosure may comprise an epitope(s) that binds (specifically or non-specifically) to an antibody. Particular embodiments comprise an activating antibody, for example, an anti-IL-10R1/R2 – complex antibody that mimics IL-10 activation through these receptors.

[0026] The antibody may be monoclonal or polyclonal, and may be, for example, human or humanized. Embodiments include an antibody that comprises a light chain variable region and a heavy chain variable region present in separate polypeptides or in a single polypeptide, or an antibody that comprises a heavy chain constant region that is, e.g., an IgG1, IgG2, IgG3, or IgG4 isotope. The antibody may be, for example, a Fv, scFv, Fab, F(ab')₂, or Fab' antibody, or it may be a single chain Fv (scFv) antibody (which may be multimerized).

[0027] In further embodiments, an antibody of the present disclosure binds the peptides with an affinity of from about 10^7 M^{-1} to about 10^{12} M^{-1} . An antibody may comprise a covalently linked moiety selected from a lipid moiety, a fatty acid moiety, a polysaccharide moiety, and a carbohydrate moiety. Embodiments are also contemplated wherein an antibody comprises an affinity domain, may be immobilized on a solid support, comprises a covalently linked non-peptide polymer (e.g., a poly(ethylene) glycol polymer) or is detectably labeled.

[0028] The present disclosure includes pharmaceutical compositions comprising the peptides or antibodies described herein, and a pharmaceutically acceptable diluent, carrier or excipient. In some embodiments, the excipient is an isotonic injection solution. The pharmaceutical compositions may be suitable for administration to a subject (e.g., a human), and

may comprise one or more additional prophylactic or therapeutic agents. In certain embodiments, the pharmaceutical compositions are contained in a sterile container (e.g., a single- or multi-use vial or a syringe). A kit may contain the sterile container(s), and the kit may also contain one or more additional sterile containers comprising at least one additional prophylactic or therapeutic agent or any other agent that may be used in pharmacological therapy. Examples of such aspects are set forth herein.

[0029] Additional embodiments of the present disclosure comprise a method of treating or preventing a disease, disorder or condition in a subject (e.g., a human), comprising administering a therapeutically effective amount of a peptide described herein. Further embodiments comprise a method of treating or preventing a disease, disorder or condition in a subject, comprising administering a therapeutically effective amount of an antibody described herein. In various embodiments of the present disclosure, the disease, disorder or condition is a proliferative disorder, including a cancer or a cancer-related disorder (e.g., a solid tumor or a hematological disorder) or a fibrotic disorder, such as cirrhosis, NASH and NAFLD; an immune or inflammatory disorder, including inflammatory bowel disease, psoriasis, rheumatoid arthritis, multiple sclerosis, and Alzheimer's disease; thrombosis or a thrombotic condition or disorder, including a state of hypercoagulation; a fibrotic disorder; a viral disorder, including, but not limited to, human immunodeficiency virus, hepatitis B virus, hepatitis C virus and cytomegalovirus; a cardiovascular disorder, including atherosclerosis or other cardiovascular-related disorders wherein the subject may have elevated cholesterol and/or other abnormal metabolic-related parameters (e.g., abnormal blood glucose levels, insulin levels, or lipid levels).

[0030] In the methods of treating or preventing a disease, disorder or condition, administration of the therapeutically effective amount of a peptide (or an antibody) described herein may be by any route appropriate for the peptide (or antibody), including parenteral injection (e.g., subcutaneously). One or more additional prophylactic or therapeutic agents may be administered with (e.g., prior to, simultaneously with, or subsequent to) the peptide (or antibody), and/or it may be administered separate from or combined with the peptide (or antibody).

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] FIG. 1A is a protein crystal structure ribbon representation (top view) of the human IL-10 monomer. The six helices are labeled A-F.

[0032] FIG. 1B is a protein crystal structure ribbon representation (side view) of the human IL-10 monomer. The six helices are labeled A-F.

[0033] FIG. 2A is a protein crystal structure ribbon representation (top view) of the human IL-10 homodimer. One monomer is gray and the other monomer is black. The six helices are labeled A-F.

[0034] FIG. 2B is a protein crystal structure ribbon representation (side view) of the human IL-10 homodimer. One monomer is gray and the other monomer is black.

[0035] FIG. 3A depicts the complete 178 amino acid human IL-10 sequence (SEQ ID NO:1). The 18 amino acid signal peptide is underlined.

[0036] FIG. 3B depicts the 160 amino acid mature human IL-10 sequence. (SEQ ID NO:2)

[0037] FIG. 3C depicts the mature human IL-10 amino acid sequence indicating the regions corresponding to Helices A-F, the regions corresponding to each of the Loops, and the regions/locations of the Kinks.

[0038] FIG. 4A is a protein crystal structure ribbon representation (top view) of the human IL-10 homodimer (gray) bound to two human IL10R1/ α receptors (black).

[0039] FIG. 4B is a protein crystal structure ribbon representation (side view) of the human IL-10 homodimer (gray) bound to two human IL10R1/ α receptors (black).

[0040] FIG. 5 illustrates which amino acid residues of the mature human IL-10 amino acid sequence are candidates for pegylation.

DETAILED DESCRIPTION

[0041] Before the present disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments set forth herein, and it is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0042] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated

range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0043] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology such as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0044] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

Overview

[0045] The present disclosure contemplates mutant IL-10 molecules (e.g., muteins) and other IL-10 – related molecules, as well as methods of their identification and their use. As described herein, the IL-10 molecules may be modified to, for example, enhance a property of native human IL-10, including half-life extension. Particular IL-10 molecules have comparable immunogenicity to human IL-10, and/or bioactivity at least comparable to human IL-10, and/or an improvement in at least one property (e.g., a physical property, including solubility, bioavailability, serum half-life, and circulation time).

[0046] Thus, for example, IL-10 molecules that have comparable immunogenicity to hIL-10 but have substantially less bioactivity than hIL-10 are encompassed herein. The skilled artisan will recognize that such molecules may be viable therapeutics due to, e.g., a very long half-life. The IL-10 molecules described herein, and compositions (e.g., pharmaceutical compositions) thereof, may be used to treat and/or prevent various diseases, disorders and conditions, and/or the symptoms thereof, including, for example, inflammatory- and immune-

related disorders, fibrotic disorders, cancer and cancer-related disorders, and cardiovascular disorders (e.g., atherosclerosis).

[0047] It should be noted that any reference to “human” in connection with the polypeptides and nucleic acid molecules of the present disclosure is not meant to be limiting with respect to the manner in which the polypeptide or nucleic acid is obtained or the source, but rather is only with reference to the sequence as it may correspond to a sequence of a naturally occurring human polypeptide or nucleic acid molecule. In addition to the human polypeptides and the nucleic acid molecules which encode them, the present disclosure contemplates IL-10 – related polypeptides and corresponding nucleic acid molecules from other species.

Definitions

[0048] Unless otherwise indicated, the following terms are intended to have the meaning set forth below. Other terms are defined elsewhere throughout the specification.

[0049] The terms “patient” or “subject” are used interchangeably to refer to a human or a non-human animal (e.g., a mammal).

[0050] The terms “administration”, “administer” and the like, as they apply to, for example, a subject, cell, tissue, organ, or biological fluid, refer to contact of, for example, IL-10 or PEG-IL-10), a nucleic acid (e.g., a nucleic acid encoding native human IL-10), a pharmaceutical composition comprising the foregoing, or a diagnostic agent; to the subject, cell, tissue, organ, or biological fluid. In the context of a cell, administration includes contact (e.g., in vitro or ex vivo) of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.

[0051] The terms “treat”, “treating”, “treatment” and the like refer to a course of action (such as administering IL-10 or a pharmaceutical composition comprising IL-10) initiated after a disease, disorder or condition, or a symptom thereof, has been diagnosed, observed, and the like so as to eliminate, reduce, suppress, mitigate, or ameliorate, either temporarily or permanently, at least one of the underlying causes of a disease, disorder, or condition afflicting a subject, or at least one of the symptoms associated with a disease, disorder, or condition afflicting a subject. Thus, treatment includes inhibiting (e.g., arresting the development or further development of the disease, disorder or condition or clinical symptoms association therewith) an active disease. The terms may also be used in other contexts, such as situations

where IL-10 or PEG-IL-10 contacts an IL-10 receptor in, for example, the fluid phase or colloidal phase.

[0052] The term “in need of treatment” as used herein refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of the physician’s or caregiver’s expertise.

[0053] The terms “prevent”, “preventing”, “prevention” and the like refer to a course of action (such as administering IL-10 or a pharmaceutical composition comprising IL-10) initiated in a manner (e.g., prior to the onset of a disease, disorder, condition or symptom thereof) so as to prevent, suppress, inhibit or reduce, either temporarily or permanently, a subject’s risk of developing a disease, disorder, condition or the like (as determined by, for example, the absence of clinical symptoms) or delaying the onset thereof, generally in the context of a subject predisposed to having a particular disease, disorder or condition. In certain instances, the terms also refer to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.

[0054] The term “in need of prevention” as used herein refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from preventative care. This judgment is made based on a variety of factors that are in the realm of a physician’s or caregiver’s expertise.

[0055] The phrase “therapeutically effective amount” refers to the administration of an agent to a subject, either alone or as part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount capable of having any detectable, positive effect on any symptom, aspect, or characteristic of a disease, disorder or condition when administered to the subject. The therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject’s condition, and the like. By way of example, measurement of the amount of inflammatory cytokines produced following administration may be indicative of whether a therapeutically effective amount has been used.

[0056] The phrase “in a sufficient amount to effect a change” means that there is a detectable difference between a level of an indicator measured before (e.g., a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (e.g., serum concentration of IL-10) or subjective parameter (e.g., a subject’s feeling of well-being).

[0057] The term “small molecules” refers to chemical compounds having a molecular weight that is less than about 10kDa, less than about 2kDa, or less than about 1kDa. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing an inorganic component, molecules comprising a radioactive atom, and synthetic molecules. Therapeutically, a small molecule may be more permeable to cells, less susceptible to degradation, and less likely to elicit an immune response than large molecules.

[0058] The term “ligand” refers to, for example, a peptide, a polypeptide, a membrane-associated or membrane-bound molecule, or a complex thereof, that can act as an agonist or antagonist of a receptor. “Ligand” encompasses natural and synthetic ligands, e.g., cytokines, cytokine variants, analogs, muteins, and binding compositions derived from antibodies, as well as, e.g., peptide mimetics of cytokines and peptide mimetics of antibodies. The term also encompasses an agent that is neither an agonist nor antagonist, but that can bind to a receptor without significantly influencing its biological properties, e.g., signaling or adhesion. Moreover, the term includes a membrane-bound ligand that has been changed, e.g., by chemical or recombinant methods, to a soluble version of the membrane-bound ligand. A ligand or receptor may be entirely intracellular, that is, it may reside in the cytosol, nucleus, or some other intracellular compartment. The complex of a ligand and receptor is termed a “ligand-receptor complex.”

[0059] The terms “inhibitors” and “antagonists”, or “activators” and “agonists” refer to inhibitory or activating molecules, respectively, for example, for the activation of, e.g., a ligand, receptor, cofactor, gene, cell, tissue, or organ. Inhibitors are molecules that decrease, block, prevent, delay activation, inactivate, desensitize, or down-regulate, e.g., a gene, protein, ligand, receptor, or cell. Activators are molecules that increase, activate, facilitate, enhance activation, sensitize, or up-regulate, e.g., a gene, protein, ligand, receptor, or cell. An inhibitor may also be defined as a molecule that reduces, blocks, or inactivates a constitutive activity. An “agonist” is a molecule that interacts with a target to cause or promote an increase in the activation of the target. An “antagonist” is a molecule that opposes the action(s) of an agonist. An antagonist prevents, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist can also prevent, inhibit, or reduce constitutive activity of a target, e.g., a target receptor, even where there is no identified agonist.

[0060] The terms “modulate”, “modulation” and the like refer to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of an

IL-10 molecule (or the nucleic acid molecules encoding them), either directly or indirectly; or to enhance the ability of a molecule to produce an effect comparable to that of an IL-10 molecule. The term “modulator” is meant to refer broadly to molecules that can effect the activities described above. By way of example, a modulator of, e.g., a gene, a receptor, a ligand, or a cell, is a molecule that alters an activity of the gene, receptor, ligand, or cell, where activity can be activated, inhibited, or altered in its regulatory properties. A modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. The term “modulator” includes agents that operate through the same mechanism of action as IL-10 (i.e., agents that modulate the same signaling pathway as IL-10 in a manner analogous thereto) and are capable of eliciting a biological response comparable to (or greater than) that of IL-10.

[0061] Examples of modulators include small molecule compounds and other bioorganic molecules. Numerous libraries of small molecule compounds (e.g., combinatorial libraries) are commercially available and can serve as a starting point for identifying a modulator. The skilled artisan is able to develop one or more assays (e.g., biochemical or cell-based assays) in which such compound libraries can be screened in order to identify one or more compounds having the desired properties; thereafter, the skilled medicinal chemist is able to optimize such one or more compounds by, for example, synthesizing and evaluating analogs and derivatives thereof. Synthetic and/or molecular modeling studies can also be utilized in the identification of an Activator.

[0062] The “activity” of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of other molecules; and the like. The term may also refer to activity in modulating or maintaining cell-to-cell interactions (e.g., adhesion), or activity in maintaining a structure of a cell (e.g., a cell membrane). “Activity” can also mean specific activity, e.g., [catalytic activity]/[mg protein], or [immunological activity]/[mg protein], concentration in a biological compartment, or the like. The term “proliferative activity” encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.

[0063] As used herein, “comparable”, “comparable activity”, “activity comparable to”, “comparable effect”, “effect comparable to”, and the like are relative terms that can be viewed quantitatively and/or qualitatively. The meaning of the terms is frequently dependent on the

context in which they are used. By way of example, two agents that both activate a receptor can be viewed as having a comparable effect from a qualitative perspective, but the two agents can be viewed as lacking a comparable effect from a quantitative perspective if one agent is only able to achieve 20% of the activity of the other agent as determined in an art-accepted assay (e.g., a dose-response assay) or in an art-accepted animal model. When comparing one result to another result (e.g., one result to a reference standard), “comparable” frequently (though not always) means that one result deviates from a reference standard by less than 35%, by less than 30%, by less than 25%, by less than 20%, by less than 15%, by less than 10%, by less than 7%, by less than 5%, by less than 4%, by less than 3%, by less than 2%, or by less than 1%. In particular embodiments, one result is comparable to a reference standard if it deviates by less than 15%, by less than 10%, or by less than 5% from the reference standard. By way of example, but not limitation, the activity or effect may refer to efficacy, stability, solubility, or immunogenicity. As previously indicated, the skilled artisan recognizes that use of different methodologies may result in IL-10 that is more or less active – either in apparent activity due to differences in calculating protein concentration or in actual activity – than a hIL-10 reference standard. The skilled artisan will be able to factor in these differences in determining the relative bioactivities of an IL-10 molecule versus hIL-10.

[0064] The term “response,” for example, of a cell, tissue, organ, or organism, encompasses a change in biochemical or physiological behavior, e.g., concentration, density, adhesion, or migration within a biological compartment, rate of gene expression, or state of differentiation, where the change is correlated with activation, stimulation, or treatment, or with internal mechanisms such as genetic programming. In certain contexts, the terms “activation”, “stimulation”, and the like refer to cell activation as regulated by internal mechanisms, as well as by external or environmental factors; whereas the terms “inhibition”, “down-regulation” and the like refer to the opposite effects.

[0065] The terms “polypeptide,” “peptide,” and “protein”, used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones. The terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like.

[0066] As used herein, the terms “variants” and “homologs” are used interchangeably to refer to amino acid or DNA sequences that are similar to reference amino acid or nucleic acid sequences, respectively. The term encompasses naturally-occurring variants and non-naturally-occurring variants. Naturally-occurring variants include homologs (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one species to another), and allelic variants (polypeptides and nucleic acids that differ in amino acid or nucleotide sequence, respectively, from one individual to another within a species). Thus, variants and homologs encompass naturally occurring DNA sequences and proteins encoded thereby and their isoforms, as well as splice variants of a protein or gene. The terms also encompass nucleic acid sequences that vary in one or more bases from a naturally-occurring DNA sequence but still translate into an amino acid sequence that corresponds to the naturally-occurring protein due to degeneracy of the genetic code. Non-naturally-occurring variants and homologs include polypeptides and nucleic acids that comprise a change in amino acid or nucleotide sequence, respectively, where the change in sequence is artificially introduced (e.g., muteins); for example, the change is generated in the laboratory by human intervention (“hand of man”). Therefore, non-naturally occurring variants and homologs may also refer to those that differ from the naturally-occurring sequences by one or more conservative substitutions and/or tags and/or conjugates.

[0067] The term “muteins” as used herein refers broadly to mutated recombinant proteins. These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes. Unless otherwise indicated, use of terms such as “mutant of IL-10” refer to IL-10 muteins.

[0068] The terms “DNA”, “nucleic acid”, “nucleic acid molecule”, “polynucleotide” and the like are used interchangeably herein to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA), complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.

[0069] It will be appreciated that throughout this disclosure reference is made to amino acids according to the single letter or three letter codes. For the reader’s convenience, the single and three letter amino acid codes are provided below:

G	Glycine	Gly	P	Proline	Pro
A	Alanine	Ala	V	Valine	Val
L	Leucine	Leu	I	Isoleucine	Ile
M	Methionine	Met	C	Cysteine	Cys
F	Phenylalanine	Phe	Y	Tyrosine	Tyr
W	Tryptophan	Trp	H	Histidine	His
K	Lysine	Lys	R	Arginine	Arg
Q	Glutamine	Gln	N	Asparagine	Asn
E	Glutamic Acid	Glu	D	Aspartic Acid	Asp
S	Serine	Ser	T	Threonine	Thr

[0070] As used herein in reference to native human IL-10 or an IL-10 mutein, the terms “modified”, “modification” and the like refer to one or more changes that enhance a desired property of human IL-10 or an IL-10 mutein. Such desired properties include, for example, prolonging the circulation half-life, increasing the stability, reducing the clearance, altering the immunogenicity or allergenicity, and enabling the raising of particular antibodies (e.g., by introduction of unique epitopes) for use in detection assays. As discussed in detail hereafter, modifications to human IL-10 or an IL-10 mutein that may be carried out include, but are not limited to, pegylation (covalent attachment of one or more molecules of polyethylene glycol (PEG), or derivatives thereof); glycosylation (e.g., N-glycosylation), polysialylation and hesylation; albumin fusion; albumin binding through, for example, a conjugated fatty acid chain (acylation); Fc-fusion; and fusion with a PEG mimetic. In some embodiments, linkers are used in such modifications and are described hereafter.

[0071] As used herein in the context of the structure of a polypeptide, “N-terminus” (or “amino terminus”) and “C-terminus” (or “carboxyl terminus”) refer to the extreme amino and carboxyl ends of the polypeptide, respectively, while the terms “N-terminal” and “C-terminal” refer to relative positions in the amino acid sequence of the polypeptide toward the N-terminus and the C-terminus, respectively, and can include the residues at the N-terminus and C-terminus, respectively. “Immediately N-terminal” or “immediately C-terminal” refers to a position of a first amino acid residue relative to a second amino acid residue where the first and second amino acid residues are covalently bound to provide a contiguous amino acid sequence.

[0072] “Derived from”, in the context of an amino acid sequence or polynucleotide sequence (e.g., an amino acid sequence “derived from” an IL-10 polypeptide), is meant to

indicate that the polypeptide or nucleic acid has a sequence that is based on that of a reference polypeptide or nucleic acid (e.g., a naturally occurring IL-10 polypeptide or an IL-10-encoding nucleic acid), and is not meant to be limiting as to the source or method in which the protein or nucleic acid is made. By way of example, the term “derived from” includes homologs or variants of reference amino acid or DNA sequences.

[0073] In the context of a polypeptide, the term “isolated” refers to a polypeptide of interest that, if naturally occurring, is in an environment different from that in which it may naturally occur. “Isolated” is meant to include polypeptides that are within samples that are substantially enriched for the polypeptide of interest and/or in which the polypeptide of interest is partially or substantially purified. Where the polypeptide is not naturally occurring, “isolated” indicates that the polypeptide has been separated from an environment in which it was made by either synthetic or recombinant means.

[0074] “Enriched” means that a sample is non-naturally manipulated (e.g., by a scientist) so that a polypeptide of interest is present in a) a greater concentration (e.g., at least 3-fold greater, at least 4-fold greater, at least 8-fold greater, at least 64-fold greater, or more) than the concentration of the polypeptide in the starting sample, such as a biological sample (e.g., a sample in which the polypeptide naturally occurs or in which it is present after administration), or b) a concentration greater than the environment in which the polypeptide was made (e.g., as in a bacterial cell).

[0075] “Substantially pure” indicates that a component (e.g., a polypeptide) makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, “substantially pure” refers to compositions in which at least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition.

[0076] The terms “specifically binds” or “selectively binds”, when referring to a ligand/receptor, antibody/antigen, or other binding pair, indicates a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds to a particular receptor and does not bind in a significant amount to other proteins present in the sample. The antibody, or binding composition derived from the antigen-binding site of an antibody, of the contemplated method binds to its antigen, or a variant or mutein thereof, with an affinity that is

at least two-fold greater, at least ten times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antibody, or binding composition derived therefrom. In a particular embodiment, the antibody will have an affinity that is greater than about 10^9 liters/mol, as determined by, e.g., Scatchard analysis (Munsen, et al. 1980 *Analyt. Biochem.* 107:220-239).

IL-10 and PEG-IL-10

[0077] The anti-inflammatory cytokine IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), is classified as a type(class)-2 cytokine, a set of cytokines that includes IL-19, IL-20, IL-22, IL-24 (Mda-7), and IL-26, interferons (IFN- α , - β , - γ , - δ , - ϵ , - κ , - Ω , and - τ) and interferon-like molecules (limitin, IL-28A, IL-28B, and IL-29).

[0078] IL-10 is a cytokine with pleiotropic effects in immunoregulation and inflammation. It is produced by mast cells, counteracting the inflammatory effect that these cells have at the site of an allergic reaction. While it is capable of inhibiting the synthesis of pro-inflammatory cytokines such as IFN- γ , IL-2, IL-3, TNF α and GM-CSF, IL-10, it is also stimulatory towards certain T cells and mast cells and stimulates B-cell maturation, proliferation and antibody production. IL-10 can block NF- κ B activity and is involved in the regulation of the JAK-STAT signaling pathway. It also induces the cytotoxic activity of CD8⁺ T-cells and the antibody production of B-cells, and it suppresses macrophage activity and tumor-promoting inflammation. The regulation of CD8⁺ T-cells is dose-dependent, wherein higher doses induce stronger cytotoxic responses.

[0079] Human IL-10 is a homodimer with a molecular mass of 37kDa, wherein each 18.5kDa monomer comprises 178 amino acids, the first 18 of which comprise a signal peptide, and two pairs of cysteine residues that form two intramolecular disulfide bonds. Each monomer of mature hIL-10 comprises 160 amino acid residues. The IL-10 dimer becomes biologically inactive upon disruption of the non-covalent interactions between the two monomer subunits. FIG. 3A depicts the complete 178 amino acid human IL-10 sequence (the 18 amino acid signal peptide is underlined), and FIG. 3B depicts the 160 amino acid mature human IL-10 sequence.

[0080] The present disclosure contemplates human IL-10 and murine IL-10, which exhibit 80% homology, and use thereof. In addition, the scope of the present disclosure includes IL-10 orthologs, and modified forms thereof, from other mammalian species, including rat (accession NP_036986.2; GI 148747382); cow (accession NP_776513.1; GI 41386772);

sheep (accession NP_001009327.1; GI 57164347); dog (accession ABY86619.1; GI 166244598); and rabbit (accession AAC23839.1; GI 3242896).

[0081] The IL-10 receptor, a type II cytokine receptor, consists of alpha and beta subunits, which are also referred to as R1 and R2, respectively. Receptor activation requires binding to both alpha and beta. One homodimer of an IL-10 polypeptide binds to alpha and the other homodimer of the same IL-10 polypeptide binds to beta.

[0082] The utility of recombinant human IL-10 is frequently limited by its relatively short serum half-life, which may be due to, for example, renal clearance, proteolytic degradation, receptor mediated uptake and monomerization in the blood stream. As a result, various approaches have been explored to improve the pharmacokinetic profile of IL-10 without disrupting its dimeric structure and thus adversely affecting its activity. Pegylation of IL-10 results in improvement of certain pharmacokinetic parameters (e.g., serum half-life) and/or enhancement of activity. For example, particular embodiments of the present disclosure involve methods of optimizing the treatment of proliferative disorders (e.g., cancer) with pegylated IL-10 muteins.

[0083] As previously indicated, the present disclosure also contemplates the use of gene therapy in conjunction with the teachings herein. Gene therapy is effected by delivering genetic material, usually packaged in a vector, to endogenous cells within a subject in order to introduce novel genes, to introduce additional copies of pre-existing genes, to impair the functioning of existing genes, or to repair existing but non-functioning genes. Once inside cells, the nucleic acid is expressed by the cell machinery, resulting in the production of the protein of interest. In the context of the present disclosure, gene therapy is used as a therapeutic to deliver nucleic acid that encodes an IL-10 agent for use in the treatment or prevention of a disease, disorder or condition described herein.

[0084] As alluded to above, for gene therapy uses and methods, a cell in a subject can be transformed with a nucleic acid that encodes an IL-10 – related polypeptide as set forth herein in vivo. Alternatively, a cell can be transformed in vitro with a transgene or polynucleotide, and then transplanted into a tissue of a subject in order to effect treatment. In addition, a primary cell isolate or an established cell line can be transformed with a transgene or polynucleotide that encodes an IL-10 – related polypeptide, and then optionally transplanted into a tissue of a subject.

[0085] As used herein, the terms “pegylated IL-10” and PEG-IL-10” refer to an IL-10 molecule having one or more polyethylene glycol molecules covalently attached to at least one amino acid residue of the IL-10 protein, generally via a linker, such that the attachment is stable. The terms “monopegylated IL-10” and “mono-PEG-IL-10” indicate that one polyethylene glycol molecule is covalently attached to a single amino acid residue on one subunit of the IL-10 dimer, generally via a linker. In certain embodiments, the PEG-IL-10 used in the present disclosure is a mono-PEG-IL-10 in which one to nine PEG molecules are covalently attached via a linker to the alpha amino group of the amino acid residue at the N-terminus of one subunit of the IL-10 dimer. Linkers are described further hereafter.

[0086] Monopegylation on one IL-10 subunit generally results in a non-homogeneous mixture of non-pegylated, monopegylated and dipegylated IL-10 due to subunit shuffling. Moreover, allowing a pegylation reaction to proceed to completion will generally result in non-specific and multi-pegylated IL-10, thus reducing its bioactivity. Thus, particular embodiments of the present disclosure comprise the administration of a mixture of mono- and di-pegylated IL-10 produced by the methods described herein. As previously indicated, references herein to “mono-pegylated” or “di-pegylated”, or equivalents thereof, are meant to be construed more broadly than to just mono-pegylated and di-pegylated IL-10. Thus, two or more different sites on each IL-10 monomer might be modified by introducing more than one mutation and then modifying each of them. By way of further example, tyrosine 59 might be pegylated in combination with one or more modified mutant; or tyrosine 59 might be pegylated in combination with pegylation of the N-terminus. Exemplary pegylation conditions are described in, e.g., the Experimental section.

[0087] In particular embodiments, the average molecular weight of the PEG moiety is between about 5kDa and about 50kDa. For example, the PEG moiety may have a molecular mass greater than about 5kDa, greater than about 10kDa, greater than about 15kDa, greater than about 20kDa, greater than about 30kDa, greater than about 40kDa, or greater than about 50kDa. In some embodiments, the molecular mass is from about 5kDa to about 10kDa, from about 5kDa to about 15kDa, from about 5kDa to about 20kDa, from about 10kDa to about 15kDa, from about 10kDa to about 20kDa, from about 10kDa to about 25kDa or from about 10kDa to about 30kDa. Although the present disclosure does not require use of a specific method or site of PEG attachment to IL-10, it is frequently advantageous that pegylation does not alter, or only minimally alters, the activity of the IL-10 molecule. In certain embodiments, the impact of any

increase in half-life is greater than the impact of any decrease in biological activity. The biological activity of PEG-IL-10 is typically measured by assessing the levels of inflammatory cytokines (e.g., TNF- α or IFN- γ) in the serum of subjects challenged with a bacterial antigen (lipopolysaccharide (LPS)) and treated with PEG-IL-10, as described in U.S. Pat. No. 7,052,686.

[0088] IL-10 variants can be prepared with various objectives in mind, including increasing serum half-life, reducing an immune response against the IL-10, facilitating purification or preparation, decreasing conversion of IL-10 into its monomeric subunits, improving therapeutic efficacy, and lessening the severity or occurrence of side effects during therapeutic use. The amino acid sequence variants are usually predetermined variants not found in nature, although some may be post-translational variants, e.g., glycosylated variants. Any variant of IL-10 can be used provided it retains a suitable level of IL-10 activity. In the tumor context, suitable IL-10 activity includes, for example, CD8+ T cell infiltration into tumor sites, expression of inflammatory cytokines such as IFN- γ , IL-4, IL-6, IL-10, and RANK-L, from these infiltrating cells, and increased levels of TNF- α or IFN- γ in biological samples.

[0089] The phrase “conservative amino acid substitution” refers to substitutions that preserve the activity of the protein by replacing an amino acid(s) in the protein with an amino acid with a side chain of similar acidity, basicity, charge, polarity, or size of the side chain. Conservative amino acid substitutions generally entail substitution of amino acid residues within the following groups: 1) L, I, M, V, F; 2) R, K; 3) F, Y, H, W, R; 4) G, A, T, S; 5) Q, N; and 6) D, E. Guidance for substitutions, insertions, or deletions may be based on alignments of amino acid sequences of different variant proteins or proteins from different species. Thus, in addition to any naturally-occurring IL-10 polypeptide, the present disclosure contemplates having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 usually no more than 20, 10, or 5 amino acid substitutions, where the substitution is usually a conservative amino acid substitution. It should be noted that one or more unnatural amino acids may be introduced into IL-10 as a means of fostering site-specific conjugation.

[0090] The present disclosure also contemplates active fragments (e.g., subsequences) of mature IL-10 containing contiguous amino acid residues derived from the mature IL-10. The length of contiguous amino acid residues of a peptide or a polypeptide subsequence varies depending on the specific naturally-occurring amino acid sequence from which the subsequence is derived. In general, peptides and polypeptides may be from about 20 amino acids to about 40

amino acids, from about 40 amino acids to about 60 amino acids, from about 60 amino acids to about 80 amino acids, from about 80 amino acids to about 100 amino acids, from about 100 amino acids to about 120 amino acids, from about 120 amino acids to about 140 amino acids, from about 140 amino acids to about 150 amino acids, from about 150 amino acids to about 155 amino acids, from about 155 amino acids up to the full-length peptide or polypeptide.

[0091] Additionally, IL-10 polypeptides can have a defined sequence identity compared to a reference sequence over a defined length of contiguous amino acids (e.g., a “comparison window”). Methods of alignment of sequences for comparison are well-known in the art.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Madison, Wis.), or by manual alignment and visual inspection (see, e.g., *Current Protocols in Molecular Biology* (Ausubel et al., eds. 1995 supplement)).

[0092] As an example, a suitable IL-10 polypeptide can comprise an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to a contiguous stretch of from about 20 amino acids to about 40 amino acids, from about 40 amino acids to about 60 amino acids, from about 60 amino acids to about 80 amino acids, from about 80 amino acids to about 100 amino acids, from about 100 amino acids to about 120 amino acids, from about 120 amino acids to about 140 amino acids, from about 140 amino acids to about 150 amino acids, from about 150 amino acids to about 155 amino acids, from about 155 amino acids up to the full-length peptide or polypeptide.

[0093] As discussed further below, the IL-10 polypeptides may be isolated from a natural source (e.g., an environment other than its naturally-occurring environment) and may also be recombinantly made (e.g., in a genetically modified host cell such as bacteria, yeast, *Pichia*, insect cells, and the like), where the genetically modified host cell is modified with a nucleic acid comprising a nucleotide sequence encoding the polypeptide. The IL-10 polypeptides may also be synthetically produced (e.g., by cell-free chemical synthesis).

[0094] Nucleic acid molecules encoding the IL-10 molecules are contemplated by the present disclosure, including their naturally-occurring and non-naturally occurring isoforms,

allelic variants and splice variants. The present disclosure also encompasses nucleic acid sequences that vary in one or more bases from a naturally-occurring DNA sequence but still translate into an amino acid sequence that corresponds to an IL-10 polypeptide due to degeneracy of the genetic code.

Identification of Modified IL-10 Molecules with Desirable Characteristics

[0095] The present disclosure is drawn, in part, to the manipulation of protein function through mutagenesis of, and other modifications to, IL-10. In some embodiments, the present disclosure contemplates modified IL-10 molecules wherein one or more advantageous characteristics have been added to IL-10 (in cases where the characteristic(s) is not present in the unmodified IL-10), and/or enhanced (in cases where the characteristic(s) is present in the unmodified IL-10, albeit in a less-than-optimal amount). As discussed further hereafter, such molecules may be identified and synthesized through rational drug design approaches comprising, for example, generation of a series of point mutations in human IL-10. This series of point mutations may be evaluated to determine the nature and extent of the properties (e.g., efficacy) of the members in the series.

[0096] In some embodiments, the point mutations are used to facilitate the synthesis of, for example, modified IL-10 peptides, wherein the peptides comprise covalent or non-covalent modifications (e.g., pegylation, Fc-fusions, and HSA fusions). In turn, systematic assessment of the modified peptides can be performed to define the locations of the IL-10 primary amino acid sequence where modifications can be effected while a) retaining protein bioactivity; b) enhancing certain protein functions (e.g., increasing duration of the IL-10 – IL-10 receptor docking interaction; c) deemphasizing certain IL-10 functions while maintaining others; or d) some combination of a) – c).

[0097] One goal of the rational drug design approaches contemplated herein is identification of those amino acid residues and regions of IL-10 that can be modified without having deleterious effects on bioactivity, while allowing other attributes to be added or enhanced. Another goal of these rational drug design approaches is to define amino acid residues and regions of IL-10 where modifications can be used to selectively deemphasize certain IL-10 functions while maintaining or enhancing the others. Thus, in certain embodiments, the IL-10 molecules (e.g., muteins) or modified IL-10 molecules accentuate one or more roles of IL-10 while deemphasizing one or more different roles; accentuate one or more

roles of IL-10 while not affecting the others (e.g., retaining normal levels of IL-10 activity); or deemphasize one or more roles of IL-10 while not affecting the others.

[0098] In particular embodiments, the modification(s) described herein improves at least one property or other characteristic (e.g., efficacy) of the peptides compared to unmodified versions of the peptides thereof. Further embodiments of the present disclosure pertain to methods and other technologies for identifying specific amino acid residues or domains of IL-10 that may be modified according to the methods described herein. Methods of using (e.g., in the treatment or prevention of a disorder or a symptom thereof), identifying and/or generating the peptides described herein are also aspects of the present disclosure. Other aspects include, for example, pharmaceutical compositions comprising the peptides.

[0099] Although identification of certain IL-10 functional domains and generation of particular types of IL-10 conjugates have been described, the literature is devoid of any description of the types of IL-10 molecules described herein and the methods for identifying them. Thus, while Gesser, B., et al. ((1997) Proc. Natl. Acad. Sci. 94:14620-25) describe the identification of two nonapeptides found to possess certain IL-10 – like activities, one located at the C-terminal portion of IL-10 and the other close to the N-terminal part, Gesser et al. do not describe any IL-10 mutants or modified IL-10 mutants. Furthermore, IL-10 polypeptides wherein an amino acid residue having an attachment group for a non-polypeptide moiety is introduced or removed in order to adapt the polypeptides to make them more susceptible to conjugation with a non-polypeptide moiety (U.S. Patent Publn. No. 2003/0186386) are also vastly different from the IL-10 molecules and methodologies described herein.

[00100] In particular embodiments, the present disclosure contemplates generation of a series of point mutations in human IL-10 and expression of those mutated IL-10 proteins (e.g., muteins) in, for example, a mammalian or bacterial system. The present disclosure contemplates the use of any expression system compatible with the mutant IL-10 molecules described herein. Mammalian protein expression systems are contemplated in particular embodiments, while in other embodiments candidate protein expression systems include those derived from bacteria (e.g., *E. coli*, *Corynebacterium*, *P. fluorescens*, and *B. subtilis*), yeast (e.g., *S. cerevisiae*), and baculovirus-infected insect cells. Cell-based or cell-free expression systems may be used. Most recombinant cytokines are produced in bacterial inclusion bodies, then purified and refolded.

[00101] Bacterial cells are frequently employed to express cytokines, a method which typically involves protein refolding. However, it can be advantageous to initially use a mammalian expression system in order to determine whether a mutated protein will be expressed. If the mammalian cell can express the mutated protein, then protein folding likely was not disrupted by the mutation. There is frequently a close correlation between the ability of a mammalian cell line to fold and secrete a mutant molecule and the viability of that molecule as a candidate for further evaluation. Conversely, if initial expression is carried out in bacteria and a mutated protein is not properly refolded, then it would not be clear whether the mutation was disruptive or the protein refolding protocol was sub-optimal.

[00102] Mutant IL-10 molecules that do not significantly disrupt protein folding and secretion in an expression system (e.g., a mammalian cell line-based expression system) may be candidates for further evaluation. For example, such mutant IL-10 molecules may be sufficiently purified to enable bioactivity analysis in one or more in vivo or in vitro/ex vivo assays, including the TNF α inhibition assay and the MC/9 cell proliferation assays described herein. By way of further example, such mutant IL-10 molecules may be evaluated in an in vitro assay that provides an IL-10/IL10R1 or IL-10/IL10R1/IL10R2 affinity measurement. In addition, in vivo models (e.g., an in vivo murine endotoxemia model) have been described and may be used in assessment of the IL-10 molecules described herein (see, e.g., Howard, M. et al., (1993) J. Exp. Med. 177:1205-08).

[00103] In particular embodiments, the mutant IL-10 polypeptide molecules (e.g., muteins) are modified by, for example, pegylation. These modified IL-10 molecules may then be evaluated to determine their impact on protein function. Modified IL-10 molecules exhibiting favorable characteristics (e.g., nominal or no impact on protein function) may be candidates for further modification (e.g., larger or branched PEGs) and evaluation (e.g., solubility).

[00104] In addition, the present disclosure contemplates evaluation of the mutant IL-10 peptides and modified IL-10 peptides using one or more assays for determining immunogenicity, such as those in vitro, ex vivo, or in silico immunogenicity assays described herein. Modified IL-10 molecules exhibiting particular favorable characteristics (e.g., enhanced efficacy without an increase in immunogenicity as determined in silico) may be candidates for further evaluation, including in vivo immunogenicity analysis and/or additional analyses in an in

vivo setting. In particular embodiments, these modified IL-10 molecules are not more immunogenic than the corresponding unmodified IL-10 molecules.

[00105] Also encompassed herein are other IL-10 molecules, including IL-10 fragments; polypeptides based on IL-10 monomers; molecules that comprise an IL-10 monomer complexed with a heterologous protein; and IL-10 fusion proteins that comprise IL-10 fused, at the nucleic acid level, to one or more therapeutic agents (e.g., an anti-inflammatory biologic). Such molecules may be modified using the approaches described herein or any other approach known to the skilled artisan.

[00106] The rational drug design approaches of the present disclosure may utilize crystallographic data from a number of sources, including data obtained from the published crystal structure of IL-10 (Zdanov, A. et al, (1995) Structure (Lond) 3:591-601 and Walter, M. and Nagabhushan, T., (1995) Biochemistry (38):12118-25); a model of the crystal structure of hIL-10 with its soluble receptor (Zdanov, A. et al., (1996) Protein Sci. (10):1955-62); and the crystal structure of the IL-10/IL-10R1 complex (Josephson, K. et al., (2001) Immunity (1):35-46). Though insufficient and incomplete in and of themselves, the information and data described in such sources may represent a component used in the identification of IL-10 amino acid residues and domains that may be modified. As a result of leveraging such information and data, mutant IL-10 molecules (e.g., muteins) and modified mutant IL-10 molecules (and, in some embodiments, modified native hIL-10) were identified having the advantageous and/or desirable characteristics described herein.

[00107] Each 160 amino acid monomer of mature human IL-10 (hIL-10) comprises six helices linked by short loops, also referred to herein as inter-helix junctions. FIGs 1A and 1B depict protein crystal structure ribbon representations (top view and side view, respectively) of the hIL-10 monomer, wherein the six helices are labeled A-F. FIGs 2A and 2B depict protein crystal structure ribbon representations (top view and side view, respectively) of the hIL-10 homodimer; the six helices of each monomer are labeled A-F in FIG 2A. FIG. 3C depicts the mature hIL-10 amino acid sequence indicating the regions corresponding to Helices A-F and the regions corresponding to each of the inter-helix junctions (loops). FIG. 3C also indicates that Helices A, C and F have kinks (regions within the hIL-10 three-dimensional structure wherein the sequence has, e.g., a severe bend) comprising stretches of several amino acids. Although the amino acid residues defining each helix, inter-helix junction and kink are accepted in the literature, it will be appreciated that skilled artisans may differ regarding which residues form

the precise boundaries of each domain and inter-helix junction, and that any such differences do not impact the teachings set forth herein.

[00108] As previously noted, the IL-10 receptor comprises alpha and beta subunits, which are also referred to as R1 and R2, respectively. While the mechanics of IL-10 receptor binding have not been thoroughly elucidated, it has been shown that IL-10 signalling requires contributions from both IL-10R1 and IL-10R2. This may occur through one IL-10 homodimer independently binding both IL-10R1 and IL-10R2 combined with some type of clustering event, or by one IL-10 homodimer forming a single complex with both IL-10R1 and IL-10R2. FIGs. 4A and 4B depict protein crystal structure ribbon representations (top view and side view, respectively) of the human IL10 homodimer (gray) bound to two human IL10R1/ α receptors (black).

[00109] Amino acid residues likely to be poor candidates for modification (e.g., pegylation) include: residues in a hydrophobic core, which are likely to be inaccessible to modification; residues contacting IL10R1/2 receptors; residues in close proximity to the IL10R1/2 – IL-10 – binding interface; and cysteine residues involved in disulfide bonds, which are generally non-reactive with cysteine-based pegylation chemistries (though cysteine pegylation of disulfide bonds has been accomplished using defined pegylation conditions). In contrast, amino acid residues likely to be good candidates for potential modification (e.g., pegylation) include: surface-exposed residues not involved in protein-protein interactions; residues that form the inter-helices junctions; or the residues prior to Helix A (“Pre-helix A”, as defined hereafter) or the residue subsequent to Helix F (“Post-helix F”, as defined hereafter). The tyrosine at amino acid residue 59 is one candidate for modification (e.g., pegylation). Modification of the amino acid residues that form a kink may have a more limited set of substitutions that will be tolerated.

[00110] As set forth elsewhere herein, chemistries currently exist for pegylation of a polypeptide’s N-terminus, lysine residues, cysteine residues, histidine residues, arginine residues, aspartic acid residues, glutamic acid residues, serine residues, threonine residues, tyrosine residues, and C-terminus. As indicated above, the present disclosure contemplates the introduction of unnatural amino acid residues which may, in turn, be pegylated. However, only some of these amino acid residues (e.g., tyrosine residues (and the N-terminus)) can routinely be pegylated in a site-specific manner. Pegylation of other amino acids can only be effected in a

site-specific manner under complex conditions, while pegylation of other amino acids (e.g., glutamic acid and serine residues) results in too many positional isomers to be useful.

[00111] Based on the teachings set forth herein, modification of amino acid residues via a combination of mutagenesis and site-specific chemistries is not predicted to be feasible for 58 residues likely to be buried within a hydrophobic core; 4 residues likely to be involved in disulfide bonds; and 27 residues likely to be in contact with IL-10R1/ α (7 of which are also predicted to be buried within a hydrophobic core region). In addition, 10 residues are in close proximity to the putative IL-10 and IL-10R1/ α binding interface but may not directly interact with IL-10R1/ α ; although it is predicted that modification of these residues will also not be feasible, the present disclosure recognizes that one or more of these residues might tolerate modification and, if so, such modifications are encompassed herein. Conversely, based on the teachings set forth herein, modification of amino acid residues via a combination of mutagenesis and site-specific chemistries is predicted to be feasible for 78 residues likely to be surface-exposed and not integrally involved in IL-10R1/ α binding or disulfide bonding.

[00112] The amino acid residues corresponding to each helix and inter-helix junction are set forth hereafter, as are the residues that occur before Helix A (“Pre-helix A”) and after Helix F (“Post-helix F”): Pre-helix A = 1-17; Helix A = 18-41; A/B Inter-helix Junction = 42-48; Helix B = 49-58; B/C Inter-helix Junction = 59; Helix C = 60-82; C/D Inter-helix Junction = 83-86; Helix D = 87-108; D/E Inter-helix Junction = 109-117; Helix E = 118-131; E/F Inter-helix Junction = 132; Helix F = 133-159; and Post-helix F = 160. Based on the teachings of the present disclosure, in particular embodiments the peptides comprise at least one substitution in the 160 amino acid IL-10 monomer at amino acid residues and regions identified herein as being able to accommodate such substitutions. These peptides may be modified as described herein.

[00113] Thus, the peptides of the present disclosure may comprise a) a Pre-helix A; b) a Helix A; c) an A/B Inter-helix Junction; d) a Helix B; e) a B/C Inter-helix Junction; f) a Helix C; g) a C/D Inter-helix Junction; h) a Helix D; i) a D/E Inter-helix Junction; j) a Helix E; k) an E/F Inter-helix Junction; l) a Helix F; and m) a Post-helix F; wherein such peptides further comprise at least one of: i) substitution of at least one amino acid residue of Pre-helix A other than amino acid residues 12 (C), 15 (F) or 16 (P); or ii) substitution of at least one amino acid residue of Helix A other than amino acid residues 19-24 (LPNMLR (SEQ ID NO:33)), 26-30 (LRDAF (SEQ ID NO:34)), 33-39 (VKTFQMQ (SEQ ID NO:35)), or 41 (D); or iii) substitution of at least one amino acid residue of Helix B other than amino acid residues 52 (L), 53 (L), or 56 (F);

or iv) substitution of the amino acid residue of the B/C Inter-helix Junction; or v) substitution of at least one amino acid residue of Helix C other than amino acid residues 62 (C), 64 (A), 65 (L), 68 (M), 69 (I), 71-73 (FYI), 76 (V), 77 (M), or 80 (A); or vi) substitution of at least one amino acid residue of the C/D Inter-helix Junction; or vii) substitution of at least one amino acid residue of Helix D other than amino acid residues 87 (I), 91 (V), 94 (L), 98 (L), 101 (L), 105 (L), or 108 (C); or viii) substitution of at least one amino acid residue of the D/E Inter-helix Junction other than amino acid residues 111 (F), 112 (L), or 114 (C); or ix) substitution of at least one amino acid residue of Helix E other than amino acid residues 120 (A), 121 (V), 124 (V), 127 (A), 128 (F) or 131 (L); or x) substitution of the amino acid residue of the E/F Inter-helix Junction; or xi) substitution of at least one amino acid residue of Helix F other than amino acid residues 136-156 (IYKAMSEFDIFINYIEAYMTM ((SEQ ID NO:36)), 158 (I) or 159 (R); or xii) substitution of the amino acid residue of Post-helix F. These peptides may be modified as described herein.

[00114] As described in detail in the Experimental section and as indicated in FIG. 5, 78 residues of the mature human IL-10 polypeptide are more likely surface exposed in the homodimer and are less likely to be involved in receptor binding, and these 78 residues represent sites that might possibly tolerate mutations by substitution of an amino acid that will serve as an anchor for a PEG. Of these 78 possible locations, some mutants are eliminated at specific locations for various reasons: residue 59 (Y) cannot be mutated to a tyrosine because human IL-10 already contains a tyrosine at that position; for residues at 10 (N), and 60 (L), 106 (R), introducing an N-glycosylation site would interfere with cysteine bonding and probably destroy the protein's bioactivity; residue 116 (N) already contains an N-X-S N-glycosylation motif so only an N-X-T motif can be introduced; for residue 160 (N), because the N-glycosylation motif is three amino acids long (N-X-S or N-X-T), an N-glycosylation site cannot be introduced at the last residue of a protein. Due to the motif for an N-glycosylation site spanning three amino acids (N-X-S or N-X-T, where X $\neq$ P), it was frequently necessary to introduce a mutation outside of the 78 residues described, but it should be noted that these mutations were designed so that the N-glycosylation would occur at these 78 locations on human IL-10, and hence the N-glycosylation mutation still serves as a means of testing these 78 locations.

[00115] The mutants (e.g., cysteine, tyrosine, N-X-S and N-X-T; see FIG. 5) were generated using the methods described herein and were evaluated in an MC/9 assay to

determine biological activity. Of those mutants possessing biological activity, 76 mutants were identified as being potential candidates for serving as an anchor site for a PEG moiety.

[00116] Some embodiments of the present disclosure contemplate peptides comprising at least one amino acid substitution in at least one of the following regions: 1-11, 49-51, 57-61, 81-86, 88-90, 102-104, 115-119, or 132-134. In other embodiments, the peptides comprise at least one amino acid substitution at least at one of the following positions: 1-11, 13, 14, 17, 18, 25, 31, 32, 40, 49-51, 54, 55, 57-61, 63, 66, 67, 70, 74, 75, 78, 79, 81-86, 88-90, 92, 93, 96, 97, 99, 100, 102-104, 106, 107, 109, 110, 113, 115-119, 122, 123, 125, 126, 129, 130, 132-134, 157 or 160.

Immunogenicity Considerations of Modified Forms of IL-10

[00117] Immunogenicity, the ability of an antigen to elicit humoral (B-cell) and/or cell-mediated (T-cell) immune responses in a subject, can be categorized as ‘desirable’ or ‘undesirable’. Desirable immunogenicity typically refers to the subject’s immune response mounted against a pathogen (e.g., a virus or bacterium) that is provoked by vaccine injection. In this context, the immune response is advantageous. Conversely, undesirable immunogenicity typically refers to the subject’s immune response mounted against an antigen like a therapeutic protein (e.g., IL-10); the immune response can, for example, result in anti-drug-antibodies (ADAs) that adversely impact the therapeutic protein’s effectiveness or its pharmacokinetic parameters, and/or contribute to other adverse effects. In this context, the immune response is disadvantageous.

[00118] There are a number of subject-specific and product-specific factors that affect a subject’s immune reaction to a protein therapeutic. Subject-specific factors include the immunologic status and competence of the subject; prior sensitization/history of allergy; route of administration; dose and frequency of administration; genetic status of the subject; and the subject’s status of immune tolerance to endogenous protein. Product-specific factors affecting immunogenicity include product origin (foreign or endogenous); product’s primary molecular structure/post-translational modifications, tertiary and quaternary structure, etc.; presence of product aggregates; conjugation/modification (e.g., glycosylation and pegylation); impurities with adjuvant activity; product’s immunomodulatory properties; and formulation.

[00119] Autologous or human-like polypeptide therapeutics have proven to be surprisingly immunogenic in some applications, and surprisingly non-immunogenic in others.

Particular IL-10 muteins and other modified versions of IL-10 (e.g., pegylated IL-10 and IL and IL-10 domains) are likely to provoke a range of humoral and cell-mediated immune responses.

[00120] As discussed further herein, the removal or modification of T-cell epitopes and/or B-cell epitopes can reduce immunogenicity. Indeed, in certain contexts, conjugation of one or more amino acid residues with a ‘masking agent’ (e.g., a PEG) and/or changes to the amino acids residues themselves (by, e.g., substitutions) may dramatically reduce the immunogenicity of an otherwise highly immunogenic protein.

[00121] T-cell Epitopes. As discussed further below, in contrast to the complex three-dimensional B-cell epitopes that often depend on secondary and tertiary protein structure, CD4+ T-cell epitopes are linear peptide sequences typically ranging from about 11 to about 20 amino acid residues in length. Comparative analysis of a range of proteins for which clinical immunogenicity data exists shows a strong relationship between the presence and potency of T-cell epitopes with the immunogenicity of the corresponding protein.

[00122] In silico screening tools are frequently used as an initial step in a comprehensive T-cell epitope assessment. The induction of helper CD4+ T-cell responses to a peptide requires peptide binding to MHC class II. Analysis of such peptide binding data can be exploited in the development process of therapeutic proteins. By way of example, Antitope Ltd (Cambridge, UK) has a proprietary in silico molecular modeling technology (iTope™) that models the binding of peptides to 34 MHC class II alleles. The contribution of individual amino acid residues to peptide binding can be determined for each allele, and these data can then be used in the design of ‘de-immunized’ sequence variants in which T-cell epitopes are mutated to disrupt binding.

[00123] In addition, ‘immunoinformatics’ algorithms and other technologies for identifying T-cell epitopes can be used to triage protein therapeutics into higher-risk and lower-risk categories. To illustrate, protein sequences can be parsed into overlapping 9-mer peptide frames which are then evaluated for binding potential to each of eight common class II HLA alleles that “cover” the genetic backgrounds of most humans. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein’s overall “immunogenicity score”. In addition, sub-regions of densely-packed, high scoring frames or “clusters” of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. A protein’s “immunogenicity score”, along with other determinants of

immunogenicity, can then be used to determine the likelihood that a protein will illicit an immune response.

[00124] Additional means of reducing a therapeutic protein's immunogenicity may be employed. Technologies (e.g., Antitope's proprietary EpiScreen™ human ex vivo T cell assay system) can be used to determine helper CD4+ T-cell responses to proteins, peptides, formulations, etc. Data generated from the use of such technologies can be used to map helper CD4+ T-cell epitopes within the sequence of the starting protein, and the T-cell epitopes can then be removed from the protein by one or more of the following: designing mutations in order to reduce/eliminate binding to human MHC class II; targeting T-cell receptor contact residues to disrupt recognition of peptide/MHC class II complexes; conducting structural and homology analysis to guide the targeting and substitution of key amino acid residues in order to maintain desired protein activity; and prioritizing T-cell epitopes for removal based on potency.

[00125] B-cell Epitopes. While accurate predictors for T-cell epitopes exist, currently the prediction of B-cell epitopes is inherently more difficult.

[00126] B-cell epitopes can be placed in one of two categories. In the first category, epitopes are defined by the primary amino acid sequence of a particular region of a protein, and the components of the epitope are situated sequentially on the protein. These linear B-cell epitopes generally range from about 5 to about 20 amino acid residues in length. In the second category, epitopes are defined by the conformational structure of a protein, and the components of the epitope are situated on separate parts of the protein that are brought into proximity of each other in the folded secondary or tertiary structure of the native protein. Because most B-cell epitopes are based on the conformational structure of a protein, B-cell epitopes are more difficult to identify than T-cell epitopes (which are determined by their primary amino acid sequence).

[00127] Examples of previously used sequence-based B-cell epitope predictors include technologies described by Saha S, and Raghava GP ("ABCPred technology") (Proteins (2006) 65:40-48); Chen et al. (Amino Acids (2007) 33:423-28); El-Manzalawy Y, et al. ("BCPred" technology) (J Mol Recognit (2008) 21:243-55); Sweredoski MJ, and Baldi P ("COBEpro" technology) (Protein Eng Des Sel (2009) 22:113-20); Wee LJ, et al. ("BayesB" technology) (BMC Genomics (2010) 11:S21); and Ansari HR, and Raghava GP ("CBTOPE" technology) (Immunome Res (2010) 6:6).

[00128] B-cell Epitope prediction using Support vector machine Tool (“BEST”) is a promising new B-cell epitope technology (Gao J, et al. (2012) PLoS ONE 7(6): e40104. doi:10.1371/journal.pone.0040104). The BEST method predicts epitopes from antigen sequences, in contrast to many previous methods that predict only from short sequence fragments, using a new architecture based on averaging selected scores generated from sliding 20-mers by a Support Vector Machine (SVM). The SVM predictor utilizes a comprehensive and custom-designed set of inputs generated by combining information derived from the chain, sequence conservation, similarity to known (training) epitopes, and predicted secondary structure and relative solvent accessibility. In addition, several commercial entities utilize proprietary technologies to assess B-cell epitopes (e.g., ProImmune’s B-cell ELISpot technology; ProImmune Ltd.; Oxford, UK).

[00129] For purposes of assessing immunogenicity, it is useful to focus on potential T-cell epitopes, which generally, though not always, drive antigen-specific B-cell responses.

Methods of Production of IL-10

[00130] A polypeptide of the present disclosure can be produced by any suitable method, including non-recombinant (e.g., chemical synthesis) and recombinant methods.

Chemical Synthesis

[00131] Where a polypeptide is chemically synthesized, the synthesis may proceed via liquid-phase or solid-phase. Solid-phase peptide synthesis (SPPS) allows the incorporation of unnatural amino acids and/or peptide/protein backbone modification. Various forms of SPPS, such as 9-fluorenylmethoxycarbonyl (Fmoc) and t-butyloxycarbonyl (Boc), are available for synthesizing polypeptides of the present disclosure. Details of the chemical syntheses are known in the art (e.g., Ganesan A. (2006) Mini Rev. Med. Chem. 6:3-10; and Camarero J.A. et al., (2005) Protein Pept Lett. 12:723-8).

[00132] Solid phase peptide synthesis may be performed as described hereafter. The alpha functions ($N\alpha$) and any reactive side chains are protected with acid-labile or base-labile groups. The protective groups are stable under the conditions for linking amide bonds but can readily be cleaved without impairing the peptide chain that has formed. Suitable protective groups for the α -amino function include, but are not limited to, the following: Boc, benzyloxycarbonyl (Z), O-chlorbenzyloxycarbonyl, bi-phenylisopropyloxycarbonyl, tert-

amyloxycarbonyl (Amoc), α , α -dimethyl-3,5-dimethoxy-benzyloxycarbonyl, o-nitrosulfenyl, 2-cyano-t-butoxy-carbonyl, Fmoc, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) and the like.

[00133] Suitable side chain protective groups include, but are not limited to: acetyl, allyl (All), allyloxycarbonyl (Alloc), benzyl (Bzl), benzyloxycarbonyl (Z), t-butyloxycarbonyl (Boc), benzyloxymethyl (Bom), o-bromobenzyloxycarbonyl, t-butyl (tBu), t-butyldimethylsilyl, 2-chlorobenzyl, 2-chlorobenzyloxycarbonyl, 2,6-dichlorobenzyl, cyclohexyl, cyclopentyl, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde), isopropyl, 4-methoxy-2,3,6-trimethylbenzylsulfonyl (Mtr), 2,3,5,7,8-pentamethylchroman-6-sulfonyl (Pmc), pivalyl, tetrahydropyran-2-yl, tosyl (Tos), 2,4,6-trimethoxybenzyl, trimethylsilyl and trityl (Trt).

[00134] In the solid phase synthesis, the C-terminal amino acid is coupled to a suitable support material. Suitable support materials are those which are inert towards the reagents and reaction conditions for the step-wise condensation and cleavage reactions of the synthesis process and which do not dissolve in the reaction media being used. Examples of commercially-available support materials include styrene/divinylbenzene copolymers which have been modified with reactive groups and/or polyethylene glycol; chloromethylated styrene/divinylbenzene copolymers; hydroxymethylated or aminomethylated styrene/divinylbenzene copolymers; and the like. When preparation of the peptidic acid is desired, polystyrene (1%)-divinylbenzene or TentaGel® derivatized with 4-benzyloxybenzyl-alcohol (Wang-anchor) or 2-chlorotrityl chloride can be used. In the case of the peptide amide, polystyrene (1%) divinylbenzene or TentaGel® derivatized with 5-(4'-aminomethyl)-3',5'-dimethoxyphenoxy)valeric acid (PAL-anchor) or p-(2,4-dimethoxyphenyl-amino methyl)-phenoxy group (Rink amide anchor) can be used.

[00135] The linkage to the polymeric support can be achieved by reacting the C-terminal Fmoc-protected amino acid with the support material by the addition of an activation reagent in ethanol, acetonitrile, N,N-dimethylformamide (DMF), dichloromethane, tetrahydrofuran, N-methylpyrrolidone or similar solvents at room temperature or elevated temperatures (e.g., between 40°C and 60°C) and with reaction times of, e.g., 2 to 72 hours.

[00136] The coupling of the N α -protected amino acid (e.g., the Fmoc amino acid) to the PAL, Wang or Rink anchor can, for example, be carried out with the aid of coupling reagents such as N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC) or other carbodiimides, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)

or other uronium salts, O-acyl-ureas, benzotriazol-1-yl-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) or other phosphonium salts, N-hydroxysuccinimides, other N-hydroxyimides or oximes in the presence or absence of 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole, e.g., with the aid of TBTU with addition of HOBt, with or without the addition of a base such as, for example, diisopropylethylamine (DIEA), triethylamine or N-methylmorpholine, e.g., diisopropylethylamine with reaction times of 2 to 72 hours (e.g., 3 hours in a 1.5 to 3-fold excess of the amino acid and the coupling reagents, for example, in a 2-fold excess and at temperatures between about 10°C and 50°C, for example, 25°C in a solvent such as dimethylformamide, N-methylpyrrolidone or dichloromethane, e.g., dimethylformamide).

[00137] Instead of the coupling reagents, it is also possible to use the active esters (e.g., pentafluorophenyl, p-nitrophenyl or the like), the symmetric anhydride of the N α -Fmoc-amino acid, its acid chloride or acid fluoride, under the conditions described above.

[00138] The N α -protected amino acid (e.g., the Fmoc amino acid) can be coupled to the 2-chlorotrityl resin in dichloromethane with the addition of DIEA and having reaction times of 10 to 120 minutes, e.g., 20 minutes, but is not limited to the use of this solvent and this base.

[00139] The successive coupling of the protected amino acids can be carried out according to conventional methods in peptide synthesis, typically in an automated peptide synthesizer. After cleavage of the N α -Fmoc protective group of the coupled amino acid on the solid phase by treatment with, e.g., piperidine (10% to 50%) in dimethylformamide for 5 to 20 minutes, e.g., 2 x 2 minutes with 50% piperidine in DMF and 1 x 15 minutes with 20% piperidine in DMF, the next protected amino acid in a 3 to 10-fold excess, e.g., in a 10-fold excess, is coupled to the previous amino acid in an inert, non-aqueous, polar solvent such as dichloromethane, DMF or mixtures of the two and at temperatures between about 10°C and 50°C, e.g., at 25°C. The previously mentioned reagents for coupling the first N α -Fmoc amino acid to the PAL, Wang or Rink anchor are suitable as coupling reagents. Active esters of the protected amino acid, or chlorides or fluorides or symmetric anhydrides thereof, can also be used as an alternative.

[00140] At the end of the solid phase synthesis, the peptide is cleaved from the support material while simultaneously cleaving the side chain protecting groups. Cleavage can be carried out with trifluoroacetic acid or other strongly acidic media with addition of 5%-20% V/V of scavengers such as dimethylsulfide, ethylmethylsulfide, thioanisole, thiocresol, m-

cresol, anisole ethanedithiol, phenol or water, e.g., 15% v/v dimethylsulfide/ethanedithiol/m-cresol 1:1:1, within 0.5 to 3 hours, e.g., 2 hours. Peptides with fully protected side chains are obtained by cleaving the 2-chlorotrityl anchor with glacial acetic acid/trifluoroethanol/dichloromethane 2:2:6. The protected peptide can be purified by chromatography on silica gel. If the peptide is linked to the solid phase via the Wang anchor and if it is intended to obtain a peptide with a C-terminal alkylamidation, the cleavage can be carried out by aminolysis with an alkylamine or fluoroalkylamine. The aminolysis is carried out at temperatures between about -10°C and 50°C (e.g., about 25°C), and reaction times between about 12 and 24 hours (e.g., about 18 hours). In addition, the peptide can be cleaved from the support by re-esterification, e.g., with methanol.

[00141] The acidic solution that is obtained may be admixed with a 3 to 20-fold amount of cold ether or n-hexane, e.g., a 10-fold excess of diethyl ether, in order to precipitate the peptide and hence to separate the scavengers and cleaved protective groups that remain in the ether. A further purification can be carried out by re-precipitating the peptide several times from glacial acetic acid. The precipitate that is obtained can be taken up in water or tert-butanol or mixtures of the two solvents, e.g., a 1:1 mixture of tert-butanol/water, and freeze-dried.

[00142] The peptide obtained can be purified by various chromatographic methods, including ion exchange over a weakly basic resin in the acetate form; hydrophobic adsorption chromatography on non-derivatized polystyrene/divinylbenzene copolymers (e.g., Amberlite® XAD); adsorption chromatography on silica gel; ion exchange chromatography, e.g., on carboxymethyl cellulose; distribution chromatography, e.g., on Sephadex® G-25; countercurrent distribution chromatography; or high pressure liquid chromatography (HPLC) e.g., reversed-phase HPLC on octyl or octadecylsilylsilica (ODS) phases.

Recombinant Production

[00143] Methods describing the preparation of human and mouse IL-10 can be found in, for example, U.S. Patent No. 5,231,012, which teaches methods for the production of proteins having IL-10 activity, including recombinant and other synthetic techniques. IL-10 can be of viral origin, and the cloning and expression of a viral IL-10 from Epstein Barr virus (BCRF1 protein) is disclosed in Moore et al., (1990) Science 248:1230. IL-10 can be obtained in a number of ways using standard techniques known in the art, such as those described herein. Recombinant human IL-10 is also commercially available, e.g., from PeproTech, Inc., Rocky Hill, N.J.

[00144] Site-specific mutagenesis (also referred to as site-directed mutagenesis and oligonucleotide-directed mutagenesis) can be used to generate specific mutations in DNA to produce rationally-designed proteins of the present disclosure (e.g., particular IL-10 muteins and other modified versions of IL-10, including domains thereof) having improved or desirable properties. Techniques for site-specific mutagenesis are well known in the art. Early site-specific mutagenesis methods (e.g., Kunkel's method; cassette mutagenesis; PCR site-directed mutagenesis; and whole plasmid mutagenesis, including SPRINP) have been replaced by more precise and efficient methods, such as various in vivo methods that include Delitto perfetto (see Storici F. and Resnick MA, (2006) *Methods in Enzymology* 409:329-45); transplacement "pop-in pop-out"; direct gene deletion and site-specific mutagenesis with PCR and one recyclable marker; direct gene deletion and site-specific mutagenesis with PCR and one recyclable marker using long homologous regions; and in vivo site-directed mutagenesis with synthetic oligonucleotides (and see, e.g., *In Vitro Mutagenesis Protocols* (Methods in Molecular Biology), 2nd Ed. ISBN 978-0896039100). In addition, tools for effecting site-specific mutagenesis are commercially available (e.g., Stratagene Corp., La Jolla, CA).

[00145] Where a polypeptide is produced using recombinant techniques, the polypeptide may be produced as an intracellular protein or as a secreted protein, using any suitable construct and any suitable host cell, which can be a prokaryotic or eukaryotic cell, such as a bacterial (e.g., *E. coli*) or a yeast host cell, respectively. Other examples of eukaryotic cells that may be used as host cells include insect cells, mammalian cells, and/or plant cells. Where mammalian host cells are used, they may include human cells (e.g., HeLa, 293, H9 and Jurkat cells); mouse cells (e.g., NIH3T3, L cells, and C127 cells); primate cells (e.g., Cos 1, Cos 7 and CV1); and hamster cells (e.g., Chinese hamster ovary (CHO) cells).

[00146] A variety of host-vector systems suitable for the expression of a polypeptide may be employed according to standard procedures known in the art. See, e.g., Sambrook et al., 1989 *Current Protocols in Molecular Biology* Cold Spring Harbor Press, New York; and Ausubel et al. 1995 *Current Protocols in Molecular Biology*, Eds. Wiley and Sons. Methods for introduction of genetic material into host cells include, for example, transformation, electroporation, conjugation, calcium phosphate methods and the like. The method for transfer can be selected so as to provide for stable expression of the introduced polypeptide-encoding nucleic acid. The polypeptide-encoding nucleic acid can be provided as an inheritable episomal

element (e.g., a plasmid) or can be genomically integrated. A variety of appropriate vectors for use in production of a polypeptide of interest are commercially available.

[00147] Vectors can provide for extrachromosomal maintenance in a host cell or can provide for integration into the host cell genome. The expression vector provides transcriptional and translational regulatory sequences, and may provide for inducible or constitutive expression where the coding region is operably-linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. Promoters can be either constitutive or inducible, and can be a strong constitutive promoter (e.g., T7).

[00148] Expression constructs generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding proteins of interest. A selectable marker operative in the expression host may be present to facilitate selection of cells containing the vector. Moreover, the expression construct may include additional elements. For example, the expression vector may have one or two replication systems, thus allowing it to be maintained in organisms, for example, in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification. In addition, the expression construct may contain a selectable marker gene to allow the selection of transformed host cells. Selectable genes are well known in the art and will vary with the host cell used.

[00149] Isolation and purification of a protein can be accomplished according to methods known in the art. For example, a protein can be isolated from a lysate of cells genetically modified to express the protein constitutively and/or upon induction, or from a synthetic reaction mixture by immunoaffinity purification, which generally involves contacting the sample with an anti-protein antibody, washing to remove non-specifically bound material, and eluting the specifically bound protein. The isolated protein can be further purified by dialysis and other methods normally employed in protein purification. In one embodiment, the protein may be isolated using metal chelate chromatography methods. Proteins may contain modifications to facilitate isolation.

[00150] The polypeptides may be prepared in substantially pure or isolated form (e.g., free from other polypeptides). The polypeptides can be present in a composition that is enriched for the polypeptide relative to other components that may be present (e.g., other polypeptides or

other host cell components). For example, purified polypeptide may be provided such that the polypeptide is present in a composition that is substantially free of other expressed proteins, e.g., less than about 90%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less than about 1%.

[00151] An IL-10 polypeptide may be generated using recombinant techniques to manipulate different IL-10 – related nucleic acids known in the art to provide constructs capable of encoding the IL-10 polypeptide. It will be appreciated that, when provided a particular amino acid sequence, the ordinary skilled artisan will recognize a variety of different nucleic acid molecules encoding such amino acid sequence in view of her background and experience in, for example, molecular biology.

Amide Bond Substitutions

[00152] In some cases, IL-10 includes one or more linkages other than peptide bonds, e.g., at least two adjacent amino acids are joined via a linkage other than an amide bond. For example, in order to reduce or eliminate undesired proteolysis or other means of degradation, and/or to increase serum stability, and/or to restrict or increase conformational flexibility, one or more amide bonds within the backbone of IL-10 can be substituted.

[00153] In another example, one or more amide linkages (-CO-NH-) in IL-10 can be replaced with a linkage which is an isostere of an amide linkage, such as -CH₂NH-, -CH₂S-, -CH₂CH₂-, -CH=CH-(cis and trans), -COCH₂-, -CH(OH)CH₂- or -CH₂SO-. One or more amide linkages in IL-10 can also be replaced by, for example, a reduced isostere pseudopeptide bond. See Couder et al. (1993) Int. J. Peptide Protein Res. 41:181-184. Such replacements and how to effect them are known to those of ordinary skill in the art.

Amino Acid Substitutions

[00154] One or more amino acid substitutions can be made in an IL-10 polypeptide. The following are non-limiting examples:

[00155] a) substitution of alkyl-substituted hydrophobic amino acids, including alanine, leucine, isoleucine, valine, norleucine, (S)-2-aminobutyric acid, (S)-cyclohexylalanine or other simple alpha-amino acids substituted by an aliphatic side chain from C₁-C₁₀ carbons including branched, cyclic and straight chain alkyl, alkenyl or alkynyl substitutions;

[00156] b) substitution of aromatic-substituted hydrophobic amino acids, including phenylalanine, tryptophan, tyrosine, sulfotyrosine, biphenylalanine, 1-naphthylalanine, 2-naphthylalanine, 2-benzothienylalanine, 3-benzothienylalanine, histidine, including amino, alkylamino, dialkylamino, aza, halogenated (fluoro, chloro, bromo, or iodo) or alkoxy (from C₁-C₄)-substituted forms of the above-listed aromatic amino acids, illustrative examples of which are: 2-, 3- or 4-aminophenylalanine, 2-, 3- or 4-chlorophenylalanine, 2-, 3- or 4-methylphenylalanine, 2-, 3- or 4-methoxyphenylalanine, 5-amino-, 5-chloro-, 5-methyl- or 5-methoxytryptophan, 2'-, 3'-, or 4'-amino-, 2'-, 3'-, or 4'-chloro-, 2, 3, or 4-biphenylalanine, 2'-, 3'-, or 4'-methyl-, 2-, 3- or 4-biphenylalanine, and 2- or 3-pyridylalanine;

[00157] c) substitution of amino acids containing basic side chains, including arginine, lysine, histidine, ornithine, 2,3-diaminopropionic acid, homoarginine, including alkyl, alkenyl, or aryl-substituted (from C₁-C₁₀ branched, linear, or cyclic) derivatives of the previous amino acids, whether the substituent is on the heteroatoms (such as the alpha nitrogen, or the distal nitrogen or nitrogens, or on the alpha carbon, in the pro-R position for example. Compounds that serve as illustrative examples include: N-epsilon-isopropyl-lysine, 3-(4-tetrahydropyridyl)-glycine, 3-(4-tetrahydropyridyl)-alanine, N,N-gamma, gamma'-diethyl-homoarginine. Included also are compounds such as alpha-methyl-arginine, alpha-methyl-2,3-diaminopropionic acid, alpha-methyl-histidine, alpha-methyl-ornithine where the alkyl group occupies the pro-R position of the alpha-carbon. Also included are the amides formed from alkyl, aromatic, heteroaromatic (where the heteroaromatic group has one or more nitrogens, oxygens or sulfur atoms singly or in combination), carboxylic acids or any of the many well-known activated derivatives such as acid chlorides, active esters, active azolides and related derivatives, and lysine, ornithine, or 2,3-diaminopropionic acid;

[00158] d) substitution of acidic amino acids, including aspartic acid, glutamic acid, homoglutamic acid, tyrosine, alkyl, aryl, arylalkyl, and heteroaryl sulfonamides of 2,4-diaminopropionic acid, ornithine or lysine and tetrazole-substituted alkyl amino acids;

[00159] e) substitution of side chain amide residues, including asparagine, glutamine, and alkyl or aromatic substituted derivatives of asparagine or glutamine; and

[00160] f) substitution of hydroxyl-containing amino acids, including serine, threonine, homoserine, 2,3-diaminopropionic acid, and alkyl or aromatic substituted derivatives of serine or threonine.

[00161] In some cases, IL-10 comprises one or more naturally occurring non-genetically encoded L-amino acids, synthetic L-amino acids, or D-enantiomers of an amino acid. In some embodiments, IL-10 comprises only D-amino acids. For example, an IL-10 polypeptide can comprise one or more of the following residues: hydroxyproline, β -alanine, o-aminobenzoic acid, m-aminobenzoic acid, p-aminobenzoic acid, m-aminomethylbenzoic acid, 2,3-diaminopropionic acid, α -aminoisobutyric acid, N-methylglycine (sarcosine), ornithine, citrulline, t-butylalanine, t-butylglycine, N-methylisoleucine, phenylglycine, cyclohexylalanine, norleucine, naphthylalanine, pyridylalanine 3-benzothienyl alanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, β -2-thienylalanine, methionine sulfoxide, homoarginine, N-acetyl lysine, 2,4-diamino butyric acid, rho-aminophenylalanine, N-methylvaline, homocysteine, homoserine, ϵ -amino hexanoic acid, ω -aminohexanoic acid, ω -aminoheptanoic acid, ω -aminooctanoic acid, ω -aminodecanoic acid, ω -aminotetradecanoic acid, cyclohexylalanine, α,γ -diaminobutyric acid, α,β -diaminopropionic acid, δ -amino valeric acid, and 2,3-diaminobutyric acid.

Additional modifications

[00162] A cysteine residue or a cysteine analog can be introduced into an IL-10 polypeptide to provide for linkage to another peptide via a disulfide linkage or to provide for cyclization of the IL-10 polypeptide. Methods of introducing a cysteine or cysteine analog are known in the art (see, e.g., U.S. Patent No. 8,067,532).

[00163] An IL-10 polypeptide can be cyclized. One or more cysteines or cysteine analogs can be introduced into an IL-10 polypeptide, where the introduced cysteine or cysteine analog can form a disulfide bond with a second introduced cysteine or cysteine analog. Other means of cyclization include introduction of an oxime linker or a lanthionine linker; see, e.g., U.S. Patent No. 8,044,175. Any combination of amino acids (or non-amino acid moieties) that can form a cyclizing bond can be used and/or introduced. A cyclizing bond can be generated with any combination of amino acids (or with an amino acid and $-(CH_2)_n-CO-$ or $-(CH_2)_n-C_6H_4-CO-$) with functional groups which allow for the introduction of a bridge. Some examples are disulfides, disulfide mimetics such as the $-(CH_2)_n-$ carba bridge, thioacetal, thioether bridges (cystathionine or lanthionine) and bridges containing esters and ethers. In these examples, n can be any integer, but is frequently less than ten.

[00164] Other modifications include, for example, an N-alkyl (or aryl) substitution (ψ [CONR]), or backbone crosslinking to construct lactams and other cyclic structures. Other derivatives include C-terminal hydroxymethyl derivatives, o-modified derivatives (e.g., C-terminal hydroxymethyl benzyl ether), N-terminally modified derivatives including substituted amides such as alkylamides and hydrazides.

[00165] In some cases, one or more L-amino acids in an IL-10 polypeptide is replaced with one or more D-amino acids.

[00166] In some cases, an IL-10 polypeptide is a retroinverso analog (see, e.g., Sela and Zisman (1997) FASEB J. 11:449). Retro-inverso peptide analogs are isomers of linear polypeptides in which the direction of the amino acid sequence is reversed (retro) and the chirality, D- or L-, of one or more amino acids therein is inverted (inverso), e.g., using D-amino acids rather than L-amino acids. [See, e.g., Jameson et al. (1994) Nature 368:744; and Brady et al. (1994) Nature 368:692].

[00167] An IL-10 polypeptide can include a “Protein Transduction Domain” (PTD), which refers to a polypeptide, polynucleotide, carbohydrate, or organic or inorganic molecule that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD attached to another molecule facilitates the molecule traversing a membrane, for example going from extracellular space to intracellular space, or cytosol to within an organelle. In some embodiments, a PTD is covalently linked to the amino terminus of an IL-10 polypeptide, while in other embodiments, a PTD is covalently linked to the carboxyl terminus of an IL-10 polypeptide. Exemplary protein transduction domains include, but are not limited to, a minimal undecapeptide protein transduction domain (corresponding to residues 47-57 of HIV-1 TAT comprising YGRKKRRQRRR; SEQ ID NO:3); a polyarginine sequence comprising a number of arginine residues sufficient to direct entry into a cell (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines); a VP22 domain (Zender et al. (2002) Cancer Gene Ther. 9(6):489-96); a Drosophila Antennapedia protein transduction domain (Noguchi et al. (2003) Diabetes 52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al. (2004) Pharm. Research 21:1248-1256); polylysine (Wender et al. (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008); RRQRRTSKLMKR (SEQ ID NO:4); Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:5); KALAWKAKLAKALAKHLAKALAKALKCEA (SEQ ID NO:6); and RQIKIWFQNRRMKWKK (SEQ ID NO:7). Exemplary PTDs include, but are not limited to, YGRKKRRQRRR (SEQ ID NO:8), RKKRRQRRR (SEQ ID NO:9); an arginine homopolymer

of from 3 arginine residues to 50 arginine residues; exemplary PTD domain amino acid sequences include, but are not limited to, any of the following: YGRKKRRQRRR (SEQ ID NO:10); RKKRRQRR (SEQ ID NO:11); YARAAARQARA (SEQ ID NO:12); THRLPRRRRRR (SEQ ID NO:13); and GGRRARRRRRR (SEQ ID NO:14).

[00168] The carboxyl group COR_3 of the amino acid at the C-terminal end of an IL-10 polypeptide can be present in a free form ($\text{R}_3 = \text{OH}$) or in the form of a physiologically-tolerated alkaline or alkaline earth salt such as, e.g., a sodium, potassium or calcium salt. The carboxyl group can also be esterified with primary, secondary or tertiary alcohols such as, e.g., methanol, branched or unbranched C_1 - C_6 -alkyl alcohols, e.g., ethyl alcohol or tert-butanol. The carboxyl group can also be amidated with primary or secondary amines such as ammonia, branched or unbranched C_1 - C_6 -alkylamines or C_1 - C_6 di-alkylamines, e.g., methylamine or dimethylamine.

[00169] The amino group of the amino acid NR_1R_2 at the N-terminus of an IL-10 polypeptide can be present in a free form ($\text{R}_1 = \text{H}$ and $\text{R}_2 = \text{H}$) or in the form of a physiologically-tolerated salt such as, e.g., a chloride or acetate. The amino group can also be acetylated with acids such that $\text{R}_1 = \text{H}$ and $\text{R}_2 = \text{acetyl}$, trifluoroacetyl, or adamantyl. The amino group can be present in a form protected by amino-protecting groups conventionally used in peptide chemistry, such as those provided above (e.g., Fmoc, Benzyloxy-carbonyl (Z), Boc, and Alloc). The amino group can be N-alkylated in which R_1 and/or $\text{R}_2 = \text{C}_1$ - C_6 alkyl or C_2 - C_8 alkenyl or C_7 - C_9 aralkyl. Alkyl residues can be straight-chained, branched or cyclic (e.g., ethyl, isopropyl and cyclohexyl, respectively).

Particular Modifications to Enhance and/or Mimic IL-10 Function

[00170] It is frequently beneficial, and sometimes imperative, to improve one of more physical properties of the treatment modalities disclosed herein (e.g., an IL-10 mutein) and/or the manner in which they are administered. Improvements of physical properties include, for example, modulating immunogenicity; methods of increasing water solubility, bioavailability, serum half-life, and/or therapeutic half-life; and/or modulating biological activity. Certain modifications may also be useful to, for example, raise antibodies for use in detection assays (e.g., epitope tags) and to provide for ease of protein purification. Such improvements must generally be imparted without adversely impacting the bioactivity of the treatment modality and/or increasing its immunogenicity.

[00171] Pegylation of IL-10 is one particular modification contemplated by the present disclosure, while other modifications include, but are not limited to, glycosylation (N- and O-linked); polysialylation; albumin fusion molecules comprising serum albumin (e.g., human serum albumin (HSA), cyno serum albumin, or bovine serum albumin (BSA)); albumin binding through, for example a conjugated fatty acid chain (acylation); and Fc-fusion proteins. In addition, PEG mimetics represent other modifications contemplated herein.

[00172] Pegylation: The clinical effectiveness of protein therapeutics is often limited by short plasma half-life and susceptibility to protease degradation. Studies of various therapeutic proteins have shown that such difficulties may be overcome by various modifications, including conjugating or linking the polypeptide sequence to any of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes. This is frequently effected by a linking moiety covalently bound to both the protein and the nonproteinaceous polymer, e.g., a PEG. Such PEG-conjugated biomolecules have been shown to possess clinically useful properties, including better physical and thermal stability, protection against susceptibility to enzymatic degradation, increased solubility, longer in vivo circulating half-life and decreased clearance, reduced immunogenicity and antigenicity, and reduced toxicity.

[00173] In addition to the beneficial effects of pegylation on pharmacokinetic parameters, pegylation itself may enhance activity. For example, PEG-IL-10 has been shown to be more efficacious against certain cancers than unpegylated IL-10 (see, e.g., EP 206636A2).

[00174] PEGs suitable for conjugation to a polypeptide sequence are generally soluble in water at room temperature, and have the general formula $R(O-CH_2-CH_2)_nO-R$, where R is hydrogen or a protective group such as an alkyl or an alkanol group, and where n is an integer from 1 to 1000. When R is a protective group, it generally has from 1 to 8 carbons. The PEG conjugated to the polypeptide sequence can be linear or branched. Branched PEG derivatives, “star-PEGs” and multi-armed PEGs are contemplated by the present disclosure. A molecular weight (molecular mass) of the PEG used in the present disclosure is not restricted to any particular range. Certain embodiments have molecular weights between 5kDa and 20kDa, while other embodiments have molecular weights between 4kDa and 10kDa. Further embodiments describing PEGs having additional molecular weights are described elsewhere herein.

[00175] The present disclosure also contemplates compositions of conjugates wherein the PEGs have different n values, and thus the various different PEGs are present in specific ratios. For example, some compositions comprise a mixture of conjugates where $n=1, 2, 3$ and 4 . In some compositions, the percentage of conjugates where $n=1$ is 18-25%, the percentage of conjugates where $n=2$ is 50-66%, the percentage of conjugates where $n=3$ is 12-16%, and the percentage of conjugates where $n=4$ is up to 5%. Such compositions can be produced by reaction conditions and purification methods known in the art. Exemplary reaction conditions are described throughout the specification. Cation exchange chromatography may be used to separate conjugates, and a fraction is then identified which contains the conjugate having, for example, the desired number of PEGs attached, purified free from unmodified protein sequences and from conjugates having other numbers of PEGs attached.

[00176] Pegylation most frequently occurs at the alpha amino group at the N-terminus of the polypeptide, the epsilon amino group on the side chain of lysine residues, and the imidazole group on the side chain of histidine residues. Since most recombinant polypeptides possess a single alpha and a number of epsilon amino and imidazole groups, numerous positional isomers can be generated depending on the linker chemistry. General pegylation strategies known in the art can be applied herein. PEG may be bound to a polypeptide of the present disclosure via a terminal reactive group (a "spacer") which mediates a bond between the free amino or carboxyl groups of one or more of the polypeptide sequences and polyethylene glycol. The PEG having the spacer which may be bound to the free amino group includes N-hydroxysuccinylimide polyethylene glycol, which may be prepared by activating succinic acid ester of polyethylene glycol with N-hydroxysuccinylimide. Another activated polyethylene glycol which may be bound to a free amino group is 2,4-bis(O-methoxypolyethyleneglycol)-6-chloro-s-triazine, which may be prepared by reacting polyethylene glycol monomethyl ether with cyanuric chloride. The activated polyethylene glycol which is bound to the free carboxyl group includes polyoxyethylenediamine.

[00177] Conjugation of one or more of the polypeptide sequences of the present disclosure to PEG having a spacer may be carried out by various conventional methods. For example, the conjugation reaction can be carried out in solution at a pH of from 5 to 10, at temperature from 4°C to room temperature, for 30 minutes to 20 hours, utilizing a molar ratio of reagent to protein of from 4:1 to 30:1. Reaction conditions may be selected to direct the reaction towards producing predominantly a desired degree of substitution. In general, low

temperature, low pH (e.g., pH=5), and short reaction time tend to decrease the number of PEGs attached, whereas high temperature, neutral to high pH (e.g., pH $\geq$ 7), and longer reaction time tend to increase the number of PEGs attached. Various means known in the art may be used to terminate the reaction. In some embodiments the reaction is terminated by acidifying the reaction mixture and freezing at, e.g., -20°C. Pegylation of various molecules is discussed in, for example, U.S. Pat. Nos. 5,252,714; 5,643,575; 5,919,455; 5,932,462; and 5,985,263. PEG-IL-10 is described in, e.g., U.S. Pat. No. 7,052,686. Specific reaction conditions contemplated for use herein are set forth in the Experimental section.

[00178] As indicated above, pegylation most frequently occurs at the N-terminus, the side chain of lysine residues, and the imidazole group on the side chain of histidine residues. The usefulness of such pegylation has been enhanced by refinement by, for example, optimization of reaction conditions and improvement of purification processes. More recent residue-specific chemistries have enabled pegylation of arginine, aspartic acid, cysteine, glutamic acid, serine, threonine, and tyrosine, as well as the carboxy-terminus. Some of these amino acid residues can be specifically pegylated, while others are more promiscuous or only result in site-specific pegylation under certain conditions.

[00179] Current approaches allowing pegylation of additional amino acid residues include bridging pegylation (disulfide bridges), enzymatic pegylation (glutamines and C-terminus) and glycopegylation (sites of O- and N-glycosylation or the glycans of a glycoprotein), and heterobifunctional pegylation. Further approaches are drawn to pegylation of proteins containing unnatural amino acids, intein fusion proteins for C-terminal pegylation, transglutaminase-mediated pegylation, sortase A-mediated pegylation, and releasable and non-covalent pegylation. In addition, combination of specific pegylation approaches with genetic engineering techniques has enabled the polyethylene glycan polymer to essentially couple at any position on the protein surface due to, for example, substitution of specific amino acid residues in a polypeptide with a natural or unnatural amino acid bearing an orthogonal reactive group. See generally, e.g., Pasut, G. and Veronese, F.M., (2012) *J. Controlled Release* 161:461-72; Roberts, M.J. et al., (2012) *Advanced Drug Delivery Rev.* 64:116-27; Jevsevar, S. et al., (2010) *Biotechnol. J.* 5:113-28; and Yoshioka, Y. (2011) *Chem. Central J.* 5:25.

[00180] The therapeutic value of pegylation molecules is well validated. Previous and/or current pharmaceutical products include: OMONTYS (Affymax/Takeda); PEGLOTICASE (Savient); CIMZIA (Nektar/UCB Pharma); MACUGEN (Prizer); NEULASTA (Amgen);

SOMAVERT (Prizer); PEGASYS (Roche); DOXIL (Ortho Biotech) and PEGINTRON (Schering-Plough).

[00181] The present disclosure also contemplates the use of PEG mimetics. Recombinant PEG mimetics have been developed that retain the attributes of PEG (e.g., enhanced serum half-life) while conferring several additional advantageous properties. By way of example, simple polypeptide chains (comprising, for example, Ala, Glu, Gly, Pro, Ser and Thr) capable of forming an extended conformation similar to PEG can be produced recombinantly already fused to the peptide or protein drug of interest (e.g., Amunix' XTEN technology; Mountain View, CA). This obviates the need for an additional conjugation step during the manufacturing process. Moreover, established molecular biology techniques enable control of the side chain composition of the polypeptide chains, allowing optimization of immunogenicity and manufacturing properties.

[00182] Glycosylation: For purposes of the present disclosure, "glycosylation" is meant to broadly refer to the enzymatic process that attaches glycans to proteins, lipids or other organic molecules. The use of the term "glycosylation" in conjunction with the present disclosure is generally intended to mean adding or deleting one or more carbohydrate moieties (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that may or may not be present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins involving a change in the nature and proportions of the various carbohydrate moieties present.

[00183] Glycosylation can dramatically affect the physical properties (e.g., solubility) of polypeptides such as IL-10 and can also be important in protein stability, secretion, and subcellular localization. Glycosylated polypeptides may also exhibit enhanced stability or may improve one or more pharmacokinetic properties, such as half-life. In addition, solubility improvements can, for example, enable the generation of formulations more suitable for pharmaceutical administration than formulations comprising the non-glycosylated polypeptide.

[00184] Proper glycosylation can be essential for biological activity. In fact, some genes from eukaryotic organisms, when expressed in bacteria (e.g., E. coli) which lack cellular processes for glycosylating proteins, yield proteins that are recovered with little or no activity by virtue of their lack of glycosylation.

[00185] Addition of glycosylation sites can be accomplished by altering the amino acid sequence. The alteration to the polypeptide may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues (for O-linked glycosylation sites) or asparagine residues (for N-linked glycosylation sites). The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type may be different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (hereafter referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycoprotein. A particular embodiment of the present disclosure comprises the generation and use of N-glycosylation variants.

[00186] The polypeptide sequences of the present disclosure may optionally be altered through changes at the nucleic acid level, particularly by mutating the nucleic acid encoding the polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. Another means of increasing the number of carbohydrate moieties on the polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Removal of carbohydrates may be accomplished chemically or enzymatically, or by substitution of codons encoding amino acid residues that are glycosylated. Chemical deglycosylation techniques are known, and enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases.

[00187] Dihydrofolate reductase (DHFR) - deficient Chinese Hamster Ovary (CHO) cells are a commonly used host cell for the production of recombinant glycoproteins. These cells do not express the enzyme beta-galactoside alpha-2,6-sialyltransferase and therefore do not add sialic acid in the alpha-2,6 linkage to N-linked oligosaccharides of glycoproteins produced in these cells.

[00188] Polysialylation: The present disclosure also contemplates the use of polysialylation, the conjugation of polypeptides to the naturally occurring, biodegradable α -(2 $\rightarrow$ 8) – linked polysialic acid (“PSA”) in order to improve the polypeptides’ stability and in vivo pharmacokinetics. PSA is a biodegradable, non-toxic natural polymer that is highly hydrophilic, giving it a high apparent molecular weight in the blood which increases its serum half-life. In addition, polysialylation of a range of peptide and protein therapeutics has led to markedly reduced proteolysis, retention of in vivo activity, and reduction in immunogenicity and antigenicity (see, e.g., G. Gregoriadis et al., Int. J. Pharmaceutics (2005) 300(1-2):125-30).

As with modifications with other conjugates (e.g., PEG), various techniques for site-specific polysialylation are available (see, e.g., T. Lindhout et al., (2011) PNAS 108(18)7397-7402).

[00189] Albumin Fusion: Additional suitable components and molecules for conjugation include albumins such as human serum albumin (HSA), cyno serum albumin, and bovine serum albumin (BSA).

[00190] Mature HSA, a 585 amino acid polypeptide (~67kDa) having a serum half-life of ~20 days, is primarily responsible for the maintenance of colloidal osmotic blood pressure, blood pH, and transport and distribution of numerous endogenous and exogenous ligands. The protein has three structurally homologous domains (domains I, II and III), is almost entirely in the alpha-helical conformation, and is highly stabilized by 17 disulphide bridges. The three primary drug binding regions of albumin are located on each of the three domains within sub-domains IB, IIA and IIIA.

[00191] Albumin synthesis takes place in the liver, which produces the short-lived, primary product preproalbumin. Thus, the full-length HSA has a signal peptide of 18 amino acids (MKWVTFISLLFLFSSAYS; SEQ ID NO:15) followed by a pro-domain of 6 amino acids (RGVFRR; SEQ ID NO:16); this 24 amino acid residue peptide may be referred to as the pre-pro domain. HSA can be expressed and secreted using its endogenous signal peptide as a pre-pro-domain. Alternatively, HSA can be expressed and secreted using a IgK signal peptide fused to a mature construct. Preproalbumin is rapidly co-translationally cleaved in the endoplasmic reticulum lumen at its amino terminus to produce the stable, 609-amino acid precursor polypeptide, proalbumin. Proalbumin then passes to the Golgi apparatus, where it is converted to the 585 amino acid mature albumin by a furin-dependent amino-terminal cleavage.

[00192] The primary amino acid sequences, structure, and function of albumins are highly conserved across species, as are the processes of albumin synthesis and secretion. Albumin serum proteins comparable to HSA are found in, for example, cynomolgus monkeys, cows, dogs, rabbits and rats. Of the non-human species, bovine serum albumin (BSA) is the most structurally similar to HSA (see, e.g., Kosa et al., Nov 2007 J Pharm Sci. 96(11):3117-24). The present disclosure contemplates the use of albumin from non-human species, including, but not limited to, those set forth above, in, for example, the drug development process.

[00193] According to the present disclosure, albumin may be conjugated to a drug molecule (e.g., a polypeptide described herein) at the carboxyl terminus, the amino terminus,

both the carboxyl and amino termini, and internally (see, e.g., USP 5,876,969 and USP 7,056,701).

[00194] In the HSA – drug molecule conjugates contemplated by the present disclosure, various forms of albumin may be used, such as albumin secretion pre-sequences and variants thereof, fragments and variants thereof, and HSA variants. Such forms generally possess one or more desired albumin activities. In additional embodiments, the present disclosure involves fusion proteins comprising a polypeptide drug molecule fused directly or indirectly to albumin, an albumin fragment, and albumin variant, etc., wherein the fusion protein has a higher plasma stability than the unfused drug molecule and/or the fusion protein retains the therapeutic activity of the unfused drug molecule. In some embodiments, the indirect fusion is effected by a linker, such as a peptide linker or a modified version thereof.

[00195] Intracellular cleavage may be carried out enzymatically by, for example, furin or caspase. Cells express a low level of these endogenous enzymes, which are capable of cleaving a portion of the fusion molecules intracellularly. Thus, some of the polypeptides are secreted from the cell without being conjugated to HSA, while others are secreted in the form of fusion molecules that comprise HSA. Embodiments of the present disclosure contemplate the use of various furin fusion constructs. For example, constructs may be designed that comprise the sequence RGRR (SEQ ID NO:17), RKRKRR (SEQ ID NO:18), RKRR (SEQ ID NO:19), or RRRKRR (SEQ ID NO:20).

[00196] The present disclosure also contemplates extra-cellular cleavage (ex-vivo cleavage) whereby the fusion molecules are secreted from the cell, subjected to purification, and then cleaved. It is understood that the excision may dissociate the entire HSA-linker complex from the mature IL-10, or less than the entire HSA-linker complex.

[00197] As alluded to above, fusion of albumin to one or more polypeptides of the present disclosure can, for example, be achieved by genetic manipulation, such that the nucleic acid coding for HSA, or a fragment thereof, is joined to the nucleic acid coding for the one or more polypeptide sequences. Thereafter, a suitable host can be transformed or transfected with the fused nucleotide sequences in the form of, for example, a suitable plasmid, so as to express a fusion polypeptide. The expression may be effected in vitro from, for example, prokaryotic or eukaryotic cells, or in vivo from, for example, a transgenic organism. In some embodiments of the present disclosure, the expression of the fusion protein is performed in mammalian cell lines, for example, CHO cell lines. Transformation is used broadly herein to refer to the genetic

alteration of a cell resulting from the direct uptake through the cell membrane, incorporation and expression of exogenous genetic material (exogenous nucleic acid). Transformation occurs naturally in some bacteria, but it can also be effected by artificial means in other cells.

[00198] Furthermore, albumin itself may be modified to extend its circulating half-life. Fusion of the modified albumin to IL-10 can be attained by the genetic manipulation techniques described above or by chemical conjugation; the resulting fusion molecule has a half-life that exceeds that of fusions with non-modified albumin (see WO2011/051489).

[00199] Alternative Albumin Binding Strategies: Several albumin – binding strategies have been developed as alternatives to direct fusion, including albumin binding through a conjugated fatty acid chain (acylation). Because serum albumin is a transport protein for fatty acids, these natural ligands with albumin – binding activity have been used for half-life extension of small protein therapeutics. For example, insulin detemir (LEVEMIR), an approved product for diabetes, comprises a myristyl chain conjugated to a genetically-modified insulin, resulting in a long-acting insulin analog.

[00200] The present disclosure contemplates fusion proteins which comprise an albumin binding domain (ABD) polypeptide sequence and the sequence of one or more of the polypeptides described herein. Any ABD polypeptide sequence described in the literature can be a component of the fusion proteins. The components of the fusion proteins can be optionally covalently bonded through a linker, such as those linkers described herein. In some embodiments of the present disclosure, the fusion proteins comprise the ABD polypeptide sequence as an N-terminal moiety and the polypeptides described herein as a C-terminal moiety.

[00201] The present disclosure also contemplates fusion proteins comprising a fragment of an albumin binding polypeptide, which fragment substantially retains albumin binding; or a multimer of albumin binding polypeptides or fragments thereof comprising at least two albumin binding polypeptides or fragments thereof as monomer units. For a general discussion of ABD and related technologies, see WO 2012/050923, WO 2012/050930, WO 2012/004384 and WO 2009/016043.

[00202] Conjugation with Other Molecules: Additional suitable components and molecules for conjugation include, for example, thyroglobulin; tetanus toxoid; Diphtheria toxoid; polyamino acids such as poly(D-lysine:D-glutamic acid); VP6 polypeptides of rotaviruses; influenza virus hemagglutinin, influenza virus nucleoprotein; Keyhole Limpet

Hemocyanin (KLH); and hepatitis B virus core protein and surface antigen; or any combination of the foregoing.

[00203] Thus, the present disclosure contemplates conjugation of one or more additional components or molecules at the N- and/or C-terminus of a polypeptide sequence, such as another polypeptide (e.g., a polypeptide having an amino acid sequence heterologous to the subject polypeptide), or a carrier molecule. Thus, an exemplary polypeptide sequence can be provided as a conjugate with another component or molecule.

[00204] A conjugate modification may result in a polypeptide sequence that retains activity with an additional or complementary function or activity derived from the second molecule. For example, a polypeptide sequence may be conjugated to a molecule, e.g., to facilitate solubility, storage, in vivo or shelf half-life or stability, reduction in immunogenicity, delayed or controlled release in vivo, etc. Other functions or activities include a conjugate that reduces toxicity relative to an unconjugated polypeptide sequence, a conjugate that targets a type of cell or organ more efficiently than an unconjugated polypeptide sequence, or a drug to further counter the causes or effects associated with a disease, disorder or condition as set forth herein (e.g., cancer).

[00205] An IL-10 polypeptide may also be conjugated to large, slowly metabolized macromolecules such as proteins; polysaccharides, such as sepharose, agarose, cellulose, or cellulose beads; polymeric amino acids, such as polyglutamic acid or polylysine; amino acid copolymers; inactivated virus particles; inactivated bacterial toxins, such as toxoid from diphtheria, tetanus, cholera, or leukotoxin molecules; inactivated bacteria; and dendritic cells. Such conjugated forms, if desired, can be used to produce antibodies against a polypeptide of the present disclosure.

[00206] Additional candidate components and molecules for conjugation include those suitable for isolation or purification. Particular non-limiting examples include binding molecules, such as biotin (biotin-avidin specific binding pair), an antibody, a receptor, a ligand, a lectin, or molecules that comprise a solid support, including, for example, plastic or polystyrene beads, plates, magnetic beads, test strips, and membranes.

[00207] Purification methods such as cation exchange chromatography may be used to separate conjugates by charge difference, which effectively separates conjugates into their various molecular weights. For example, the cation exchange column can be loaded and then washed with ~20 mM sodium acetate, pH ~4, and then eluted with a linear (0 M to 0.5 M) NaCl

gradient buffered at a pH of from about 3 to 5.5, e.g., at pH ~4.5. The content of the fractions obtained by cation exchange chromatography may be identified by molecular weight using conventional methods, for example, mass spectroscopy, SDS-PAGE, or other known methods for separating molecular entities by molecular weight.

[00208] Fc-fusion Molecules: In certain embodiments, the amino- or carboxyl- terminus of a polypeptide sequence of the present disclosure can be fused with an immunoglobulin Fc region (e.g., human Fc) to form a fusion conjugate (or fusion molecule). Fc fusion conjugates have been shown to increase the systemic half-life of biopharmaceuticals, and thus the biopharmaceutical product may require less frequent administration.

[00209] Fc binds to the neonatal Fc receptor (FcRn) in endothelial cells that line the blood vessels, and, upon binding, the Fc fusion molecule is protected from degradation and re-released into the circulation, keeping the molecule in circulation longer. This Fc binding is believed to be the mechanism by which endogenous IgG retains its long plasma half-life. More recent Fc-fusion technology links a single copy of a biopharmaceutical to the Fc region of an antibody to optimize the pharmacokinetic and pharmacodynamic properties of the biopharmaceutical as compared to traditional Fc-fusion conjugates.

[00210] Other Modifications: The present disclosure contemplates the use of other modifications, currently known or developed in the future, of IL-10 to improve one or more properties. One such method involves modification of the polypeptide sequences by hesylation, which utilizes hydroxyethyl starch derivatives linked to other molecules in order to modify the polypeptide sequences' characteristics. Various aspects of hesylation are described in, for example, U.S. Patent Appln. Nos. 2007/0134197 and 2006/0258607.

[00211] The present disclosure also contemplates fusion molecules comprising Small Ubiquitin-like Modifier (SUMO) as a fusion tag (LifeSensors, Inc.; Malvern, PA). Fusion of a polypeptide described herein to SUMO may convey several beneficial effects, including enhancement of expression, improvement in solubility, and/or assistance in the development of purification methods. SUMO proteases recognize the tertiary structure of SUMO and cleave the fusion protein at the C-terminus of SUMO, thus releasing a polypeptide described herein with the desired N-terminal amino acid.

[00212] The present disclosure also contemplates the use of PASylation™ (XL-Protein GmbH (Freising, Germany)). This technology expands the apparent molecular size of a protein

of interest, without having a negative impact on the therapeutic bioactivity of the protein, beyond the pore size of the renal glomeruli, thereby decreasing renal clearance of the protein.

[00213] Linkers: Linkers and their use have been described above. Any of the foregoing components and molecules used to modify the polypeptide sequences of the present disclosure may optionally be conjugated via a linker. Suitable linkers include “flexible linkers” which are generally of sufficient length to permit some movement between the modified polypeptide sequences and the linked components and molecules. The linker molecules are generally about 6-50 atoms long. The linker molecules may also be, for example, aryl acetylene, ethylene glycol oligomers containing 2-10 monomer units, diamines, diacids, amino acids, or combinations thereof. Suitable linkers can be readily selected and can be of any suitable length, such as 1 amino acid (e.g., Gly), 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30, 30-50 or more than 50 amino acids.

[00214] Exemplary flexible linkers include glycine polymers (G)_n, glycine-serine polymers (for example, (GS)_n, GSGGS_n (SEQ ID NO:21), GGGS_n (SEQ ID NO:22), (G_mS_o)_n, (G_mS_oG_m)_n, (G_mS_oG_mS_oG_m)_n (SEQ ID NO:23), (GSGGS_m)_n (SEQ ID NO:24), (GSGS_mG)_n (SEQ ID NO:25) and (GGGS_m)_n (SEQ ID NO:26), and combinations thereof, where m, and and o are each independently selected from an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. Glycine and glycine-serine polymers are relatively unstructured, and therefore may serve as a neutral tether between components. Exemplary flexible linkers include, but are not limited to GGSG (SEQ ID NO:27), GGSGG (SEQ ID NO:28), GSGSG (SEQ ID NO:29), GSGGG (SEQ ID NO:30), GGGSG (SEQ ID NO:31), and GSSSG (SEQ ID NO:32).

[00215] In certain embodiments of the present disclosure, PEG is conjugated to IL-10 through an activated linker that is covalently attached to one or more PEG molecules. A linker is “activated” if it is chemically reactive and ready for covalent attachment to a reactive group on a peptide. The present disclosure contemplates the use of any activated linker provided that it can accommodate one or more PEG molecules and form a covalent bond with an amino acid residue under suitable reaction conditions. In particular aspects, the activated linker attaches to an alpha amino group in a highly selective manner over other attachment sites (e.g., the epsilon amino group of lysine or the imino group of histidine).

[00216] In some embodiments, activated PEG can be represented by the formula: (PEG)_b-L', where PEG covalently attaches to a carbon atom of the linker to form an ether bond, b is 1 to

9 (i.e., 1 to 9 PEG molecules can be attached to the linker), and L' contains a reactive group (an activated moiety) which can react with, for example, an amino or imino group on an amino acid residue to provide a covalent attachment of the PEG to IL-10. In other embodiments, an activated linker (L') contains an aldehyde of the formula RCHO, where R is a linear or branched C₁₋₁₁ alkyl; after covalent attachment of an activated linker to IL-10, the linker contains 2 to 12 carbon atoms. The present disclosure contemplates embodiments wherein propionaldehyde is an exemplary activated linker. PEG-propionaldehyde (CH₂CH₂CHO) is described in US Patent No. 5,252,714 and is commercially available (e.g., Shearwater Polymers (Huntsville, AL). Other activated PEG-linkers can be obtained commercially from, e.g., Shearwater Polymers and Enzon, Inc. (Piscataway, N.J.).

[00217] In some embodiments, it is desirable to covalently attach more than one PEG molecule to IL-10, and a suitable activated branched (i.e., “multi-armed”) linker can be used. Any suitable branched PEG linker that covalently attaches two or more PEG molecules to an amino group on an amino acid residue of IL-10 (e.g., to an alpha amino group at the N-terminus) can be used. In particular embodiments, a branched linker used in this invention contains two or three PEG molecules. By way of example, a branched PEG linker can be a linear or branched aliphatic group that is hydrolytically stable and contains an activated moiety (e.g., an aldehyde group), which reacts with an amino group of an amino acid residue, as described above; the aliphatic group of a branched linker can contain 2 to 12 carbons. In some embodiments, an aliphatic group can be a t-butyl which contains as many as three PEG molecules on each of three carbon atoms (i.e., a total of 9 PEG molecules) and a reactive aldehyde moiety on the fourth carbon of the t-butyl.

[00218] Further exemplary branched PEG linkers are described in U.S. Pat. Nos. 5,643,575, 5,919,455, 7,052,868, and 5,932,462. The skilled artisan can prepare modifications to branched PEG linkers by, e.g., addition of a reactive aldehyde moiety. Methods for preparing linkers for use are also well known in the art, and are described in, e.g., the US patents listed above.

[00219] Exemplary linkers used in HSA conjugates are known in the art and include heterobifunctional linkers, such as [succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC), 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS), and N-[γ-maleimidobutyryloxy]sulfosuccinimide ester (GMBS)]. See Ehrlich, GK et al., Bioconjug.

Chem. (2013 Dec 18); 24(12):2015-24. Further examples of HSA linkers and conjugates thereof are described in, e.g., US20120003221.

Therapeutic and Prophylactic Uses

[00220] The present disclosure contemplates the use of the IL-10 polypeptides described herein (e.g., PEG-IL-10) in the treatment or prevention of a broad range of diseases, disorders and/or conditions, and/or the symptoms thereof. While particular uses are described in detail hereafter, it is to be understood that the present disclosure is not so limited. Furthermore, although general categories of particular diseases, disorders and conditions are set forth hereafter, some of the diseases, disorders and conditions may be a member of more than one category (e.g., cancer- and fibrotic-related disorders), and others may not be a member of any of the disclosed categories.

[00221] Fibrotic Disorders and Cancer. In accordance with the present disclosure, an IL-10 molecule can be used to treat or prevent a proliferative condition or disorder, including a cancer, for example, cancer of the uterus, cervix, breast, prostate, testes, gastrointestinal tract (e.g., esophagus, oropharynx, stomach, small or large intestines, colon, or rectum), kidney, renal cell, bladder, bone, bone marrow, skin, head or neck, liver, gall bladder, heart, lung, pancreas, salivary gland, adrenal gland, thyroid, brain (e.g., gliomas), ganglia, central nervous system (CNS) and peripheral nervous system (PNS), and cancers of the hematopoietic system and the immune system (e.g., spleen or thymus). The present disclosure also provides methods of treating or preventing other cancer-related diseases, disorders or conditions, including, for example, immunogenic tumors, non-immunogenic tumors, dormant tumors, virus-induced cancers (e.g., epithelial cell cancers, endothelial cell cancers, squamous cell carcinomas and papillomavirus), adenocarcinomas, lymphomas, carcinomas, melanomas, leukemias, myelomas, sarcomas, teratocarcinomas, chemically-induced cancers, metastasis, and angiogenesis. The disclosure contemplates reducing tolerance to a tumor cell or cancer cell antigen, e.g., by modulating activity of a regulatory T-cell and/or a CD8⁺ T-cell (see, e.g., Ramirez-Montagut, et al. (2003) Oncogene 22:3180-87; and Sawaya, et al. (2003) New Engl. J. Med. 349:1501-09). In particular embodiments, the tumor or cancer is colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, or leukemia. The use of the term(s) cancer-related diseases, disorders and conditions is meant to refer broadly to conditions that are associated,

directly or indirectly, with cancer, and includes, e.g., angiogenesis and precancerous conditions such as dysplasia.

[00222] In some embodiments, the present disclosure provides methods for treating a proliferative condition, cancer, tumor, or precancerous condition with an IL-10 molecule and at least one additional therapeutic or diagnostic agent, examples of which are set forth elsewhere herein.

[00223] The present disclosure also provides methods of treating or preventing fibrotic diseases, disorders and conditions. As used herein, the phrase “fibrotic diseases, disorders and conditions”, and similar terms (e.g., “fibrotic disorders”) and phrases, is to be construed broadly such that it includes any condition which may result in the formation of fibrotic tissue or scar tissue (e.g., fibrosis in one or more tissues). By way of example, injuries (e.g., wounds) that may give rise to scar tissue include wounds to the skin, eye, lung, kidney, liver, central nervous system, and cardiovascular system. The phrase also encompasses scar tissue formation resulting from stroke, and tissue adhesion, for example, as a result of injury or surgery.

[00224] As used herein the term “fibrosis” refers to the formation of fibrous tissue as a reparative or reactive process, rather than as a normal constituent of an organ or tissue. Fibrosis is characterized by fibroblast accumulation and collagen deposition in excess of normal deposition in any particular tissue.

[00225] Fibrotic disorders include, but are not limited to, fibrosis arising from wound healing, systemic and local scleroderma, atherosclerosis, restenosis, pulmonary inflammation and fibrosis, idiopathic pulmonary fibrosis, interstitial lung disease, liver cirrhosis, fibrosis as a result of chronic hepatitis B or C infection, kidney disease (e.g., glomerulonephritis), heart disease resulting from scar tissue, keloids and hypertrophic scars, and eye diseases such as macular degeneration, and retinal and vitreal retinopathy. Additional fibrotic diseases include chemotherapeutic drug-induced fibrosis, radiation-induced fibrosis, and injuries and burns.

[00226] Fibrotic disorders are often hepatic-related, and there is frequently a nexus between such disorders and the inappropriate accumulation of liver cholesterol and triglycerides within the hepatocytes. This accumulation appears to result in a pro-inflammatory response that leads to liver fibrosis and cirrhosis. Hepatic disorders having a fibrotic component include non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NAFLD occurs when steatosis (fat deposition in the liver) is present that is not due to excessive alcohol

use. It is related to insulin resistance and the metabolic syndrome. NASH is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause.

[00227] Cardiovascular Diseases. The present disclosure also contemplates the use of the IL-10 molecules described herein to treat and/or prevent certain cardiovascular- and/or associated metabolic-related diseases, disorders and conditions, as well as disorders associated therewith.

[00228] As used herein, the terms “cardiovascular disease”, “heart disease” and the like refer to any disease that affects the cardiovascular system, primarily cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial diseases. Cardiovascular disease is a constellation of diseases that includes coronary heart disease (i.e., ischemic heart disease or coronary artery disease), atherosclerosis, cardiomyopathy, hypertension, hypertensive heart disease, cor pulmonale, cardiac dysrhythmias, endocarditis, cerebrovascular disease, and peripheral arterial disease. Cardiovascular disease is the leading cause of deaths worldwide, and while it usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life.

[00229] Particular embodiments of the present disclosure are directed to the use of IL-10 polypeptides to treat and/or prevent atherosclerosis, a chronic condition in which an artery wall thickens to form plaques as a result of the accumulation of fatty materials such as cholesterol and triglycerides. Atherosclerosis frequently involves a chronic inflammatory response in the walls of arteries, caused largely by the accumulation of macrophages and promoted by low-density lipoproteins (LDL) without adequate removal of fats and cholesterol from the macrophages by functional high-density lipoproteins. Chronically expanding atherosclerotic lesions can cause complete closure of the lumen, which may only manifest when the lumen stenosis is so severe that blood supply to downstream tissue(s) is insufficient, resulting in ischemia.

[00230] The IL-10 polypeptides may be particularly advantageous in the treatment and/or prevention of cholesterol-related disorders, which may be associated with, for example, cardiovascular disease (e.g. atherosclerosis), cerebrovascular disease (e.g., stroke), and peripheral vascular disease. By way of example, but not limitation, the IL-10 polypeptides may be used for lowering a subject's blood cholesterol level. In determining whether a subject has hypercholesterolemia, there is no firm demarcation between normal and abnormal cholesterol levels, and interpretation of values needs to be made in relation to other health conditions and

risk factors. Nonetheless, the following guidelines are generally used in the United States: total cholesterol < 200 mg/dL is desirable, 200-239 mg/dL is borderline high, and ≥ 240 mg/dL is high. Higher levels of total cholesterol increase the risk of cardiovascular disease, and levels of LDL or non-HDL cholesterol are both predictive of future coronary heart disease. When assessing hypercholesterolemia, it is frequently useful to measure all lipoprotein subfractions (VLDL, IDL, LDL and HDL). A particular therapeutic goal is to decrease LDL while maintaining or increasing HDL.

[00231] Thrombosis and Thrombotic Conditions. Thrombosis, the formation of a thrombus (blood clot) inside a blood vessel resulting in obstruction of the flow of blood through the circulatory system, may be caused by abnormalities in one or more of the following (Virchow's triad): hypercoagulability, endothelial cell injury, or disturbed blood flow (stasis, turbulence).

[00232] Thrombosis is generally categorized as venous or arterial, each of which can be presented by several subtypes. Venous thrombosis includes deep vein thrombosis (DVT), portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schroetter disease, and cerebral venous sinus thrombosis. Arterial thrombosis includes stroke and myocardial infarction.

[00233] Other diseases, disorders and conditions are contemplated by the present disclosure, including atrial thrombosis and Polycythemia vera (also known as erythema, primary polycythemia and polycythemia rubra vera), a myeloproliferative blood disorder in which the bone marrow makes too many RBCs, WBCs and/or platelets.

[00234] Immune and Inflammatory Conditions. As used herein, terms such as "immune disease", "immune condition", "immune disorder", "inflammatory disease", "inflammatory condition", "inflammatory disorder" and the like are meant to broadly encompass any immune- or inflammatory-related condition (e.g., pathological inflammation and autoimmune diseases). Such conditions frequently are inextricably intertwined with other diseases, disorders and conditions. By way of example, an "immune condition" may refer to proliferative conditions, such as cancer, tumors, and angiogenesis; including infections (acute and chronic), tumors, and cancers that resist eradication by the immune system.

[00235] A non-limiting list of immune- and inflammatory-related diseases, disorders and conditions which may, for example, be caused by inflammatory cytokines, include, arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, surgical

complications (e.g., where inflammatory cytokines prevent healing), anemia, and fibromyalgia. Other diseases and disorders which may be associated with chronic inflammation include Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), allergic contact dermatitis and other eczemas, systemic sclerosis, transplantation and multiple sclerosis.

[00236] Some of the aforementioned diseases, disorders and conditions for which an IL-10 molecule may be particularly efficacious (due to, for example, limitations of current therapies) are described in more detail hereafter.

[00237] The IL-10 polypeptides of the present disclosure may be particularly effective in the treatment and prevention of inflammatory bowel diseases (IBD). IBD comprises Crohn's disease (CD) and ulcerative colitis (UC), both of which are idiopathic chronic diseases that can affect any part of the gastrointestinal tract, and are associated with many untoward effects, and patients with prolonged UC are at an increased risk of developing colon cancer. Current IBD treatments are aimed at controlling inflammatory symptoms, and while certain agents (e.g., corticosteroids, aminosalicylates and standard immunosuppressive agents (e.g., cyclosporine, azathioprine, and methotrexate)) have met with limited success, long-term therapy may cause liver damage (e.g., fibrosis or cirrhosis) and bone marrow suppression, and patients often become refractory to such treatments.

[00238] Psoriasis, a constellation of common immune-mediated chronic skin diseases, affects more than 4.5 million people in the U.S., of which 1.5 million are considered to have a moderate-to severe form of the disease. Moreover, over 10% of patients with psoriasis develop psoriatic arthritis, which damages the bone and connective tissue around the joints. An improved understanding of the underlying physiology of psoriasis has resulted in the introduction of agents that, for example, target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of the disease. Such agents include the TNF- α inhibitors (also used in the treatment of rheumatoid arthritis (RA)), including ENBREL (etanercept), REMICADE (infliximab) and HUMIRA (adalimumab), and T-cell inhibitors such as AMEVIVE (alefacept) and RAPTIVA (efalizumab). Though several of these agents are effective to some extent in certain patient populations, none have been shown to effectively treat all patients.

[00239] Rheumatoid Arthritis (RA), which is generally characterized by chronic inflammation in the membrane lining (the synovium) of the joints, affects approximately 1% of the U.S. population (~2.1 million people). Further understanding of the role of cytokines, including TNF- α and IL-1, in the inflammatory process has enabled the development and introduction of a new class of disease-modifying antirheumatic drugs (DMARDs). Agents (some of which overlap with treatment modalities for RA) include ENBREL (etanercept), REMICADE (infliximab), HUMIRA (adalimumab) and KINERET (anakinra). Though some of these agents relieve symptoms, inhibit progression of structural damage, and improve physical function in particular patient populations, there is still a need for alternative agents with improved efficacy, complementary mechanisms of action, and fewer/less severe adverse effects.

[00240] Subjects suffering from multiple sclerosis (MS), a seriously debilitating autoimmune disease comprising multiple areas of inflammation and scarring of the myelin in the brain and spinal cord, may be particularly helped by the IL-10 polypeptides described herein, as current treatments only alleviate symptoms or delay the progression of disability.

[00241] Similarly, the IL-10 polypeptides may be particularly advantageous for subjects afflicted with neurodegenerative disorders, such as Alzheimer's disease (AD), a brain disorder that seriously impairs patients' thought, memory, and language processes; and Parkinson's disease (PD), a progressive disorder of the CNS characterized by, for example, abnormal movement, rigidity and tremor. These disorders are progressive and debilitating, and no curative agents are available.

[00242] Viral Diseases. There has been increased interest in the role of IL-10 in viral diseases. IL-10 has been postulated to produce both stimulatory and inhibitory effects depending on its receptor binding activity.

[00243] The effect of inhibiting IL-10 function in order to increase antiviral immunity and vaccine efficacy has been considered (see Wilson, E., (2011) Curr. Top. Microbiol. Immunol. 350:39–65). Moreover, the role of IL-10 in human immunodeficiency virus (HIV) function has been studied. In addition to the inhibition of human immunodeficiency virus type 1 (HIV-1) replication, IL-10 may also promote viral persistence by inactivation of effector immune mechanisms (Naicker, D., et al., (2009) J. Infect. Dis. 200 (3):448-452). Another study has identified an IL-10 – producing subset of B-cells able to regulate T-cell immunity in chronic hepatitis B virus (HBV) infection. A close temporal correlation was observed between IL-10 levels and fluctuations in viral load, and in vitro blockade of IL-10 was found to rescue

polyfunctional, virus-specific CD8⁺ T-cell responses (Das, A., et al., J. Immunol., Sept. 12, 2012 1103139 (on-line)).

[00244] Although the aforementioned studies indicate that IL-10 inhibition may be beneficial, particular viral infections that comprise a CD8⁺ T-cell component may be candidates for treatment and/or prevention through the administration of IL-10. This is supported by the positive role that IL-10 plays in certain cancers by modulation of regulatory T cells and/or CD8⁺ T cells. The use of IL-10 therapy in viral contexts has also been discussed elsewhere (see, e.g., J. Virol. July 2011 vol. 85 no. 14 6822-683; and Loebbermann J, et al. (2012) PLoS ONE 7(2): e32371. doi:10.1371/journal.pone.0032371).

[00245] The present disclosure contemplates the use of the IL-10 polypeptides in the treatment and/or prevention of any viral disease, disorder or condition for which treatment with IL-10 may be beneficial. Examples of viral diseases, disorders and conditions that are contemplated include hepatitis B, hepatitis C, HIV, herpes virus and cytomegalovirus (CMV).

Pharmaceutical Compositions

[00246] The IL-10 polypeptides of the present disclosure may be in the form of compositions suitable for administration to a subject. In general, such compositions are “pharmaceutical compositions” comprising IL-10 and one or more pharmaceutically acceptable or physiologically acceptable diluents, carriers or excipients. In certain embodiments, the IL-10 polypeptides are present in a therapeutically acceptable amount. The pharmaceutical compositions may be used in the methods of the present disclosure; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic and prophylactic methods and uses described herein.

[00247] The pharmaceutical compositions of the present disclosure can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein. Furthermore, the pharmaceutical compositions may be used in combination with other therapeutically active agents or compounds as described herein in order to treat or prevent the diseases, disorders and conditions as contemplated by the present disclosure.

[00248] The pharmaceutical compositions typically comprise a therapeutically effective amount of an IL-10 polypeptide contemplated by the present disclosure and one or more pharmaceutically and physiologically acceptable formulation agents. Suitable pharmaceutically

acceptable or physiologically acceptable diluents, carriers or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl alcohol, methyl parabens, ethyl or n-propyl, p-hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants. For example, a suitable vehicle may be physiological saline solution or citrate buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffering agents include, for example, a Tris buffer, N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-Morpholino)propanesulfonic acid (MOPS), and N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

[00249] After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampoule, syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas a multi-use container (e.g., a multi-use vial) is provided in other embodiments. Any drug delivery apparatus may be used to deliver IL-10, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan. Depot injections, which are generally administered subcutaneously or intramuscularly, may also be utilized to release the polypeptides disclosed herein over a defined period of time. Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein. One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.

[00250] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or

[00251] oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Acceptable diluents, solvents and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. Moreover, fatty acids such as oleic acid, find use in the preparation of injectables. Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).

[00252] The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs. Pharmaceutical compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents such as, for example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.

[00253] The tablets, capsules and the like suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action. For example, a time-delay material

such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by techniques known in the art to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers in order to control delivery of an administered composition. For example, the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly (methylmethacrolate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations will be apparent to those skilled in the art.

[00254] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[00255] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., polyoxy-ethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives.

[00256] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil

such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[00257] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.

[00258] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.

[00259] Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including implants, liposomes, hydrogels, prodrugs and microencapsulated delivery systems. For example, a time delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed.

[00260] The present disclosure contemplates the administration of the IL-10 polypeptides in the form of suppositories for rectal administration. The suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols.

[00261] The IL-10 polypeptides contemplated by the present disclosure may be in the form of any other suitable pharmaceutical composition (e.g., sprays for nasal or inhalation use) currently known or developed in the future.

[00262] The concentration of a polypeptide or fragment thereof in a formulation can vary widely (e.g., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight) and will usually be selected primarily based on fluid volumes,

viscosities, and subject-based factors in accordance with, for example, the particular mode of administration selected.

Routes of Administration

[00263] The present disclosure contemplates the administration of IL-10 molecules, and compositions thereof, in any appropriate manner. Suitable routes of administration include parenteral (e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebroventricular), oral, nasal, vaginal, sublingual, intraocular, rectal, topical (e.g., transdermal), sublingual and inhalation. Depot injections, which are generally administered subcutaneously or intramuscularly, may also be utilized to release the IL-10 molecules disclosed herein over a defined period of time.

[00264] Particular embodiments of the present disclosure contemplate parenteral administration, and in further particular embodiments the parenteral administration is subcutaneous.

Combination Therapy

[00265] The present disclosure contemplates the use of IL-10 molecules in combination with one or more active therapeutic agents (e.g., cytokines) or other prophylactic or therapeutic modalities (e.g., radiation). In such combination therapy, the various active agents frequently have different, complementary mechanisms of action. Such combination therapy may be especially advantageous by allowing a dose reduction of one or more of the agents, thereby reducing or eliminating the adverse effects associated with one or more of the agents. Furthermore, such combination therapy may have a synergistic therapeutic or prophylactic effect on the underlying disease, disorder, or condition.

[00266] As used herein, “combination” is meant to include therapies that can be administered separately, for example, formulated separately for separate administration (e.g., as may be provided in a kit), and therapies that can be administered together in a single formulation (i.e., a “co-formulation”).

[00267] In certain embodiments, the IL-10 polypeptides and the one or more active therapeutic agents or other prophylactic or therapeutic modalities are administered or applied sequentially, e.g., where one agent is administered prior to one or more other agents. In other

embodiments, the IL-10 polypeptides and the one or more active therapeutic agents or other prophylactic or therapeutic modalities are administered simultaneously, e.g., where two or more agents are administered at or about the same time; the two or more agents may be present in two or more separate formulations or combined into a single formulation (i.e., a co-formulation). Regardless of whether the two or more agents are administered sequentially or simultaneously, they are considered to be administered in combination for purposes of the present disclosure.

[00268] The IL-10 polypeptides of the present disclosure may be used in combination with at least one other (active) agent in any manner appropriate under the circumstances. In one embodiment, treatment with the at least one active agent and at least one IL-10 polypeptide of the present disclosure is maintained over a period of time. In another embodiment, treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with the IL-10 polypeptide of the present disclosure is maintained at a constant dosing regimen. In a further embodiment, treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with the IL-10 polypeptide of the present disclosure is reduced (e.g., lower dose, less frequent dosing or shorter treatment regimen). In yet another embodiment, treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), and treatment with the IL-10 polypeptide of the present disclosure is increased (e.g., higher dose, more frequent dosing or longer treatment regimen). In yet another embodiment, treatment with the at least one active agent is maintained and treatment with the IL-10 polypeptide of the present disclosure is reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen). In yet another embodiment, treatment with the at least one active agent and treatment with the IL-10 polypeptide of the present disclosure are reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen).

[00269] Fibrotic Disorders and Cancer. The present disclosure provides methods for treating and/or preventing a proliferative condition; a fibrotic disease, disorder, or condition; cancer, tumor, or precancerous disease, disorder or condition with an IL-10 molecule and at least one additional therapeutic or diagnostic agent.

[00270] Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine,

triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabycin, caminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenishers such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (Ara-C); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel and doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum and platinum coordination complexes such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT11; topoisomerase inhibitors; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

[00271] Chemotherapeutic agents also include anti-hormonal agents that act to regulate or inhibit hormonal action on tumors such as anti-estrogens, including for example tamoxifen,

raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, onapristone, and toremifene; and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. In certain embodiments, combination therapy comprises administration of a hormone or related hormonal agent.

[00272] Additional treatment modalities that may be used in combination with the IL-10 polypeptides include a cytokine or cytokine antagonist, such as IL-12, $\text{INF}\alpha$, or anti-epidermal growth factor receptor, radiotherapy, a monoclonal antibody against another tumor antigen, a complex of a monoclonal antibody and toxin, a T-cell adjuvant, bone marrow transplant, or antigen presenting cells (e.g., dendritic cell therapy). Vaccines (e.g., as a soluble protein or as a nucleic acid encoding the protein) are also provided herein.

[00273] Therapeutic agents useful in combination therapy for the treatment of fibrotic disorders are well known to the skilled artisan. By way of example, agents such as those described herein for the treatment of insulin resistant-states (e.g., diabetes mellitus type 2) and the metabolic syndrome (e.g., metformin, thiazolidinediones, and statins) may help control NAFLD and NASH, particularly manifestations thereof. Vitamin E has also been shown to help control NAFLD and NASH in some patients.

[00274] The present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.

[00275] Cardiovascular Diseases. The present disclosure provides methods for treating and/or preventing certain cardiovascular- and/or metabolic-related diseases, disorders and conditions, as well as disorders associated therewith, with an IL-10 molecule and at least one additional therapeutic or diagnostic agent.

[00276] Examples of therapeutic agents useful in combination therapy for the treatment of hypercholesterolemia (and atherosclerosis as well) include statins (e.g., CRESTOR, LESCOL, LIPITOR, MEVACOR, PRAVACOL, and ZOCOR), which inhibit the enzymatic synthesis of cholesterol; bile acid resins (e.g., COLESTID, LO-CHOLEST, PREVALITE, QUESTRAN, and WELCHOL), which sequester cholesterol and prevent its absorption; ezetimibe (ZETIA), which blocks cholesterol absorption; fibric acid (e.g., TRICOR), which reduces triglycerides and may modestly increase HDL; niacin (e.g., NIACOR), which modestly lowers LDL cholesterol and triglycerides; and/or a combination of the aforementioned (e.g., VYTORIN (ezetimibe with simvastatin). Alternative cholesterol treatments that may be

candidates for use in combination with the IL-10 polypeptides described herein include various supplements and herbs (e.g., garlic, policosanol, and guggul). The present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.

[00277] Immune and Inflammatory Conditions. The present disclosure provides methods for treating and/or preventing immune- and/or inflammatory-related diseases, disorders and conditions, as well as disorders associated therewith, with an IL-10 molecule and at least one additional therapeutic or diagnostic agent.

[00278] Examples of therapeutic agents useful in combination therapy include, but are not limited to, the following: non-steroidal anti-inflammatory drug (NSAID) such as aspirin, ibuprofen, and other propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, piroprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone). Other combinations include cyclooxygenase-2 (COX-2) inhibitors.

[00279] Other active agents for combination include steroids such as prednisolone, prednisone, methylprednisolone, betamethasone, dexamethasone, or hydrocortisone. Such a combination may be especially advantageous since one or more adverse affects of the steroid can be reduced or even eliminated by tapering the steroid dose required.

[00280] Additional examples of active agents that may be used in combinations for treating, for example, rheumatoid arthritis, include cytokine suppressive anti-inflammatory drug(s) (CSAIDs); antibodies to, or antagonists of, other human cytokines or growth factors, for example, TNF, LT, IL-1 β , IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, or PDGF.

[00281] Particular combinations of active agents may interfere at different points in the autoimmune and subsequent inflammatory cascade, and include TNF antagonists such as chimeric, humanized or human TNF antibodies, REMICADE, anti-TNF antibody fragments

(e.g., CDP870), and soluble p55 or p75 TNF receptors, derivatives thereof, p75TNFR1gG (ENBREL.) or p55TNFR1gG (LENERCEPT), soluble IL-13 receptor (sIL-13), and also TNF α -converting enzyme (TACE) inhibitors; similarly, IL-1 inhibitors (e.g., Interleukin-1-converting enzyme inhibitors) may be effective. Other combinations include Interleukin 11, anti-P7s and p-selectin glycoprotein ligand (PSGL). Other examples of agents useful in combination with the IL-10 polypeptides described herein include interferon- β 1a (AVONEX); interferon- β 1b (BETASERON); copaxone; hyperbaric oxygen; intravenous immunoglobulin; clabribine; and antibodies to, or antagonists of, other human cytokines or growth factors (e.g., antibodies to CD40 ligand and CD80).

[00282] The present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.

[00283] Viral Diseases. The present disclosure provides methods for treating and/or preventing viral diseases, disorders and conditions, as well as disorders associated therewith, with an IL-10 molecule and at least one additional therapeutic or diagnostic agent (e.g., one or more other antiviral agents and/or one or more agents not associated with viral therapy).

[00284] Such combination therapy includes anti-viral agents targeting various viral life-cycle stages and having different mechanisms of action, including, but not limiting to, the following: inhibitors of viral uncoating (e.g., amantadine and rimantidine); reverse transcriptase inhibitors (e.g., acyclovir, zidovudine, and lamivudine); agents that target integrase; agents that block attachment of transcription factors to viral DNA; agents (e.g., antisense molecules) that impact translation (e.g., fomivirsen); agents that modulate translation/ribozyme function; protease inhibitors; viral assembly modulators (e.g., rifampicin); and agents that prevent release of viral particles (e.g., zanamivir and oseltamivir). Treatment and/or prevention of certain viral infections (e.g., HIV) frequently entail a group (“cocktail”) of antiviral agents.

[00285] Other antiviral agents contemplated for use in combination with IL-10 polypeptides include, but are not limited to, the following: abacavir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, various interferons (e.g., peginterferon alfa-2a), lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, ritonavir, pyrimidine,

saquinavir, stavudine, telaprevir, tenofovir, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, and zalcitabine.

[00286] The present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.

Dosing

[00287] The IL-10 polypeptides of the present disclosure may be administered to a subject in an amount that is dependent upon, for example, the goal of administration (e.g., the degree of resolution desired); the age, weight, sex, and health and physical condition of the subject to which the formulation is being administered; the route of administration; and the nature of the disease, disorder, condition or symptom thereof. The dosing regimen may take into consideration the existence, nature, and extent of any adverse effects associated with the agent(s) being administered. Effective dosage amounts and dosage regimens can readily be determined from, for example, safety and dose-escalation trials, in vivo studies (e.g., animal models), and other methods known to the skilled artisan.

[00288] In general, dosing parameters dictate that the dosage amount be less than an amount that could be irreversibly toxic to the subject (the maximum tolerated dose (MTD)) and not less than an amount required to produce a measurable effect on the subject. Such amounts are determined by, for example, the pharmacokinetic and pharmacodynamic parameters associated with ADME, taking into consideration the route of administration and other factors.

[00289] An effective dose (ED) is the dose or amount of an agent that produces a therapeutic response or desired effect in some fraction of the subjects taking it. The “median effective dose” or ED50 of an agent is the dose or amount of an agent that produces a therapeutic response or desired effect in 50% of the population to which it is administered. Although the ED50 is commonly used as a measure of reasonable expectance of an agent’s effect, it is not necessarily the dose that a clinician might deem appropriate taking into consideration all relevant factors. Thus, in some situations the effective amount is more than the calculated ED50, in other situations the effective amount is less than the calculated ED50, and in still other situations the effective amount is the same as the calculated ED50.

[00290] In addition, an effective dose of the IL-10 molecules of the present disclosure may be an amount that, when administered in one or more doses to a subject, produces a desired result relative to a healthy subject. For example, for a subject experiencing a particular disorder,

an effective dose may be one that improves a diagnostic parameter, measure, marker and the like of that disorder by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, where 100% is defined as the diagnostic parameter, measure, marker and the like exhibited by a normal subject.

[00291] The amount of an IL-10 molecule necessary to treat a disease, disorder or condition described herein is based on the IL-10 activity of the conjugated protein, which can be determined by IL-10 activity assays known in the art. By way of example, in the tumor context suitable IL-10 activity includes, for example, CD8⁺ T-cell infiltration into tumor sites, expression of inflammatory cytokines, such as IFN- γ , IL-4, IL-6, IL-10, and RANK-L, from these infiltrating cells, and increased levels of TNF- α or IFN- γ in biological samples.

[00292] The therapeutically effective amount of an IL-10 molecule can range from about 0.01 to about 100 μ g protein/kg of body weight/day, from about 0.1 to 20 μ g protein/kg of body weight/day, from about 0.5 to 10 μ g protein/kg of body weight/day, or from about 1 to 4 μ g protein/kg of body weight/day. In some embodiments, the therapeutically effective amount of an IL-10 molecule can range from about 1 to 16 μ g protein/kg of body weight/day. The present disclosure contemplates the administration of an IL-10 molecule by continuous infusion to delivery, e.g., about 50 to 800 μ g protein/kg of body weight/day. The infusion rate may be varied based on evaluation of, for example, adverse effects and blood cell counts.

[00293] For administration of an oral agent, the compositions can be provided in the form of tablets, capsules and the like containing from 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 3.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, or 1000.0 milligrams of the active ingredient..

[00294] In certain embodiments, the dosage of the disclosed IL-10 polypeptide is contained in a “unit dosage form”. The phrase “unit dosage form” refers to physically discrete units, each unit containing a predetermined amount of a IL-10 polypeptide of the present disclosure, either alone or in combination with one or more additional agents, sufficient to produce the desired effect. It will be appreciated that the parameters of a unit dosage form will depend on the particular agent and the effect to be achieved.

Kits

[00295] The present disclosure also contemplates kits comprising IL-10, and pharmaceutical compositions thereof. The kits are generally in the form of a physical structure housing various components, as described below, and may be utilized, for example, in practicing the methods described herein (e.g., administration of an IL-10 molecule to a subject in need of restoring cholesterol homeostasis).

[00296] A kit can include one or more of the IL-10 polypeptides disclosed herein (provided in, e.g., a sterile container), which may be in the form of a pharmaceutical composition suitable for administration to a subject. The IL-10 polypeptides can be provided in a form that is ready for use or in a form requiring, for example, reconstitution or dilution prior to administration. When the IL-10 polypeptides are in a form that needs to be reconstituted by a user, the kit may also include buffers, pharmaceutically acceptable excipients, and the like, packaged with or separately from the IL-10 polypeptides. When combination therapy is contemplated, the kit may contain the several agents separately or they may already be combined in the kit. Each component of the kit may be enclosed within an individual container, and all of the various containers may be within a single package. A kit of the present disclosure may be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing).

[00297] A kit may contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism of action, pharmacokinetics and pharmacodynamics, adverse effects, contraindications, etc.). Labels or inserts can include manufacturer information such as lot numbers and expiration dates. The label or packaging insert may be, e.g., integrated into the physical structure housing the components, contained separately within the physical structure, or affixed to a component of the kit (e.g., an ampule, tube or vial).

[00298] Labels or inserts can additionally include, or be incorporated into, a computer readable medium, such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory-type cards. In some embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g., via the internet, are provided.

EXPERIMENTAL

[00299] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below were performed and are all of the experiments that may be performed. It is to be understood that exemplary descriptions written in the present tense were not necessarily performed, but rather that the descriptions can be performed to generate the data and the like described therein. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental errors and deviations should be accounted for.

[00300] Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius (°C), and pressure is at or near atmospheric. Standard abbreviations are used, including the following: bp = base pair(s); kb = kilobase(s); pl = picoliter(s); s or sec = second(s); min = minute(s); h or hr = hour(s); aa = amino acid(s); kb = kilobase(s); nt = nucleotide(s); ng = nanogram; µg = microgram; mg = milligram; g = gram; kg = kilogram; dl or dL = deciliter; µl or µL = microliter; ml or mL = milliliter; l or L = liter; nM = nanomolar; µM = micromolar; mM = millimolar; M = molar; kDa = kilodalton; i.m. = intramuscular(ly); i.p. = intraperitoneal(ly); s.c. = subcutaneous(ly); QD = daily; BID = twice daily; QW = weekly; QM = monthly; HPLC = high performance liquid chromatography; BW = body weight; U = unit; ns = not statistically significant; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; NHS = N-Hydroxysuccinimide; DMEM = Dulbecco's Modification of Eagle's Medium; GC = genome copy; ELISA = enzyme-linked immuno sorbent assay; EDTA = ethylenediaminetetraacetic acid; PMA = phorbol myristate acetate; rhIL-10 = recombinant human IL-10; LPS = lipopolysaccarhide.

Materials and Methods

[00301] The following general materials and methods may be used in the Examples below:

[00302] Standard methods in molecular biology are described (see, e.g., Sambrook and Russell (2001) Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; and Ausubel, et al. (2001) Current Protocols in Molecular Biology, Vols. 1-4,

John Wiley and Sons, Inc. New York, N.Y., which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4)).

[00303] The scientific literature describes methods for protein purification, including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization, as well as chemical analysis, chemical modification, post-translational modification, production of fusion proteins, and glycosylation of proteins (see, e.g., Coligan, et al. (2000) *Current Protocols in Protein Science*, Vols. 1-2, John Wiley and Sons, Inc., NY).

[00304] Production, purification, and fragmentation of polyclonal and monoclonal antibodies are described (e.g., Harlow and Lane (1999) *Using Antibodies*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY); standard techniques for characterizing ligand/receptor interactions are available (see, e.g., Coligan et al. (2001) *Current Protocols in Immunology*, Vol. 4, John Wiley, Inc., NY); methods for flow cytometry, including fluorescence-activated cell sorting (FACS), are available (see, e.g., Shapiro (2003) *Practical Flow Cytometry*, John Wiley and Sons, Hoboken, NJ); and fluorescent reagents suitable for modifying nucleic acids, including nucleic acid primers and probes, polypeptides, and antibodies, for use, for example, as diagnostic reagents, are available (*Molecular Probes* (2003) Catalogue, Molecular Probes, Inc., Eugene, OR.; *Sigma-Aldrich* (2003) Catalogue, St. Louis, MO.).

[00305] Standard methods of histology of the immune system are described (see, e.g., Louis et al. (2002) *Basic Histology: Text and Atlas*, McGraw-Hill, New York, NY).

[00306] Depletion of immune cells (CD4⁺ and CD8⁺ T-cells) may be effected by antibody-mediated elimination. For example, 250 µg of CD4- or CD8-specific antibodies may be injected weekly, and cell depletions verified using FACS and IHC analysis.

[00307] Software packages and databases for determining, e.g., antigenic fragments, leader sequences, protein folding, functional domains, glycosylation sites, and sequence alignments, are available (see, e.g., GCG Wisconsin Package (Accelrys, Inc., San Diego, CA); and DeCypher™ (TimeLogic Corp., Crystal Bay, NV).

[00308] Immunocompetent Balb/C or B-cell – deficient Balb/C mice were obtained from The Jackson Lab., Bar Harbor, ME and used in accordance with standard procedures (see, e.g., Martin et al (2001) *Infect. Immun.*, 69(11):7067-73 and Compton et al. (2004) *Comp. Med.* 54(6):681-89). Other mice strains suitable for the experimental work contemplated by the

present disclosure are known to the skilled artisan and are generally available from The Jackson Lab.

[00309] Unless otherwise indicated, PDV6 squamous cell carcinoma of the skin was used in the experiments described herein (see, e.g., Langowski et al. (2006) Nature 442:461-465). Other oncology-related models and cell lines, such as Ep2 mammary carcinoma, CT26 colon carcinoma, and 4T1 breast carcinoma models, may be used (see, e.g., Langowski et al. (2006) Nature 442:461-465) and are known to the skilled artisan. Non-oncology – related models and cell lines (e.g., models of inflammation) may also be used and are known to the skilled artisan.

[00310] Serum IL-10 concentration levels and exposure levels may be determined by standard methods used in the art. For example, a serum exposure level assay can be performed by collecting whole blood (~50 μ L/mouse) from mouse tail snips into plain capillary tubes, separating serum and blood cells by centrifugation, and determining IL-10 exposure levels by standard ELISA kits (e.g., R&D Systems) and techniques. Alternatively, or in addition, the ELISA protocol described below (or a similar protocol) can be adapted to measure serum levels of human IL-10 as a means of determining in vivo half-life of a mutein or modified mutein.

Generation and Assessment of Muteins

[00311] Assembly of the Human IL-10 Expression Vector, pSecTag2hygro-huIL10. A human IL-10 mammalian expression vector was assembled by amplifying the complete human IL-10 open reading frame via PCR using Platinum Pfx DNA Polymerase (Life Technologies #11708-039, following manufacturer's protocol) using pCMV6-XL5-human-IL10 (Origene #SC300099, Genbank accession #NM 00057.2) as a DNA template and primers 5'-tataGCTAGCCACCATGCACAGCTCAGCACTGC-3' (SEQ ID NO:34) and 5'-tataGGGCCCTCAGTTTCGTATCTTCATTG-3' (SEQ ID NO:35), and the resultant PCR reaction was purified using a QIAquick PCR Purification Kit (Qiagen #28106). The purified human IL-10 PCR fragment and the mammalian expression vector pSecTag2hygro (B) (Life Technologies #V910-20) were digested with ApaI and NheI (New England Biolabs, Ipswich, MA) for one hour at 37°C with Calf Intestinal Phosphatase (New England Biolabs, Ipswich, MA) added to the pSecTag2hygro (B) digestion. The digested DNA fragments were run on a 1% agarose gel (Lonza #54803) for one hour at 100V, and then excised and purified using a QIAquick Gel Extraction Kit (Qiagen #28706). The human IL-10 PCR fragment was ligated into the pSecTag2hygro (B) vector using the Rapid DNA Ligation Kit (Roche #11635379001),

transformed into One Shot TOP10 Chemically Competent E. coli (Life Technologies #C404006), plated to agar plates containing 100 µg/mL ampicillin and grown overnight at 37°C. The following day, bacterial colonies were picked individually and placed into 3 mL cultures containing LB + 100 µg/mL ampicillin and grown for 8-20 hours at 37°C in a shaking incubator at 200 RPM. Two (2) ml of each culture was then aliquoted to 2 mL tubes, the cells pelleted at 6000 RPM in a table-top centrifuge for 10 minutes, the media aspirated, and the DNA purified away from the bacteria using a QIAprep Spin Miniprep Kit (Qiagen #27106). Correct expression vectors were identified via DNA sequencing (MC Lab, South San Francisco, CA).

[00312] Generation of Mutein Expression Vectors. Human IL10 mutein expression vectors were assembled by mutating the previously described human IL-10 mammalian expression vector pSecTag2hygro-huIL10 using a Quikchange II Site-Directed Mutagenesis Kit (Agilent Technologies #200524) following the manufacturer's protocol with the following clarifications: primers did not always meet the recommended T_m; the PCR reaction was cycled for 16-18 rounds with an extension time of 6-7 minutes; 4 µL of the DpnI – treated reaction was transformed into One Shot TOP10 Chemically Competent Cells (Life Technologies #C404006) as previously described. Three (3) mL miniprep cultures were grown, purified, and sequence-verified as previously described. For muteins in which a Cysteine was inserted, a 400 mL culture was grown and purified. Briefly, one bacterial colony was picked into 400 mL LB + 100 µg/mL ampicillin, and grown for 12-20 hours at 37°C in a shaking incubator at 200 RPM in a 2L baffled Erlenmeyer flask. The culture was then pelleted in a centrifuge (6000 RPM in a Beckman Avanti J-25T in a JA-10 rotor for 20 minutes), the media aspirated, and the DNA extracted using an EndoFree Plasmid Mega Kit (Qiagen, #12381), following the manufacturer's protocol (with very minor changes, of a type familiar to the skilled artisan, made to the DNA precipitation methodology to increase the final DNA concentration).

[00313] Muteins which required multiple amino acid changes were assembled by inserting one mutation at a time. The introduction of the N-glycosylation motifs, N-X-S and N-X-T, sometimes required the introduction of three mutations since X ≠ P (Proline). Table 1 details the DNA template and primer sets used for the generation of the pSecTag2hygro-huIL10 expression vector, as well as all mutein expression vectors. The numbering convention used for the muteins assigns the start codon as the first position, hence the first 18 residues (MHSSALLCCLVLLTGVRA (SEQ ID NO:37)) comprise the signal peptide and the first residue of the mature protein would be Serine 19.

Table 1

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10	pCMV-XL6-human IL-10 (Accession # NM00572.2, Origene #SC300099)	tataGCTAGCCACCATGCACAGCTCAGCACTGC	SEQ NO ID:38
		tataGGGCCCTCAGTTTCGTATCTTCATTG	SEQ NO ID:39
pSecTag2hygro-huIL10 S19C	pSecTag2hygro-huIL10	CTGACTGGGGTGAGGGCCtGCCCAGGCCAGGGCA C	SEQ NO ID:40
		GTGCCCTGGCCTGGGCaGGCCCTCACCCCAGTCAG	SEQ NO ID:41
pSecTag2hygro-huIL10 P20C	pSecTag2hygro-huIL10	GGGGTGAGGGCCAGCtgcGGCCAGGGCACCCAG	SEQ NO ID:42
		CTGGGTGCCCTGGCCgcaGCTGGCCCTCACCCC	SEQ NO ID:43
pSecTag2hygro-huIL10 G21C	pSecTag2hygro-huIL10	GGGTGAGGGCCAGCCCAtGCCAGGGGCACCCAGTC	SEQ NO ID:44
		GACTGGGTGCCCTGGCaTGGGCTGGCCCTCACCCC	SEQ NO ID:45
pSecTag2hygro-huIL10 Q22C	pSecTag2hygro-huIL10	GAGGGCCAGCCCAGGCtgcGGCACCCAGTCTGAG	SEQ NO ID:46
		CTCAGACTGGGTGCCgcaGCCTGGGCTGGCCCTC	SEQ NO ID:47
pSecTag2hygro-huIL10 G23C	pSecTag2hygro-huIL10	GGGCCAGCCCAGGCCAGtGCACCCAGTCTGAGAA C	SEQ NO ID:48
		GTTCTCAGACTGGGTGCaCTGGCCTGGGCTGGCCC	SEQ NO ID:49
pSecTag2hygro-huIL10 T24C	pSecTag2hygro-huIL10	CCAGCCCAGGCCAGGGCtgCCAGTCTGAGAACAGC	SEQ NO ID:50
		GCTGTTCTCAGACTGGcaGCCCTGGCCTGGGCTGG	SEQ NO ID:51
pSecTag2hygro-huIL10 Q25C	pSecTag2hygro-huIL10	CCAGGCCAGGGCACCTgcTCTGAGAACAGCTGCAC	SEQ NO ID:52
		GTGCAGCTGTTCTCAGAgcaGGTGCCCTGGCCTGG	SEQ NO ID:53
pSecTag2hygro-huIL10 S26C	pSecTag2hygro-huIL10	GGCCAGGGCACCCAGTgTGAGAACAGCTGCACCC	SEQ NO ID:54
		GGGTGCAGCTGTTCTCAcACTGGGTGCCCTGGCC	SEQ NO ID:55
pSecTag2hygro-huIL10 E27C	pSecTag2hygro-huIL10	GCCAGGGCACCCAGTCTtgcAACAGCTGCACCCAC	SEQ NO ID:56
		GTGGGTGCAGCTGTTgcaAGACTGGGTGCCCTGGC	SEQ NO ID:57
pSecTag2hygro-huIL10 N28C	pSecTag2hygro-huIL10	GGGCACCCAGTCTGAGtgCAGCTGCACCCACTTCC	SEQ NO ID:58
		GGAAGTGGGTGCAGCTGcaCTCAGACTGGGTGCCC	SEQ NO ID:59
pSecTag2hygro-huIL10 S29C	pSecTag2hygro-huIL10	GCACCCAGTCTGAGAACiGCTGCACCCACTTCCC	SEQ NO ID:60
		GGGAAGTGGGTGCAGCaGTTCTCAGACTGGGTGC	SEQ NO ID:61
pSecTag2hygro-huIL10 T31C	pSecTag2hygro-huIL10	GTCTGAGAACAGCTGcTGcCACTTCCCAGGCAACC	SEQ NO ID:62
		GGTTGCCTGGGAAGTGGcaGCAGCTGTTCTCAGAC	SEQ NO ID:63
pSecTag2hygro-huIL10 H32C	pSecTag2hygro-huIL10	GAGAACAGCTGCACctgCTTCCCAGGCAACCTGCC	SEQ NO ID:64
		GGCAGGTTGCCTGGGAAGcaGGTGCAGCTGTTCTC	SEQ NO ID:65
pSecTag2hygro-huIL10 G35C	pSecTag2hygro-huIL10	GCTGCACCCACTTCCCAtGCAACCTGCCTAACATG	SEQ NO ID:66
		CATGTTAGGCAGGTTGCaTGGGAAGTGGGTGCAG C	SEQ NO ID:67
pSecTag2hygro-huIL10 N36C	pSecTag2hygro-huIL10	CACCCACTTCCCAGGCtgCCTGCCTAACATGCTTC	SEQ NO ID:68
		GAAGCATGTTAGGCAGGcaGCCTGGGAAGTGGGT G	SEQ NO ID:69
pSecTag2hygro-huIL10 D43C	pSecTag2hygro-huIL10	GCCTAACATGCTTTCGAtgTCTCCGAGATGCCTTC	SEQ NO ID:70
		GAAGGCATCTCGGAGAcATCGAAGCATGTTAGGC	SEQ NO ID:71
pSecTag2hygro-huIL10 S49C	pSecTag2hygro-huIL10	ATCTCCGAGATGCCTTCiGCAGAGTGAAGACTTTC	SEQ NO ID:72
		GAAAGTCTTCACTCTGCaGAAGGCATCTCGGAGAT	SEQ NO ID:73
pSecTag2hygro-huIL10 R50C	pSecTag2hygro-huIL10	CCGAGATGCCTTCAGCiGcGTGAAGACTTTCTTTC	SEQ NO ID:74
		GAAAGAAAGTCTTCACgCaGCTGAAGGCATCTCGG	SEQ NO ID:75
pSecTag2hygro-huIL10 K58C	pSecTag2hygro-huIL10	CTTTCTTTCAAATGtgcGATCAGCTGGACAACCTTG	SEQ NO ID:76
		CAAGTTGTCCAGCTGATCgcaCATTTGAAAGAAAG	SEQ NO ID:77
pSecTag2hygro	pSecTag2hy	GGACAACCTTGTTGTTAtgcGAGTCCTTGCTGGAGG	SEQ NO ID:78

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 K67C	gro-huIL10	CCTCCAGCAAGGACTCgcaTAACAACAAGTTGTCC	SEQ NO ID:79
pSecTag2hygro	pSecTag2hy	CAACTTGTTGTTAAAGtgcTCCTTGCTGGAGGAC	SEQ NO ID:80
-huIL10 E68C	gro-huIL10	GTCCTCCAGCAAGGAgcaCTTTAACAACAAGTTG	SEQ NO ID:81
pSecTag2hygro	pSecTag2hy	CTTGTTGTTAAAGGAGTgCTTGCTGGAGGACTTTA	SEQ NO ID:82
-huIL10 S69C	gro-huIL10	TAAAGTCCTCCAGCAAGcACTCCTTTAACAACAAG	SEQ NO ID:83
pSecTag2hygro	pSecTag2hy	GGAGTCCTTGCTGtgcGACTTTAAGGGTTACCTGG	SEQ NO ID:84
-huIL10 E72C	gro-huIL10	CCAGGTAACCCTTAAAGTCgcaCAGCAAGGACTCC	SEQ NO ID:85
pSecTag2hygro	pSecTag2hy	GGAGTCCTTGCTGGAGtgcCTTTAAGGGTTACCTGG	SEQ NO ID:86
-huIL10 D73C	gro-huIL10	CCAGGTAACCCTTAAAGcaCTCCAGCAAGGACTCC	SEQ NO ID:87
pSecTag2hygro	pSecTag2hy	CTTGCTGGAGGACTTTtgcGGTTACCTGGGTTGCC	SEQ NO ID:88
-huIL10 K75C	gro-huIL10	GGCAACCCAGGTAACCGcaAAAGTCCTCCAGCAAG	SEQ NO ID:89
pSecTag2hygro	pSecTag2hy	GCTGGAGGACTTTAAGtGTTACCTGGGTTGCCAAG	SEQ NO ID:90
-huIL10 G76C	gro-huIL10	CTTGCAACCCAGGTAACaCTTAAAGTCCTCCAGC	SEQ NO ID:91
pSecTag2hygro	pSecTag2hy	GGAGGACTTTAAGGGTTgCCTGGGTTGCCAAGCC	SEQ NO ID:92
-huIL10 Y77C	gro-huIL10	GGCTTGGCAACCCAGGcAACCTTAAAGTCCTCC	SEQ NO ID:93
pSecTag2hygro	pSecTag2hy	CTTTAAGGGTTACtgcGGTTGCCAAGCC	SEQ NO ID:94
-huIL10 L78C	gro-huIL10	GGCTTGGCAACCGcaGTAACCCTTAAAG	SEQ NO ID:95
pSecTag2hygro	pSecTag2hy	CTTTAAGGGTTACCTGtGTTGCCAAGCCTTGTCTG	SEQ NO ID:96
-huIL10 G79C	gro-huIL10	CAGACAAGGCTTGGCAACaCAGGTAACCCTTAAAG	SEQ NO ID:97
pSecTag2hygro	pSecTag2hy	GGGTTACCTGGGTTGcGCCTTGTCTGAGATG	SEQ NO ID:98
-huIL10 Q81C	gro-huIL10	CATCTCAGACAAGGCgcaGCAACCCAGGTAACCC	SEQ NO ID:99
pSecTag2hygro	pSecTag2hy	GTTGCCAAGCCTTGTgTGAGATGATCCAGTTTTAC	SEQ NO ID:100
-huIL10 S84C	gro-huIL10	GTAAAACTGGATCATCTCAcACAAGGCTTGGCAA	SEQ NO ID:101
pSecTag2hygro	pSecTag2hy	GTTGCCAAGCCTTGTCTtgcATGATCCAGTTTTAC	SEQ NO ID:102
-huIL10 E85C	gro-huIL10	GTAAAACTGGATCATgcaAGACAAGGCTTGGCAAC	SEQ NO ID:103
pSecTag2hygro	pSecTag2hy	CTTGCTGAGATGATCtgcTTTTACCTGGAGGAGG	SEQ NO ID:104
-huIL10 Q88C	gro-huIL10	CCTCCTCCAGGTAAAGcaGATCATCTCAGACAAG	SEQ NO ID:105
pSecTag2hygro	pSecTag2hy	GATCCAGTTTTACCTGtgcGAGGTGATGCCCCAAG	SEQ NO ID:106
-huIL10 E92C	gro-huIL10	CTTGGGGCATCACCTCgcaCAGGTAAAACTGGATC	SEQ NO ID:107
pSecTag2hygro	pSecTag2hy	GTTTTACCTGGAGtgcGTGATGCCCCAAGC	SEQ NO ID:108
-huIL10 E93C	gro-huIL10	GCTTGGGGCATCACgcaCTCCAGGTAAAC	SEQ NO ID:109
pSecTag2hygro	pSecTag2hy	CCTGGAGGAGGTGATGtgCCAAGCTGAGAACCAA	SEQ NO ID:110
-huIL10 P96C	gro-huIL10	CTTGGTTCTCAGCTTGGcaCATCACCTCCTCCAGG	SEQ NO ID:111
pSecTag2hygro	pSecTag2hy	GGAGGAGGTGATGCCctgcGCTGAGAACCAAGACC	SEQ NO ID:112
-huIL10 Q97C	gro-huIL10	GGTCTTGGTTCTCAGCgcaGGGCATCACCTCCTCC	SEQ NO ID:113
pSecTag2hygro	pSecTag2hy	GGTGATGCCCCAAGCTtgcAACCAAGACCCAGAC	SEQ NO ID:114
-huIL10 E99C	gro-huIL10	GTCTGGGTCTTGTTgcaAGCTTGGGGCATCACC	SEQ NO ID:115
pSecTag2hygro	pSecTag2hy	GATGCCCCAAGCTGAGtgCCAAGACCCAGACATC	SEQ NO ID:116
-huIL10 N100C	gro-huIL10	GATGTCTGGGTCTTGgcaCTCAGCTTGGGGCATC	SEQ NO ID:117
pSecTag2hygro	pSecTag2hy	CCAAGCTGAGAACTgcGACCCAGACATCAAGGCGC	SEQ NO ID:118
-huIL10 Q101C	gro-huIL10	GCGCCTTGATGTCTGGGTCgcaGTTCTCAGCTTGG	SEQ NO ID:119
pSecTag2hygro	pSecTag2hy	CAAGCTGAGAACCAAtgCCCAGACATCAAGGCGC	SEQ NO ID:120
-huIL10 D102C	gro-huIL10	GCGCCTTGATGTCTGGGcaTTGGTTCTCAGCTTG	SEQ NO ID:121
pSecTag2hygro	pSecTag2hy	GCTGAGAACCAAGACTgcGACATCAAGGCGCATG	SEQ NO ID:122
-huIL10 P103C	gro-huIL10	CATGCGCCTTGATGTcGcaGTCTTGGTTCTCAGC	SEQ NO ID:123
pSecTag2hygro	pSecTag2hy	CTGAGAACCAAGACCCAtgCATCAAGGCGCATGTG	SEQ NO ID:124
-huIL10 D104C	gro-huIL10	CACATGCGCCTTGATGcaTGGGTCTTGGTTCTCAG	SEQ NO ID:125
pSecTag2hygro	pSecTag2hy	CCAAGACCCAGACATCtgcGCGCATGTGAACTCCC	SEQ NO ID:126
-huIL10 K106C	gro-huIL10	GGGAGTTCACATGCGCgcaGATGTCTGGGTCTTGG	SEQ NO ID:127

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 A107C	pSecTag2hygro-huIL10	GACCCAGACATCAAGtgcCATGTGAACTCCCTGGG	SEQ NO ID:128
		CCCAGGGAGTTCACATGgcaCTTGATGTCTGGGTC	SEQ NO ID:129
pSecTag2hygro-huIL10 H108C	pSecTag2hygro-huIL10	CCCAGACATCAAGGCGtgcGTGAACTCCCTGGGGG	SEQ NO ID:130
		CCCCCAGGGAGTTCACgcaCGCCTTGATGTCTGGG	SEQ NO ID:131
pSecTag2hygro-huIL10 N110C	pSecTag2hygro-huIL10	CATCAAGGCGCATGTGTgCTCCCTGGGGGAGAACC	SEQ NO ID:132
		GGTTCTCCCCCAGGGAGcaCACATGCGCCTTGATG	SEQ NO ID:133
pSecTag2hygro-huIL10 S111C	pSecTag2hygro-huIL10	CAAGGCGCATGTGAACTgCCTGGGGGAGAACCTG	SEQ NO ID:134
		CAGGTTCTCCCCCAGGcAGTTCACATGCGCCTTG	SEQ NO ID:135
pSecTag2hygro-huIL10 G113C	pSecTag2hygro-huIL10	GCATGTGAACTCCCTGtGcGAGAACCTGAAGACCC	SEQ NO ID:136
		GGGTCTTCAGGTTCTCgCaCAGGGAGTTCACATGC	SEQ NO ID:137
pSecTag2hygro-huIL10 E114C	pSecTag2hygro-huIL10	GTGAACTCCCTGGGGtgcAACCTGAAGACCCTCAG	SEQ NO ID:138
		CTGAGGGTCTTCAGGTTgcaCCCCAGGGAGTTCAC	SEQ NO ID:139
pSecTag2hygro-huIL10 N115C	pSecTag2hygro-huIL10	GAACTCCCTGGGGGAGtgCCTGAAGACCCTCAGGC	SEQ NO ID:140
		GCCTGAGGGTCTTCAGGcaCTCCCCCAGGGAGTTC	SEQ NO ID:141
pSecTag2hygro-huIL10 K117C	pSecTag2hygro-huIL10	CCTGGGGGAGAACCTGtgcACCCTCAGGCTGAGGC	SEQ NO ID:142
		GCCTCAGCCTGAGGGTgcaCAGGTTCTCCCCCAGG	SEQ NO ID:143
pSecTag2hygro-huIL10 T118C	pSecTag2hygro-huIL10	GGGGGAGAACCTGAAGtgCCTCAGGCTGAGGCTA C	SEQ NO ID:144
		GTAGCCTCAGCCTGAGGcaCTTCAGGTTCTCCCCC	SEQ NO ID:145
pSecTag2hygro-huIL10 R120C	pSecTag2hygro-huIL10	GAACCTGAAGACCCTCtGcCTGAGGCTACGGCGC	SEQ NO ID:146
		GCGCCGTAGCCTCAGgCaGAGGGTCTTCAGGTTC	SEQ NO ID:147
pSecTag2hygro-huIL10 L121C	pSecTag2hygro-huIL10	CCTGAAGACCCTCAGGtgcAGGCTACGGCGCTGTC	SEQ NO ID:148
		GACAGCGCCGTAGCCTgcaCCTGAGGGTCTTCAGG	SEQ NO ID:149
pSecTag2hygro-huIL10 R122C	pSecTag2hygro-huIL10	GAAGACCCTCAGGCTGtgcCTACGGCGCTGTCATC	SEQ NO ID:150
		GATGACAGCGCCGTAGgcaCAGCCTGAGGGTCTTC	SEQ NO ID:151
pSecTag2hygro-huIL10 R124C	pSecTag2hygro-huIL10	CCTCAGGCTGAGGCTAtGcCGCTGTCATCGATTTC	SEQ NO ID:152
		GAAATCGATGACAGCGgCaTAGCCTCAGCCTGAG G	SEQ NO ID:153
pSecTag2hygro-huIL10 R125C	pSecTag2hygro-huIL10	CAGGCTGAGGCTACGGtGCTGTCATCGATTTCTTC	SEQ NO ID:154
		GAAGAAATCGATGACAGCaCCGTAGCCTCAGCCT G	SEQ NO ID:155
pSecTag2hygro-huIL10 H127C	pSecTag2hygro-huIL10	GAGGCTACGGCGCTGTtgTCGATTTCTTCCCTGTG	SEQ NO ID:156
		CACAGGGAAGAAATCGAcaACAGCGCCGTAGCCT C	SEQ NO ID:157
pSecTag2hygro-huIL10 R128C	pSecTag2hygro-huIL10	GCTACGGCGCTGTCATtGcTTTCTTCCCTGTG	SEQ NO ID:158
		CACAGGGAAGAAAgCaATGACAGCGCCGTAGC	SEQ NO ID:159
pSecTag2hygro-huIL10 P131C	pSecTag2hygro-huIL10	GCTGTCATCGATTTCTTtgCTGTGAAAACAAGAGC	SEQ NO ID:160
		GCTCTTGTTTTACAGcaAAGAAATCGATGACAGC	SEQ NO ID:161
pSecTag2hygro-huIL10 E133C	pSecTag2hygro-huIL10	CGATTTCTTCCCTGTtgcAACAAGAGCAAGGCCG	SEQ NO ID:162
		CGGCCTTGCTCTTGTTgcaACAGGGAAGAAATCG	SEQ NO ID:163
pSecTag2hygro-huIL10 N134C	pSecTag2hygro-huIL10	GATTTCTTCCCTGTGAAtgCAAGAGCAAGGCCGTG	SEQ NO ID:164
		CACGGCCTTGCTCTTGcaTTCACAGGGAAGAAATC	SEQ NO ID:165
pSecTag2hygro-huIL10 K135C	pSecTag2hygro-huIL10	CTTCCCTGTGAAAActgcAGCAAGGCCGTGGAGC	SEQ NO ID:166
		GCTCCACGGCCTTGCTgcaGTTTTACAGGGAAG	SEQ NO ID:167
pSecTag2hygro-huIL10 S136C	pSecTag2hygro-huIL10	CTTCCCTGTGAAAACAAGtGCAAGGCCGTGGAGC	SEQ NO ID:168
		GCTCCACGGCCTTGCaCTTGTTTTACAGGGAAG	SEQ NO ID:169
pSecTag2hygro-huIL10 K137C	pSecTag2hygro-huIL10	CCTGTGAAAACAAGAGCtgcGCCGTGGAGCAGGTG	SEQ NO ID:170
		CACCTGCTCCACGGCgcaGCTCTTGTTTTACAGG	SEQ NO ID:171
pSecTag2hygro-huIL10 E140C	pSecTag2hygro-huIL10	GAGCAAGGCCGTGtgcCAGGTGAAGAATGCCTTTA	SEQ NO ID:172
		TAAAGGCATTCTTCACCTGgcaCACGGCCTTGCTC	SEQ NO ID:173
pSecTag2hygro-huIL10 Q141C	pSecTag2hygro-huIL10	GAGCAAGGCCGTGGAGtgcGTGAAGAATGCCTTTA	SEQ NO ID:174
		TAAAGGCATTCTTCACgcaCTCCACGGCCTTGCTC	SEQ NO ID:175

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 K143C	pSecTag2hygro-huIL10	GAGCAAGGCCGTGGAGCAGGTGtgcAATGCCTTTAATAAGCTCCAAG	SEQ NO ID:176
		CTTGGAGCTTATTAAAGGCATTgcaCACCTGCTCCA CGGCCTTGCTC	SEQ NO ID:177
pSecTag2hygro-huIL10 N144C	pSecTag2hygro-huIL10	CGTGGAGCAGGTGAAGtgcGCCTTTAATAAGCTCC	SEQ NO ID:178
		GGAGCTTATTAAAGGCgcaCTTCACCTGCTCCACG	SEQ NO ID:179
pSecTag2hygro-huIL10 N147C	pSecTag2hygro-huIL10	GGTGAAGAATGCCTTTtgTAAGCTCCAAGAGAAAG	SEQ NO ID:180
		CTTTCTCTTGGAGCTTAcaAAAGGCATTCTTCACC	SEQ NO ID:181
pSecTag2hygro-huIL10 K148C	pSecTag2hygro-huIL10	GAAGAATGCCTTTAATtgcCTCCAAGAGAAAGGC	SEQ NO ID:182
		GCCTTTCTCTTGGAGgcaATTAAAGGCATTCTTC	SEQ NO ID:183
pSecTag2hygro-huIL10 Q150C	pSecTag2hygro-huIL10	GCCTTTAATAAGCTCtgcGAGAAAGGCATCTAC	SEQ NO ID:184
		GTAGATGCCTTTCTCgcaGAGCTTATTAAAGGC	SEQ NO ID:185
pSecTag2hygro-huIL10 E151C	pSecTag2hygro-huIL10	CTTTAATAAGCTCCAAAtgcAAAGGCATCTACAAAG	SEQ NO ID:186
		CTTTGTAGATGCCTTTgcaTTGGAGCTTATTAAAG	SEQ NO ID:187
pSecTag2hygro-huIL10 K152C	pSecTag2hygro-huIL10	CTTTAATAAGCTCCAAGAGtgcGGCATCTACAAAG	SEQ NO ID:188
		CTTTGTAGATGCCgcaCTCTTGGAGCTTATTAAAG	SEQ NO ID:189
pSecTag2hygro-huIL10 G153C	pSecTag2hygro-huIL10	GCTCCAAGAGAAAAtGCATCTACAAAGCCATGAGT G	SEQ NO ID:190
		CACTCATGGCTTTGTAGATGCaTTTCTCTTGGAGC	SEQ NO ID:191
pSecTag2hygro-huIL10 K175C	pSecTag2hygro-huIL10	GCCTACATGACAATGtgcATACGAAACTGAGGGCC	SEQ NO ID:192
		GGCCCTCAGTTTCGTATgcaCATTGTCATGTAGGC	SEQ NO ID:193
pSecTag2hygro-huIL10 N178C	pSecTag2hygro-huIL10	CATGACAATGAAGATACGAtgCTGAGGGCCCGAA C	SEQ NO ID:194
		GTTCGGGGCCCTCAGcaTCGTATCTTCATTGTCATG	SEQ NO ID:195
pSecTag2hygro-huIL10 S19Y	pSecTag2hygro-huIL10	GACTGGGGTGAGGGCCtaCCCAGGCCAGGGGCACCC	SEQ NO ID:196
		GGGTGCCCTGGCCTGGGtaGGCCCTCACCCCAGTC	SEQ NO ID:197
pSecTag2hygro-huIL10 P20Y	pSecTag2hygro-huIL10	CTGGGGTGAGGGCCAGCtacGGCCAGGGGCACCCAG	SEQ NO ID:198
		CTGGGTGCCCTGGCCgtaGCTGGCCCTCACCCCAG	SEQ NO ID:199
pSecTag2hygro-huIL10 G21Y	pSecTag2hygro-huIL10	GGTGAGGGCCAGCCCAtaCCAGGGGCACCCAGTCTG	SEQ NO ID:200
		CAGACTGGGTGCCCTGGtaTGGGCTGGCCCTCACCC	SEQ NO ID:201
pSecTag2hygro-huIL10 Q22Y	pSecTag2hygro-huIL10	GAGGGCCAGCCCAGGCtAcGGCACCCAGTCTGAG	SEQ NO ID:202
		CTCAGACTGGGTGCCgTaGCCTGGGCTGGCCCTC	SEQ NO ID:203
pSecTag2hygro-huIL10 G23Y	pSecTag2hygro-huIL10	GGGCCAGCCCAGGCCAGtaCACCCAGTCTGAGAAC	SEQ NO ID:204
		GTTCTCAGACTGGGTGtaCTGGCCTGGGCTGGCCC	SEQ NO ID:205
pSecTag2hygro-huIL10 T24Y	pSecTag2hygro-huIL10	CCAGCCCAGGCCAGGGCtaCCAGTCTGAGAACAGC	SEQ NO ID:206
		GCTGTTCTCAGACTGGtaGCCCTGGCCTGGGCTGG	SEQ NO ID:207
pSecTag2hygro-huIL10 Q25Y	pSecTag2hygro-huIL10	GCCCAGGCCAGGGCACctAcTCTGAGAACAGCTGC	SEQ NO ID:208
		GCAGCTGTTCTCAGAgTaGGTGCCCTGGCCTGGGC	SEQ NO ID:209
pSecTag2hygro-huIL10 S26Y	pSecTag2hygro-huIL10	GGCCAGGGCACCCAGTAcGAGAACAGCTGCACCC	SEQ NO ID:210
		GGGTGCAGCTGTTCTCgtACTGGGTGCCCTGGCC	SEQ NO ID:211
pSecTag2hygro-huIL10 E27Y	pSecTag2hygro-huIL10	GCCAGGGCACCCAGTCTtAcAACAGCTGCACCCAC	SEQ NO ID:212
		GTGGGTGCAGCTGTTgTaAGACTGGGTGCCCTGGC	SEQ NO ID:213
pSecTag2	pSecTag2hy	GGGCACCCAGTCTGAGtACAGCTGCACCCACTTCC	SEQ NO ID:214

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
hygro-huIL10 N28Y	gro-huIL10	GGAAGTGGGTGCAGCTGTaCTCAGACTGGGTGCC C	SEQ NO ID:215
pSecTag2 hygro-huIL10 S29Y	pSecTag2hy gro-huIL10	GGCACCCAGTCTGAGAACTaCTGCACCCACTTCCC	SEQ NO ID:216
		GGGAAGTGGGTGCAGtaGTTCTCAGACTGGGTGCC	SEQ NO ID:217
pSecTag2 hygro-huIL10 T31Y	pSecTag2hy gro-huIL10	GTCTGAGAACAGCTGCTaCCACTTCCCAGGCAACC	SEQ NO ID:218
		GGTTGCCTGGGAAGTGGtaGCAGCTGTTCTCAGAC	SEQ NO ID:219
pSecTag2 hygro-huIL10 H32Y	pSecTag2hy gro-huIL10	CTGAGAACAGCTGCACCTaCTTCCCAGGCAACCTG	SEQ NO ID:220
		CAGGTTGCCTGGGAAGTaGGTGCAGCTGTTCTCAG	SEQ NO ID:221
pSecTag2 hygro-huIL10 G35Y	pSecTag2hy gro-huIL10	CTGCACCCACTTCCCAtaCAACCTGCCTAACATGC	SEQ NO ID:222
		GCATGTTAGGCAGGTTGtaTGGGAAGTGGGTGCAG	SEQ NO ID:223
pSecTag2 hygro-huIL10 N36Y	pSecTag2hy gro-huIL10	CACCCACTTCCCAGGCTaCCTGCCTAACATGCTTC	SEQ NO ID:224
		GAAGCATGTTAGGCAGGTaGCCTGGGAAGTGGGT G	SEQ NO ID:225
pSecTag2 hygro-huIL10 D43Y	pSecTag2hy gro-huIL10	GCCTAACATGCTTCGAAtAcCTCCGAGATGCCTTC	SEQ NO ID:226
		GAAGGCATCTCGGAGgTaTCGAAGCATGTTAGGC	SEQ NO ID:227
pSecTag2 hygro-huIL10 S49Y	pSecTag2hy gro-huIL10	GATCTCCGAGATGCCTTCTaCAGAGTGAAGACTTT C	SEQ NO ID:228
		GAAAGTCTTCACTCTGtaGAAGGCATCTCGGAGAT C	SEQ NO ID:229
pSecTag2 hygro-huIL10 R50Y	pSecTag2hy gro-huIL10	CCGAGATGCCTTCAGCtacGTGAAGACTTTCTTTC	SEQ NO ID:230
		GAAAGAAAGTCTTCACgtaGCTGAAGGCATCTCGG	SEQ NO ID:231
pSecTag2 hygro-huIL10 K58Y	pSecTag2hy gro-huIL10	GACTTTCTTTCAAATGtAcGATCAGCTGGACAAC	SEQ NO ID:232
		GTTGTCCAGCTGATCgTaCATTTGAAAGAAAGTC	SEQ NO ID:233
pSecTag2 hygro-huIL10 K67Y	pSecTag2hy gro-huIL10	GGACAACCTTGTTGTTAAtAcGAGTCCTTGCTGGAGG	SEQ NO ID:234
		CCTCCAGCAAGGACTCgTaTAACAACAAGTTGTCC	SEQ NO ID:235
pSecTag2 hygro-huIL10 E68Y	pSecTag2hy gro-huIL10	CAACTTGTTGTTAAAGtAcTCCTTGCTGGAGGAC	SEQ NO ID:236
		GTCCTCCAGCAAGGAGgTaCTTTAACAACAAGTTG	SEQ NO ID:237
pSecTag2 hygro-huIL10 S69Y	pSecTag2hy gro-huIL10	CTTGTTGTTAAAGGAGTaCTTGCTGGAGGACTTTA AGG	SEQ NO ID:238
		CCTTAAAGTCCTCCAGCAAGtACTCCTTTAACAAC AAG	SEQ NO ID:239
pSecTag2 hygro-huIL10 E72Y	pSecTag2hy gro-huIL10	AAAGGAGTCCTTGCTGtAcGACTTTAAGGGTTACC	SEQ NO ID:240
		GGTAACCCTTAAAGTCgTaCAGCAAGGACTCCTTT	SEQ NO ID:241
pSecTag2 hygro-huIL10 D73Y	pSecTag2hy gro-huIL10	GGAGTCCTTGCTGGAGtACTTTAAGGGTTACCTGG	SEQ NO ID:242
		CCAGGTAACCCTTAAAGTaCTCCAGCAAGGACTCC	SEQ NO ID:243
pSecTag2 hygro-huIL10 K75Y	pSecTag2hy gro-huIL10	CTTGCTGGAGGACTTTtAcGGTTACCTGGGTGCC	SEQ NO ID:244
		GGCAACCCAGGTAACCGTaAAAGTCCTCCAGCAA G	SEQ NO ID:245
pSecTag2 hygro-huIL10 G76Y	pSecTag2hy gro-huIL10	GCTGGAGGACTTTAAGtacTACCTGGGTGCCAAG	SEQ NO ID:246
		CTTGGAACCCAGGTAgtactTTAAAGTCCTCCAGC	SEQ NO ID:247
pSecTag2	pSecTag2hy	GGACTTTAAGGGTTACtacGGTTGCCAAGCCTTG	SEQ NO ID:248

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
hygro-huIL10 L78Y	gro-huIL10	CAAGGCTTGGCAACCgtaGTAACCCTTAAAGTCC	SEQ NO ID:249
pSecTag2 hygro-huIL10 G79Y	pSecTag2hy gro-huIL10	CTTTAAGGGTTACCTGtacTGCCAAGCCTTGTCTG	SEQ NO ID:250
		CAGACAAGGCTTGGCAgtaCAGGTAACCCTTAAAG	SEQ NO ID:251
pSecTag2 hygro-huIL10 Q81Y	pSecTag2hy gro-huIL10	GGGTTACCTGGGTTGcAcGCCTTGTCTGAGATG	SEQ NO ID:252
		CATCTCAGACAAGGCgTaGCAACCCAGGTAACCC	SEQ NO ID:253
pSecTag2 hygro-huIL10 S84Y	pSecTag2hy gro-huIL10	GTTGCCAAGCCTTGTacGAGATGATCCAGTTTAC	SEQ NO ID:254
		GTAAAACTGGATCATCTCgtACAAGGCTTGGCAAC	SEQ NO ID:255
pSecTag2 hygro-huIL10 E85Y	pSecTag2hy gro-huIL10	GTTGCCAAGCCTTGTCTtAcATGATCCAGTTTAC	SEQ NO ID:256
		GTAAAACTGGATCATgTaAGACAAGGCTTGGCAAC	SEQ NO ID:257
pSecTag2 hygro-huIL10 Q88Y	pSecTag2hy gro-huIL10	CTTGTCTGAGATGATCtAcTTTTACCTGGAGGAGG	SEQ NO ID:258
		CCTCCTCCAGGTAAAAgTaGATCATCTCAGACAAG	SEQ NO ID:259
pSecTag2 hygro-huIL10 E92Y	pSecTag2hy gro-huIL10	GATCCAGTTTTACCTGtAcGAGGTGATGCCCCAAG	SEQ NO ID:260
		CTTGGGGCATCACCTCgTaCAGGTAAAACTGGATC	SEQ NO ID:261
pSecTag2 hygro-huIL10 E93Y	pSecTag2hy gro-huIL10	CCAGTTTTACCTGGAGtAcGTGATGCCCCAAGCTG	SEQ NO ID:262
		CAGCTTGGGGCATCACgTaCTCCAGGTAAAACTGG	SEQ NO ID:263
pSecTag2 hygro-huIL10 P96Y	pSecTag2hy gro-huIL10	CCTGGAGGAGGTGATGtaCCAAGCTGAGAACCAA G	SEQ NO ID:264
		CTTGGTTCTCAGCTTGGtaCATCACCTCCTCCAGG	SEQ NO ID:265
pSecTag2 hygro-huIL10 Q97Y	pSecTag2hy gro-huIL10	GGAGGAGGTGATGCCCtAcGCTGAGAACCAAGAC C	SEQ NO ID:266
		GGTCTTGGTTCTCAGCgTaGGGCATCACCTCCTCC	SEQ NO ID:267
pSecTag2 hygro-huIL10 E99Y	pSecTag2hy gro-huIL10	GGTGATGCCCCAAGCTtAcAACCAAGACCCAGAC	SEQ NO ID:268
		GTCTGGGTCTTGGTTgTaAGCTTGGGGCATCACCC	SEQ NO ID:269
pSecTag2 hygro-huIL10 N100Y	pSecTag2hy gro-huIL10	GATGCCCCAAGCTGAGtACCAAGACCCAGACATC	SEQ NO ID:270
		GATGTCTGGGTCTTGGTaCTCAGCTTGGGGCATC	SEQ NO ID:271
pSecTag2 hygro-huIL10 Q101Y	pSecTag2hy gro-huIL10	GCCCCAAGCTGAGAAcAcGACCCAGACATCAAG G	SEQ NO ID:272
		CCTTGATGTCTGGGTCgTaGTTCTCAGCTTGGGGC	SEQ NO ID:273
pSecTag2 hygro-huIL10 D102Y	pSecTag2hy gro-huIL10	CCAAGCTGAGAACCAAtACCCAGACATCAAGGCG C	SEQ NO ID:274
		GCGCCTTGATGTCTGGGTaTTGGTTCTCAGCTTGG	SEQ NO ID:275
pSecTag2 hygro-huIL10 P103Y	pSecTag2hy gro-huIL10	GCTGAGAACCAAGACtacGACATCAAGGCGCATG	SEQ NO ID:276
		CATGCGCCTTGATGTcGtaGTCTTGGTTCTCAGC	SEQ NO ID:277
pSecTag2 hygro-huIL10 D104Y	pSecTag2hy gro-huIL10	CTGAGAACCAAGACCCAtACATCAAGGCGCATGT G	SEQ NO ID:278
		CACATGCGCCTTGATGTaTGGGTCTTGGTTCTCAG	SEQ NO ID:279
pSecTag2 hygro-huIL10 K106Y	pSecTag2hy gro-huIL10	CCAAGACCCAGACATCtAcGCGCATGTGAACTCCC	SEQ NO ID:280
		GGGAGTTCACATGCGCgTaGATGTCTGGGTCTTGG	SEQ NO ID:281
pSecTag2 hygro-huIL10 A107Y	pSecTag2hy gro-huIL10	GACCCAGACATCAAGtacCATGTGAACTCCCTGGG	SEQ NO ID:282
		CCCAGGGAGTTCACATGgtaCTTGATGTCTGGGTC	SEQ NO ID:283

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2 hygro-huIL10 H108Y	pSecTag2hy gro-huIL10	CCCAGACATCAAGGCGtAcGTGAACTCCCTGGGGG	SEQ NO ID:284
		CCCCCAGGGAGTTCACgTaCGCCTTGATGTCTGGG	SEQ NO ID:285
pSecTag2 hygro-huIL10 N110Y	pSecTag2hy gro-huIL10	GGCGCATGTGtACTCCCTGGGGG	SEQ NO ID:286
		CCCCCAGGGAGTaCACATGCGCC	SEQ NO ID:287
pSecTag2 hygro-huIL10 S111Y	pSecTag2hy gro-huIL10	GGCGCATGTGAACTaCCTGGGGGAGAAC	SEQ NO ID:288
		GTTCTCCCCCAGGtAGTTCACATGCGCC	SEQ NO ID:289
pSecTag2 hygro-huIL10 G113Y	pSecTag2hy gro-huIL10	GCATGTGAACTCCCTGtacGAGAACCTGAAGACCC	SEQ NO ID:290
		GGGTCTTCAGGTTCTCgtaCAGGGAGTTCACATGC	SEQ NO ID:291
pSecTag2 hygro-huIL10 E114Y	pSecTag2hy gro-huIL10	GTGAACTCCCTGGGGtAcAACCTGAAGACCCTCAG	SEQ NO ID:292
		CTGAGGGTCTTCAGGTTgTaCCCCAGGGAGTTCAC	SEQ NO ID:293
pSecTag2 hygro-huIL10 N115Y	pSecTag2hy gro-huIL10	GAACTCCCTGGGGGAGtACCTGAAGACCCTCAGG C	SEQ NO ID:294
		GCCTGAGGGTCTTCAGGTaCTCCCCAGGGAGTTC	SEQ NO ID:295
pSecTag2 hygro-huIL10 K117Y	pSecTag2hy gro-huIL10	CCTGGGGGAGAACCTGtAcACCCTCAGGCTGAGGC	SEQ NO ID:296
		GCCTCAGCCTGAGGGTgTaCAGGTTCTCCCCCAGG	SEQ NO ID:297
pSecTag2 hygro-huIL10 T118Y	pSecTag2hy gro-huIL10	GGAGAACCTGAAGtaCCTCAGGCTGAGG	SEQ NO ID:298
		CCTCAGCCTGAGGtaCTTCAGGTTCTCC	SEQ NO ID:299
pSecTag2 hygro-huIL10 R120Y	pSecTag2hy gro-huIL10	GAACCTGAAGACCCTCtacCTGAGGCTACGGCGC	SEQ NO ID:300
		GCGCCGTAGCCTCAGgtaGAGGGTCTTCAGGTTC	SEQ NO ID:301
pSecTag2 hygro-huIL10 L121Y	pSecTag2hy gro-huIL10	CCTGAAGACCCTCAGGtacAGGCTACGGCGCTGTC	SEQ NO ID:302
		GACAGCGCCGTAGCCTgtaCCTGAGGGTCTTCAGG	SEQ NO ID:303
pSecTag2 hygro-huIL10 R122Y	pSecTag2hy gro-huIL10	GAAGACCCTCAGGCTGtacCTACGGCGCTGTCATC	SEQ NO ID:304
		GATGACAGCGCCGTAGgtaCAGCCTGAGGGTCTTC	SEQ NO ID:305
pSecTag2 hygro-huIL10 R124Y	pSecTag2hy gro-huIL10	CCTCAGGCTGAGGCTAtacCGCTGTCATCGATTTC	SEQ NO ID:306
		GAAATCGATGACAGCGgtaTAGCCTCAGCCTGAGG	SEQ NO ID:307
pSecTag2 hygro-huIL10 R125Y	pSecTag2hy gro-huIL10	CAGGCTGAGGCTACGGtaCTGTCATCGATTTCTTC	SEQ NO ID:308
		GAAGAAATCGATGACAGtaCCGTAGCCTCAGCCTG	SEQ NO ID:309
pSecTag2 hygro-huIL10 H127Y	pSecTag2hy gro-huIL10	GAGGCTACGGCGCTGTtAcCGATTCTTCCCTGTG	SEQ NO ID:310
		CACAGGGAAGAAATCGgTaACAGCGCCGTAGCCT C	SEQ NO ID:311
pSecTag2 hygro-huIL10 R128Y	pSecTag2hy gro-huIL10	GCTACGGCGCTGTCATtacTTTCTTCCCTGTGAAAA C	SEQ NO ID:312
		GTTTTACAGGGAAGAAAgtaATGACAGCGCCGTA GC	SEQ NO ID:313
pSecTag2 hygro-huIL10 P131Y	pSecTag2hy gro-huIL10	GCTGTCATCGATTTCTTtaCTGTGAAAACAAGAGC	SEQ NO ID:314
		GCTCTTGTTTTTCACAGtaAAGAAATCGATGACAGC	SEQ NO ID:315
pSecTag2 hygro-huIL10 E133Y	pSecTag2hy gro-huIL10	CGATTTCTTCCCTGTtAcAACAAGAGCAAGGCCG	SEQ NO ID:316
		CGGCCTTGCTCTTGTTgTaACAGGGAAGAAATCG	SEQ NO ID:317
pSecTag2	pSecTag2hy	GATTTCTTCCCTGTGAAtACAAGAGCAAGGCCGTG	SEQ NO ID:318

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
hygro-huIL10 N134Y	gro-huIL10	CACGGCCTTGCTCTTGTaTTCACAGGGAAGAAATC	SEQ NO ID:319
pSecTag2 hygro-huIL10 K135Y	pSecTag2hy gro-huIL10	CTTCCCTGTGAAAACtAcAGCAAGGCCGTGGAGC	SEQ NO ID:320
		GCTCCACGGCCTTGCTgTaGTTTTTCACAGGGAAG	SEQ NO ID:321
pSecTag2 hygro-huIL10 S136Y	pSecTag2hy gro-huIL10	CCCTGTGAAAACAAGtAcAAGGCCGTGGAGCAGG	SEQ NO ID:322
		CCTGCTCCACGGCCTTGtaCTTGTTTTTCACAGGG	SEQ NO ID:323
pSecTag2 hygro-huIL10 K137Y	pSecTag2hy gro-huIL10	CTGTGAAAACAAGAGCtAcGCCGTGGAGCAGGTG	SEQ NO ID:324
		CACCTGCTCCACGGCgTaGCTCTTGTTTTTCACAG	SEQ NO ID:325
pSecTag2 hygro-huIL10 E140Y	pSecTag2hy gro-huIL10	CAAGAGCAAGGCCGTGtAcCAGGTGAAGAATGCC	SEQ NO ID:326
		GGCATTCTTCACCTGgTaCACGGCCTTGCTCTTG	SEQ NO ID:327
pSecTag2 hygro-huIL10 Q141Y	pSecTag2hy gro-huIL10	GAGCAAGGCCGTGGAGtAcGTGAAGAATGCCTTTA	SEQ NO ID:328
		TAAAGGCATTCTTCACgTaCTCCACGGCCTTGCTC	SEQ NO ID:329
pSecTag2 hygro-huIL10 K143Y	pSecTag2hy gro-huIL10	CAAGGCCGTGGAGCAGGTGtAcAATGCCTTTAATA AGCTCC	SEQ NO ID:330
		GGAGCTTATTAAAGGCATTgTaCACCTGCTCCACG GCCTTG	SEQ NO ID:331
pSecTag2 hygro-huIL10 N144Y	pSecTag2hy gro-huIL10	CGTGGAGCAGGTGAAGtAcGCCTTTAATAAGCTCC	SEQ NO ID:332
		GGAGCTTATTAAAGGCgTaCTTCACCTGCTCCACG	SEQ NO ID:333
pSecTag2 hygro-huIL10 N147Y	pSecTag2hy gro-huIL10	GAAGAATGCCTTTtAcAAGCTCCAAGAG	SEQ NO ID:334
		CTCTTGAGCTTgTaAAAGGCATTCTTC	SEQ NO ID:335
pSecTag2 hygro-huIL10 K148Y	pSecTag2hy gro-huIL10	GAAGAATGCCTTTAATtAcCTCCAAGAGAAAGGC	SEQ NO ID:336
		GCCTTTCTCTTGAGgTaATTAAAGGCATTCTTC	SEQ NO ID:337
pSecTag2 hygro-huIL10 Q150Y	pSecTag2hy gro-huIL10	GCCTTTAATAAGCTCtAcGAGAAAGGCATCTAC	SEQ NO ID:338
		GTAGATGCCTTTCTCgTaGAGCTTATTAAAGGC	SEQ NO ID:339
pSecTag2 hygro-huIL10 E151Y	pSecTag2hy gro-huIL10	CTTTAATAAGCTCCAAAtAcAAAGGCATCTACAAAG	SEQ NO ID:340
		CTTTGTAGATGCCTTTgTaTTGGAGCTTATTAAAG	SEQ NO ID:341
pSecTag2 hygro-huIL10 K152Y	pSecTag2hy gro-huIL10	CTTTAATAAGCTCCAAAGAGtAcGGCATCTACAAAG CC	SEQ NO ID:342
		GGCTTTGTAGATGCCgTaCTCTTGAGCTTATTAA AG	SEQ NO ID:343
pSecTag2 hygro-huIL10 G153Y	pSecTag2hy gro-huIL10	GCTCCAAGAGAAAAtaCATCTACAAAGCCATGAGTG	SEQ NO ID:344
		CACTCATGGCTTTGTAGATGtaTTTCTCTTGAGC	SEQ NO ID:345
pSecTag2 hygro-huIL10 K175Y	pSecTag2hy gro-huIL10	GCCTACATGACAATGtAcATACGAAACTGAGGGCC	SEQ NO ID:346
		GGCCCTCAGTTTCGTATgTaCATTGTCATGTAGGC	SEQ NO ID:347
pSecTag2 hygro-huIL10 N178Y	pSecTag2hy gro-huIL10	CATGACAATGAAGATACGAtACTGAGGGCCCGAA C	SEQ NO ID:348
		GTTCGGGGCCCTCAGTaTCGTATCTTCATTGTCATG	SEQ NO ID:349
pSecTag2hygro -huIL10 S19N	pSecTag2hy gro-huIL10	GACTGGGGTGAGGGCCAaCCCAGGCCAGGGCACC C	SEQ NO ID:350
		GGGTGCCCTGGCCTGGGtTGGCCCTCACCCAGTC	SEQ NO ID:351
pSecTag2hygro	pSecTag2hy	GGGTGAGGGCCAaCCCAaGCCAGGGCACCCAGTC	SEQ NO ID:352

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 S19N, G21S	gro-huIL10 S19N	GACTGGGTGCCCTGGCtTGGGtTGGCCCTCACCC	SEQ NO ID:353
pSecTag2hygro-huIL10 S19N, P20G, G21S	pSecTag2hygro-huIL10 S19N, G21S	GGGGTGAGGGCCAaCggtAGCCAGGGCACCCAG	SEQ NO ID:354
		CTGGGTGCCCTGGCtaccGtTGGCCCTCACCCC	SEQ NO ID:355
pSecTag2hygro-huIL10 S19N, G21T	pSecTag2hygro-huIL10 S19N	GGTGAGGGCCAaCCCAacCCAGGGCACCCAGTCTG	SEQ NO ID:356
		CAGACTGGGTGCCCTGGgtTGGGtTGGCCCTCACC	SEQ NO ID:357
pSecTag2hygro-huIL10 S19N, P20A, G21T	pSecTag2hygro-huIL10 S19N, G21T	GGTGAGGGCCAaCggtacCCAGGGCACCC	SEQ NO ID:358
		GGGTGCCCTGGgtaccGtTGGCCCTCACC	SEQ NO ID:359
pSecTag2hygro-huIL10 P20N	pSecTag2hygro-huIL10	GGGGTGAGGGCCAGCaacGGCCAGGGCACCCAGTC	SEQ NO ID:360
		GACTGGGTGCCCTGGCCgttGCTGGCCCTCACCCC	SEQ NO ID:361
pSecTag2hygro-huIL10 P20N, Q22S	pSecTag2hygro-huIL10 P20N	GGGCCAGCaacGGCagcGGCACCCAGTCTGAGAAC	SEQ NO ID:362
		GTTCTCAGACTGGGTGCCgctGCCgttGCTGGCCC	SEQ NO ID:363
pSecTag2hygro-huIL10 P20N, Q22T	pSecTag2hygro-huIL10 P20N	GAGGGCCAGCaacGGCaccGGCACCCAGTCTGAG	SEQ NO ID:364
		CTCAGACTGGGTGCCggtGCCgttGCTGGCCCTC	SEQ NO ID:365
pSecTag2hygro-huIL10 G21N	pSecTag2hygro-huIL10	GGTGAGGGCCAGCCCAaaCCAGGGCACCCAGTCTG	SEQ NO ID:366
		CAGACTGGGTGCCCTGGtTGGGCTGGCCCTCACC	SEQ NO ID:367
pSecTag2hygro-huIL10 G21N, G23S	pSecTag2hygro-huIL10 G21N	GGGCCAGCCCAaaCCAGaGCACCCAGTCTGAGAAC	SEQ NO ID:368
		GTTCTCAGACTGGGTGCtCTGGtTGGGCTGGCCC	SEQ NO ID:369
pSecTag2hygro-huIL10 G21N, G23T	pSecTag2hygro-huIL10 G21N	GGGCCAGCCCAaaCCAGacCACCCAGTCTGAGAAC	SEQ NO ID:370
		GTTCTCAGACTGGGTGgtCTGGtTGGGCTGGCCC	SEQ NO ID:371
pSecTag2hygro-huIL10 Q22N	pSecTag2hygro-huIL10	GAGGGCCAGCCCAGGCaAcGGCACCCAGTCTGAG	SEQ NO ID:372
		CTCAGACTGGGTGCCgTtGCCTGGGCTGGCCCTC	SEQ NO ID:373
pSecTag2hygro-huIL10 Q22N, T24S	pSecTag2hygro-huIL10 Q22N	CAGCCCAGGCaAcGGCAgCCAGTCTGAGAACAGC	SEQ NO ID:374
		GCTGTTCTCAGACTGGcTGCCgTtGCCTGGGCTG	SEQ NO ID:375
pSecTag2hygro-huIL10 G23N	pSecTag2hygro-huIL10	GGGCCAGCCCAGGCCAGaaCACCCAGTCTGAGAA	SEQ NO ID:376
		GTTCTCAGACTGGGTGtTCTGGCCTGGGCTGGCCC	SEQ NO ID:377
pSecTag2hygro-huIL10 G23N, Q25S	pSecTag2hygro-huIL10 G23N	GCCCAGGCCAGaaCACCagcTCTGAGAACAGCTGC	SEQ NO ID:378
		GCAGCTGTTCTCAGAgctGGTGtTCTGGCCTGGGC	SEQ NO ID:379
pSecTag2hygro-huIL10 G23N, Q25T	pSecTag2hygro-huIL10 G23N	CCCAGGCCAGaaCACCaccTCTGAGAACAGCTGCAC	SEQ NO ID:380
		GTGCAGCTGTTCTCAGAggtGGTGtTCTGGCCTGGG	SEQ NO ID:381
pSecTag2hygro-huIL10 T24N	pSecTag2hygro-huIL10	CCAGCCCAGGCCAGGGCAaCCAGTCTGAGAACAG	SEQ NO ID:382
		GCTGTTCTCAGACTGGtTGCCCTGGCCTGGGCTGG	SEQ NO ID:383
pSecTag2hygro-huIL10 T24N, S26T	pSecTag2hygro-huIL10 T24N	CAGGCCAGGGCAaCCAGaCcGAGAACAGCTGCACC	SEQ NO ID:384
		GGTGCAGCTGTTCTCgGtCTGGtTGCCCTGGCCTG	SEQ NO ID:385
pSecTag2hygro-huIL10 Q25N	pSecTag2hygro-huIL10	CCAGGCCAGGGCACCaAcTCTGAGAACAGCTGCA	SEQ NO ID:386
		GTGCAGCTGTTCTCAGAgTtGGTGCCCTGGCCTGG	SEQ NO ID:387

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 Q25N, E27S	pSecTag2hygro-huIL10 Q25N	GCCAGGGCACC _{CaAc} TCTagcAACAGCTGCACCCAC	SEQ NO ID:388
		GTGGGTGCAGCTGTTgctAGAgTtGGTGCCCTGGC	SEQ NO ID:389
pSecTag2hygro-huIL10 Q25N, E27T	pSecTag2hygro-huIL10 Q25N	GCCAGGGCACC _{CaAc} TCTaccAACAGCTGCACCCAC	SEQ NO ID:390
		GTGGGTGCAGCTGTTggtAGAgTtGGTGCCCTGGC	SEQ NO ID:391
pSecTag2hygro-huIL10 S26N	pSecTag2hygro-huIL10	GGCCAGGGCACCCAGaacGAGAACAGCTGCACCC	SEQ NO ID:392
		GGGTGCAGCTGTTCTCgttCTGGGTGCCCTGGCC	SEQ NO ID:393
pSecTag2hygro-huIL10 S26N, N28S	pSecTag2hygro-huIL10 S26N	GGGCACCCAGaacGAGAgCAGCTGCACCCACTTCC	SEQ NO ID:394
		GGAAGTGGGTGCAGCTGcTCTCgttCTGGGTGCCC	SEQ NO ID:395
pSecTag2hygro-huIL10 S26N, N28T	pSecTag2hygro-huIL10 S26N	GGGCACCCAGaacGAGAcCAGCTGCACCCACTTCC	SEQ NO ID:396
		GGAAGTGGGTGCAGCTGgTCTCgttCTGGGTGCCC	SEQ NO ID:397
pSecTag2hygro-huIL10 E27N	pSecTag2hygro-huIL10	CCAGGGCACCCAGTCTaAcAACAGCTGCACCCAC	SEQ NO ID:398
		GTGGGTGCAGCTGTTgTtAGACTGGGTGCCCTGG	SEQ NO ID:399
pSecTag2hygro-huIL10 E27N, S29T	pSecTag2hygro-huIL10 E27N	CACCCAGTCTaAcAACAcCTGCACCCACTTCCCAG	SEQ NO ID:400
		CTGGGAAGTGGGTGCAGgTGTTgTtAGACTGGGTG	SEQ NO ID:401
pSecTag2hygro-huIL10 S29N	pSecTag2hygro-huIL10	CACCCAGTCTGAGAACAaCTGCACCCACTTCCCAG	SEQ NO ID:402
		CTGGGAAGTGGGTGCAGtTGTTCTCAGACTGGGTG	SEQ NO ID:403
pSecTag2hygro-huIL10 S29N, T31S	pSecTag2hygro-huIL10 S29N	GTCTGAGAACAaCTGCAGCCACTTCCCAGGCAACC	SEQ NO ID:404
		GGTTGCCTGGGAAGTGGcTGCAGtTGTTCTCAGAC	SEQ NO ID:405
pSecTag2hygro-huIL10 T31N	pSecTag2hygro-huIL10	GTCTGAGAACAGCTGCAaCCACTTCCCAGGCAAC	SEQ NO ID:406
		C GGTTGCCTGGGAAGTGGtTGCAGCTGTTCTCAGAC	SEQ NO ID:407
pSecTag2hygro-huIL10 T31N, F33S	pSecTag2hygro-huIL10 T31N	GAACAGCTGCAaCCACagCCCAGGCAACCTGCC	SEQ NO ID:408
		GGCAGGTTGCCTGGGcTGTGGtTGCAGCTGTTC	SEQ NO ID:409
pSecTag2hygro-huIL10 T31N, F33T	pSecTag2hygro-huIL10 T31N	GAGAACAGCTGCAaCCACacCCCAGGCAACCTGCC	SEQ NO ID:410
		GGCAGGTTGCCTGGGgtGTGGtTGCAGCTGTTCTC	SEQ NO ID:411
pSecTag2hygro-huIL10 H32N	pSecTag2hygro-huIL10	CTGAGAACAGCTGCACC _a ACTTCCCAGGCAACCT	SEQ NO ID:412
		G CAGGTTGCCTGGGAAGTtGGTGCAGCTGTTCTCAG	SEQ NO ID:413
pSecTag2hygro-huIL10 H32N, P34S	pSecTag2hygro-huIL10 H32N	GCTGCACC _a ACTTCagcGGCAACCTGCCTAACATG	SEQ NO ID:414
		CATGTTAGGCAGGTTGCCgctGAAGTtGGTGCAGC	SEQ NO ID:415
pSecTag2hygro-huIL10 H32N, P34T	pSecTag2hygro-huIL10 H32N	CAGCTGCACC _a ACTTCaCcGGCAACCTGCCTAAC	SEQ NO ID:416
		GTTAGGCAGGTTGCCgGtGAAGTtGGTGCAGCTG	SEQ NO ID:417
pSecTag2hygro-huIL10 G35N	pSecTag2hygro-huIL10	CTGCACCCACTTCCCAaaCAACCTGCCTAACATGC	SEQ NO ID:418
		GCATGTTAGGCAGGTTGttTGGGAAGTGGGTGCAG	SEQ NO ID:419
pSecTag2hygro-huIL10 G35N, L37S	pSecTag2hygro-huIL10 G35N	CCACTTCCCAaaCAACagcCCTAACATGCTTCGAG	SEQ NO ID:420
		CTCGAAGCATGTTAGGgctGTTGttTGGGAAGTGG	SEQ NO ID:421
pSecTag2hygro-huIL10 G35N, L37T	pSecTag2hygro-huIL10 G35N	CCACTTCCCAaaCAACaccCCTAACATGCTTCGAG	SEQ NO ID:422
		CTCGAAGCATGTTAGGggtGTTGttTGGGAAGTGG	SEQ NO ID:423
pSecTag2hygro	pSecTag2hy	CTTCCCAGGCAACCTGagcAACATGCTTCGAGATC	SEQ NO ID:424

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 P38S	gro-huIL10	GATCTCGAAGCATGTTgctCAGGTTGCCTGGGAAG	SEQ NO ID:425
pSecTag2hygro	pSecTag2hy	CTTCCCAGGCAACCTGaCcAACATGCTTCGAGATC	SEQ NO ID:426
-huIL10 P38T	gro-huIL10	GATCTCGAAGCATGTTgGtCAGGTTGCCTGGGAAG	SEQ NO ID:427
pSecTag2hygro	pSecTag2hy	CCTAACATGCTTCGAaAcCTCCGAGATGCCTTCAG	SEQ NO ID:428
-huIL10 D43N	gro-huIL10	CTGAAGGCATCTCGGAGgTtTCGAAGCATGTTAGG	SEQ NO ID:429
pSecTag2hygro	pSecTag2hy	CATGCTTCGAaAcCTCagcGATGCCTTCAGCAGAG	SEQ NO ID:430
-huIL10 D43N, R45S	gro-huIL10 D43N	CTCTGCTGAAGGCATCgctGAGgTtTCGAAGCATG	SEQ NO ID:431
pSecTag2hygro	pSecTag2hy	CATGCTTCGAaAcCTCaccGATGCCTTCAGCAGAG	SEQ NO ID:432
-huIL10 D43N, R45T	gro-huIL10 D43N	CTCTGCTGAAGGCATCggtGAGgTtTCGAAGCATG	SEQ NO ID:433
pSecTag2hygro	pSecTag2hy	CTCCGAGATGCCTTCAaCAGAGTGAAGACTTTC	SEQ NO ID:434
-huIL10 S49N	gro-huIL10	GAAAGTCTTCACTCTGtTGAAGGCATCTCGGAG	SEQ NO ID:435
pSecTag2hygro	pSecTag2hy	GATGCCTTCAaCAGAagcAAGACTTTCTTTCAAAT	SEQ NO ID:436
-huIL10 S49N, V51S	gro-huIL10 S49N	ATTTGAAAGAAAGTCTTgctTCTGtTGAAGGCATC	SEQ NO ID:437
pSecTag2hygro	pSecTag2hy	GATGCCTTCAaCAGAaccAAGACTTTCTTTCAAATG	SEQ NO ID:438
-huIL10 S49N, V51T	gro-huIL10 S49N	CATTTGAAAGAAAGTCTTggtTCTGtTGAAGGCATC	SEQ NO ID:439
pSecTag2hygro	pSecTag2hy	CCGAGATGCCTTCAGCAacGTGAAGACTTTCTTTC	SEQ NO ID:440
-huIL10 R50N	gro-huIL10	GAAAGAAAGTCTTCACgtTGCTGAAGGCATCTCGG	SEQ NO ID:441
pSecTag2hygro	pSecTag2hy	CCTTCAGCAacGTGAgcACTTTCTTTCAAATGAAG	SEQ NO ID:442
-huIL10 R50N, K52S	gro-huIL10 R50N	CTTCATTTGAAAGAAAGTgcTCACgtTGCTGAAGG	SEQ NO ID:443
pSecTag2hygro	pSecTag2hy	GCCTTCAGCAacGTGAaccACTTTCTTTCAAATGAAG	SEQ NO ID:444
-huIL10 R50N, K52T	gro-huIL10 R50N	CTTCATTTGAAAGAAAGTggTCACgtTGCTGAAGGC	SEQ NO ID:445
pSecTag2hygro	pSecTag2hy	CTTTCTTTCAAATGAaCgATCAGCTGGACAACCTTG	SEQ NO ID:446
-huIL10 K58N	gro-huIL10	CAAGTTGTCCAGCTGATCgTTCATTTGAAAGAAAG	SEQ NO ID:447
pSecTag2hygro	pSecTag2hy	CTTTCAAATGAaCgATagcCTGGACAACCTTGTTG	SEQ NO ID:448
-huIL10 K58N, Q60S	gro-huIL10 K58N	CAACAAGTTGTCCAGgctATCgTTCATTTGAAAG	SEQ NO ID:449
pSecTag2hygro	pSecTag2hy	CTTTCAAATGAaCgATaccCTGGACAACCTTGTTG	SEQ NO ID:450
-huIL10 K58N, Q60T	gro-huIL10 K58N	CAACAAGTTGTCCAGggtATCgTTCATTTGAAAG	SEQ NO ID:451
pSecTag2hygro	pSecTag2hy	GTTGTTAAATGAGTCCTTGCTGGAGG	SEQ NO ID:452
-huIL10 K67N	gro-huIL10	CCTCCAGCAAGGACTCATTTAACAAC	SEQ NO ID:453
pSecTag2hygro	pSecTag2hy	TGTTGTTAAAtGAGagCTTGCTGGAGGACTTTAAG	SEQ NO ID:454
-huIL10 K67N, S69T	gro-huIL10 K67N	CTTAAAGTCCTCCAGCAAGctCTCaTTTAACAACA	SEQ NO ID:455
pSecTag2hygro	pSecTag2hy	CAACTTGTTGTTAAAGaAcTCCTTGCTGGAGGAC	SEQ NO ID:456
-huIL10 E68N	gro-huIL10	GTCCTCCAGCAAGGAGtTtCTTTAACAACAAGTTG	SEQ NO ID:457
pSecTag2hygro	pSecTag2hy	GTTGTTAAAGaAcTCCagcCTGGAGGACTTTAAGG	SEQ NO ID:458
-huIL10 E68N, L70S	gro-huIL10 E68N	CCTTAAAGTCCTCCAGgctGGAgTtCTTTAACAAC	SEQ NO ID:459
pSecTag2hygro	pSecTag2hy	GTTGTTAAAGaAcTCCaccCTGGAGGACTTTAAGG	SEQ NO ID:460
-huIL10 E68N, L70T	gro-huIL10 E68N	CCTTAAAGTCCTCCAGggtGGAgTtCTTTAACAAC	SEQ NO ID:461
pSecTag2hygro	pSecTag2hy	TGTTGTTAAAGGAGaaCTTGCTGGAGGACTTTAAG	SEQ NO ID:462
-huIL10 S69N	gro-huIL10	CTTAAAGTCCTCCAGCAAGttCTCCTTTAACAACA	SEQ NO ID:463
pSecTag2hygro	pSecTag2hy	GTAAAGGAGaaCTTGagcGAGGACTTTAAGGGTT	SEQ NO ID:464
-huIL10 S69N, L71S	gro-huIL10 S69N	AACCCTTAAAGTCCTCgctCAAGttCTCCTTTAAC	SEQ NO ID:465

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 S69N, L71T	pSecTag2hygro-huIL10 S69N	GTAAAGGAGaaCTTGaccGAGGACTTTAAGGGTTA C	SEQ NO ID:466
		GTAACCCTTAAAGTCCTCggtCAAGttCTCCTTTAAC	SEQ NO ID:467
pSecTag2hygro-huIL10 E72N	pSecTag2hygro-huIL10	GGAGTCCTTGCTGaAcGACTTTAAGGGTTACCTGG	SEQ NO ID:468
		CCAGGTAACCCTTAAAGTCgTtCAGCAAGGACTCC	SEQ NO ID:469
pSecTag2hygro-huIL10 E72N, F74S	pSecTag2hygro-huIL10 E72N	GTCCTTGCTGaAcGACagcAAGGGTTACCTGGG	SEQ NO ID:470
		CCCAGGTAACCCTTgctGTCgTtCAGCAAGGAC	SEQ NO ID:471
pSecTag2hygro-huIL10 E72N, F74T	pSecTag2hygro-huIL10 E72N	GTCCTTGCTGaAcGACaccAAGGGTTACCTGGGTTG	SEQ NO ID:472
		CAACCCAGGTAACCCTTggtGTCgTtCAGCAAGGAC	SEQ NO ID:473
pSecTag2hygro-huIL10 D73N	pSecTag2hygro-huIL10	GGAGTCCTTGCTGGAGaACTTTAAGGGTTACCTGG	SEQ NO ID:474
		CCAGGTAACCCTTAAAGTtCTCCAGCAAGGACTCC	SEQ NO ID:475
pSecTag2hygro-huIL10 D73N, K75S	pSecTag2hygro-huIL10 D73N	CTTGCTGGAGaACTTTAgcGGTTACCTGGGTTGCC	SEQ NO ID:476
		GGCAACCCAGGTAACCgcTAAAGTtCTCCAGCAAG	SEQ NO ID:477
pSecTag2hygro-huIL10 D73N, K75T	pSecTag2hygro-huIL10 D73N	CTTGCTGGAGaACTTTAccGGTTACCTGGGTTGCC	SEQ NO ID:478
		GGCAACCCAGGTAACCggTAAAGTtCTCCAGCAAG	SEQ NO ID:479
pSecTag2hygro-huIL10 K75N	pSecTag2hygro-huIL10	CTTGCTGGAGGACTTTAAcGGTTACCTGGGTTGCC	SEQ NO ID:480
		GGCAACCCAGGTAACCgTTAAAGTCCTCCAGCAA G	SEQ NO ID:481
pSecTag2hygro-huIL10 K75N, Y77S	pSecTag2hygro-huIL10 K75N	GGAGGACTTTAAcGGTagCCTGGGTTGCCAAGCC	SEQ NO ID:482
		GGCTTGGCAACCCAGGctACCgTTAAAGTCCTCC	SEQ NO ID:483
pSecTag2hygro-huIL10 K75N, Y77T	pSecTag2hygro-huIL10 K75N	GGAGGACTTTAAcGGTaccCCTGGGTTGCCAAGCC	SEQ NO ID:484
		GGCTTGGCAACCCAGGgtACCgTTAAAGTCCTCC	SEQ NO ID:485
pSecTag2hygro-huIL10 G76N	pSecTag2hygro-huIL10	GCTGGAGGACTTTAAGaacTACCTGGGTTGCCAAG	SEQ NO ID:486
		CTTGGCAACCCAGGTAgttCTTAAAGTCCTCCAGC	SEQ NO ID:487
pSecTag2hygro-huIL10 G76N, L78S	pSecTag2hygro-huIL10 G76N	GGACTTTAAGaacTACagcGGTTGCCAAGCCTTG	SEQ NO ID:488
		CAAGGCTTGGCAACCgctGTAgttCTTAAAGTCC	SEQ NO ID:489
pSecTag2hygro-huIL10 G76N, L78T	pSecTag2hygro-huIL10 G76N	GGACTTTAAGaacTACaccGGTTGCCAAGCCTTG	SEQ NO ID:490
		CAAGGCTTGGCAACCggtGTAgttCTTAAAGTCC	SEQ NO ID:491
pSecTag2hygro-huIL10 Y77N	pSecTag2hygro-huIL10	CTGGAGGACTTTAAGGGTaACCTGGGTTGCCAAG C	SEQ NO ID:492
		GCTTGGCAACCCAGGTtACCCTTAAAGTCCTCCAG	SEQ NO ID:493
pSecTag2hygro-huIL10 Y77N, G79S	pSecTag2hygro-huIL10 Y77N	TTAAGGGTaACCTGaGcTGCCAAGCCTTGTC	SEQ NO ID:494
		GACAAGGCTTGGCAgCtCAGGTtACCCTTAA	SEQ NO ID:495
pSecTag2hygro-huIL10 G79N	pSecTag2hygro-huIL10	CTTTAAGGGTTACCTGaacTGCCAAGCCTTGCTCTG	SEQ NO ID:496
		CAGACAAGGCTTGGCAgttCAGGTAACCCTTAAAG	SEQ NO ID:497
pSecTag2hygro-huIL10 G79N, Q81S	pSecTag2hygro-huIL10 G79N	GGGTTACCTGaacTGCagcGCCTTGCTCTGAGATG	SEQ NO ID:498
		CATCTCAGACAAGGCgctGCAgttCAGGTAACCC	SEQ NO ID:499
pSecTag2hygro-huIL10 G79N, Q81T	pSecTag2hygro-huIL10 G79N	GGGTTACCTGaacTGCaccGCCTTGCTCTGAGATG	SEQ NO ID:500
		CATCTCAGACAAGGCggtGCAgttCAGGTAACCC	SEQ NO ID:501
pSecTag2hygro-huIL10 Q81N	pSecTag2hygro-huIL10	GGGTTACCTGGGTTGCaAcGCCTTGCTCTGAGATG	SEQ NO ID:502
		CATCTCAGACAAGGCgTtGCAACCCAGGTAACCC	SEQ NO ID:503
pSecTag2hygro	pSecTag2hygro	CCTGGGTTGCaAcGCCagcTCTGAGATGATCCAG	SEQ NO ID:504

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 Q81N, L83S	gro-huIL10 Q81N	CTGGATCATCTCAGAgctGGCgTtGCAACCCAGG	SEQ NO ID:505
pSecTag2hygro -huIL10 Q81N, L83T	pSecTag2hy gro-huIL10 Q81N	CCTGGGTTGCaAcGCCaccTCTGAGATGATCCAG	SEQ NO ID:506
		CTGGATCATCTCAGAggtGGCgTtGCAACCCAGG	SEQ NO ID:507
pSecTag2hygro -huIL10 S84N	pSecTag2hy gro-huIL10	GTTGCCAAGCCTTGaacGAGATGATCCAGTTTTAC	SEQ NO ID:508
		GTAAAACTGGATCATCTCgttCAAGGCTTGGCAAC	SEQ NO ID:509
pSecTag2hygro -huIL10 S84N, M86S	pSecTag2hy gro-huIL10 S84N	CCAAGCCTTGaacGAGAgcATCCAGTTTTACCTGG	SEQ NO ID:510
		CCAGGTAAAACTGGATgcTCTCgttCAAGGCTTGG	SEQ NO ID:511
pSecTag2hygro -huIL10 S84N, M86T	pSecTag2hy gro-huIL10 S84N	CCAAGCCTTGaacGAGAccATCCAGTTTTACCTGG	SEQ NO ID:512
		CCAGGTAAAACTGGATggTCTCgttCAAGGCTTGG	SEQ NO ID:513
pSecTag2hygro -huIL10 E85N	pSecTag2hy gro-huIL10	GTTGCCAAGCCTTGTCTaAcATGATCCAGTTTTAC	SEQ NO ID:514
		GTAAAACTGGATCATgTtAGACAAGGCTTGGCAAC	SEQ NO ID:515
pSecTag2hygro -huIL10 E85N, I87S	pSecTag2hy gro-huIL10 E85N	GCCTTGTCTaAcATGAgCCAGTTTTACCTGGAGG	SEQ NO ID:516
		CCTCCAGGTAAAACTGGcTCATgTtAGACAAGGC	SEQ NO ID:517
pSecTag2hygro -huIL10 E85N, I87T	pSecTag2hy gro-huIL10 E85N	GCCTTGTCTaAcATGAcCCAGTTTTACCTGGAGG	SEQ NO ID:518
		CCTCCAGGTAAAACTGGgTCATgTtAGACAAGGC	SEQ NO ID:519
pSecTag2hygro -huIL10 Q88N	pSecTag2hy gro-huIL10	CTTGTCTGAGATGATCaAcTTTTACCTGGAGGAGG	SEQ NO ID:520
		CCTCCTCCAGGTAAAAgTtGATCATCTCAGACAAG	SEQ NO ID:521
pSecTag2hygro -huIL10 Q88N, Y90S	pSecTag2hy gro-huIL10 Q88N	CTGAGATGATCaAcTTTagCCTGGAGGAGGTGATG	SEQ NO ID:522
		CATCACCTCCTCCAGGctAAAgtTtGATCATCTCAG	SEQ NO ID:523
pSecTag2hygro -huIL10 Q88N, Y90T	pSecTag2hy gro-huIL10 Q88N	CTGAGATGATCaAcTTTaccCCTGGAGGAGGTGATG	SEQ NO ID:524
		CATCACCTCCTCCAGGgtAAAgtTtGATCATCTCAG	SEQ NO ID:525
pSecTag2hygro -huIL10 E92N	pSecTag2hy gro-huIL10	GATCCAGTTTTACCTGaAcGAGGTGATGCCCCAAG	SEQ NO ID:526
		CTTGGGGGCATCACCTCgTtCAGGTAAAACTGGATC	SEQ NO ID:527
pSecTag2hygro -huIL10 E92N, V94S	pSecTag2hy gro-huIL10 E92N	GTTTTACCTGaAcGAGagcATGCCCCAAGCTGAG	SEQ NO ID:528
		CTCAGCTTGGGGGCATgctCTCgTtCAGGTAAAAAC	SEQ NO ID:529
pSecTag2hygro -huIL10 E92N, V94T	pSecTag2hy gro-huIL10 E92N	GTTTTACCTGaAcGAGaccATGCCCCAAGCTGAG	SEQ NO ID:530
		CTCAGCTTGGGGGCATggtCTCgTtCAGGTAAAAAC	SEQ NO ID:531
pSecTag2hygro -huIL10 E93N	pSecTag2hy gro-huIL10	CCAGTTTTACCTGGAGaAcGTGATGCCCCAAGCTG	SEQ NO ID:532
		CAGCTTGGGGGCATCACgTtCTCCAGGTAAAACTGG	SEQ NO ID:533
pSecTag2hygro -huIL10 E93N, M95S	pSecTag2hy gro-huIL10 E93N	CCTGGAGaAcGTGAgcCCCCAAGCTGAGAACCAAG	SEQ NO ID:534
		CTTGGTTCTCAGCTTGGGGgcTCACgTtCTCCAGG	SEQ NO ID:535
pSecTag2hygro -huIL10 E93N, M95T	pSecTag2hy gro-huIL10 E93N	CCTGGAGaAcGTGAccCCCCAAGCTGAGAACCAAG	SEQ NO ID:536
		CTTGGTTCTCAGCTTGGGGggTCACgTtCTCCAGG	SEQ NO ID:537
pSecTag2hygro -huIL10 P96N	pSecTag2hy gro-huIL10	CCTGGAGGAGGTGATGaaCCAAGCTGAGAACCAA G	SEQ NO ID:538
		CTTGGTTCTCAGCTTGGttCATCACCTCCTCCAGG	SEQ NO ID:539
pSecTag2hygro -huIL10 P96N, A98S	pSecTag2hy gro-huIL10 P96N	GGAGGTGATGaaCCAAagcGAGAACCAAGACCCAG	SEQ NO ID:540
		CTGGGTCTTGGTTCTCgctTTGGttCATCACCTCC	SEQ NO ID:541
pSecTag2hygro	pSecTag2hy	GGAGGTGATGaaCCAAaCcGAGAACCAAGACCCAG	SEQ NO ID:542

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 P96N, A98T	gro-huIL10 P96N	CTGGGTCTTGGTTCTCgGtTTGGtCATCACCTCC	SEQ NO ID:543
pSecTag2hygro-huIL10 Q97N	pSecTag2hygro-huIL10	GGAGGAGGTGATGCCCaAcGCTGAGAACCAAGAC C	SEQ NO ID:544
		GGTCTTGGTTCTCAGCgTtGGGCATCACCTCCTCC	SEQ NO ID:545
pSecTag2hygro-huIL10 Q97N, E99S	pSecTag2hygro-huIL10 Q97N	GGTGATGCCCaAcGCTagcAACCAAGACCCAGAC	SEQ NO ID:546
		GTCTGGGTCTTGGTTgctAGCgTtGGGCATCACC	SEQ NO ID:547
pSecTag2hygro-huIL10 Q97N, E99T	pSecTag2hygro-huIL10 Q97N	GGTGATGCCCaAcGCTaccAACCAAGACCCAGAC	SEQ NO ID:548
		GTCTGGGTCTTGGTTggtAGCgTtGGGCATCACC	SEQ NO ID:549
pSecTag2hygro-huIL10 E99N	pSecTag2hygro-huIL10	GGTGATGCCCCAAGCTaAcAACCAAGACCCAGAC	SEQ NO ID:550
		GTCTGGGTCTTGGTTgTtAGCTTGGGGCATCACC	SEQ NO ID:551
pSecTag2hygro-huIL10 E99N, Q101S	pSecTag2hygro-huIL10 E99N	GCCCCAAGCTaAcAACagcGACCCAGACATCAAGG	SEQ NO ID:552
		CCTTGATGTCTGGGTCgctGTTgTtAGCTTGGGGC	SEQ NO ID:553
pSecTag2hygro-huIL10 E99N, Q101T	pSecTag2hygro-huIL10 E99N	GCCCCAAGCTaAcAACaccGACCCAGACATCAAGG	SEQ NO ID:554
		CCTTGATGTCTGGGTCggtGTTgTtAGCTTGGGGC	SEQ NO ID:555
pSecTag2hygro-huIL10 Q101N	pSecTag2hygro-huIL10	GCCCCAAGCTGAGAACaAcGACCCAGACATCAAG G	SEQ NO ID:556
		CCTTGATGTCTGGGTCgTtGTTCTCAGCTTGGGGC	SEQ NO ID:557
pSecTag2hygro-huIL10 Q101N, P103S	pSecTag2hygro-huIL10 Q101N	GCTGAGAACaAcGACagcGACATCAAGGCGCATG	SEQ NO ID:558
		CATGCGCCTTGATGTCgctGTCgTtGTTCTCAGC	SEQ NO ID:559
pSecTag2hygro-huIL10 Q101N, P103T	pSecTag2hygro-huIL10 Q101N	GCTGAGAACaAcGACaCcGACATCAAGGCGCATG	SEQ NO ID:560
		CATGCGCCTTGATGTCgGtGTCgTtGTTCTCAGC	SEQ NO ID:561
pSecTag2hygro-huIL10 D102S	pSecTag2hygro-huIL10	GCCCCAAGCTGAGAACCaaAGCCCAGACATCAAG GCG	SEQ NO ID:562
		CGCCTTGATGTCTGGGCTTTGGTTCTCAGCTTGGG GC	SEQ NO ID:563
pSecTag2hygro-huIL10 D102T	pSecTag2hygro-huIL10	CCAAGCTGAGAACCaaacCCCAGACATCAAGGCG C	SEQ NO ID:564
		GCGCCTTGATGTCTGGGgtTTGGTTCTCAGCTTGG	SEQ NO ID:565
pSecTag2hygro-huIL10 D102N	pSecTag2hygro-huIL10	CCAAGCTGAGAACCaaAaACCCAGACATCAAGGCG C	SEQ NO ID:566
		GCGCCTTGATGTCTGGGTtTTGGTTCTCAGCTTGG	SEQ NO ID:567
pSecTag2hygro-huIL10 D102N, D104S	pSecTag2hygro-huIL10 D102N	CTGAGAACCaaAaACCCAagCATCAAGGCGCATGTG	SEQ NO ID:568
		CACATGCGCCTTGATGctTGGGTtTTGGTTCTCAG	SEQ NO ID:569
pSecTag2hygro-huIL10 D102N, D104T	pSecTag2hygro-huIL10 D102N	CTGAGAACCaaAaACCCAacCATCAAGGCGCATGTG	SEQ NO ID:570
		CACATGCGCCTTGATGgtTGGGTtTTGGTTCTCAG	SEQ NO ID:571
pSecTag2hygro-huIL10 P103N	pSecTag2hygro-huIL10	GCTGAGAACCaaAGACaacGACATCAAGGCGCATG	SEQ NO ID:572
		CATGCGCCTTGATGTCgttGTCTTGGTTCTCAGC	SEQ NO ID:573
pSecTag2hygro-huIL10 P103N, I105S	pSecTag2hygro-huIL10 P103N	GAACCAAGACaacGACAgCAAGGCGCATGTGAAC	SEQ NO ID:574
		GTTACATGCGCCTTGcTGTCgttGTCTTGGTTC	SEQ NO ID:575
pSecTag2hygro-huIL10 P103N, I105T	pSecTag2hygro-huIL10 P103N	GAACCAAGACaacGACAcCAAGGCGCATGTGAAC	SEQ NO ID:576
		GTTACATGCGCCTTGgTGTCgttGTCTTGGTTC	SEQ NO ID:577

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 D104N	pSecTag2hygro-huIL10	CTGAGAACCAAGACCCAAaACATCAAGGCGCATGTG	SEQ NO ID:578
		CACATGCGCCTTGATGTtTGGGTCTTGGTTCTCAG	SEQ NO ID:579
pSecTag2hygro-huIL10 D104N, K106S	pSecTag2hygro-huIL10 D104N	CCAAGACCCAAaACATCAgcGCGCATGTGAACTCCC	SEQ NO ID:580
		GGGAGTTCACATGCGCgcTGATGTtTGGGTCTTGG	SEQ NO ID:581
pSecTag2hygro-huIL10 D104N, K106T	pSecTag2hygro-huIL10 D104N	CCAAGACCCAAaACATCAccGCGCATGTGAACTCCC	SEQ NO ID:582
		GGGAGTTCACATGCGCggTGATGTtTGGGTCTTGG	SEQ NO ID:583
pSecTag2hygro-huIL10 K106N	pSecTag2hygro-huIL10	CCAAGACCCAGACATCAAaGCGCATGTGAACTCC	SEQ NO ID:584
		GGGAGTTCACATGCGCgTTGATGTCTGGGTCTTGG	SEQ NO ID:585
pSecTag2hygro-huIL10 K106N, H108S	pSecTag2hygro-huIL10 K106N	CCCAGACATCAAaGCGagcGTGAACTCCCTGGGGG	SEQ NO ID:586
		CCCCCAGGGAGTTCACgctCGCgTTGATGTCTGGG	SEQ NO ID:587
pSecTag2hygro-huIL10 K106N, H108T	pSecTag2hygro-huIL10 K106N	CCCAGACATCAAaGCGaccGTGAACTCCCTGGGGG	SEQ NO ID:588
		CCCCCAGGGAGTTCACggtCGCgTTGATGTCTGGG	SEQ NO ID:589
pSecTag2hygro-huIL10 A107N	pSecTag2hygro-huIL10	GACCCAGACATCAAGaacCATGTGAACTCCCTGGG	SEQ NO ID:590
		CCCAGGGAGTTCACATGgttCTTGATGTCTGGGTC	SEQ NO ID:591
pSecTag2hygro-huIL10 A107N, V109S	pSecTag2hygro-huIL10 A107N	CAGACATCAAGaacCATagcAACTCCCTGGGGGAG	SEQ NO ID:592
		CTCCCCCAGGGAGTTgctATGgttCTTGATGTCTG	SEQ NO ID:593
pSecTag2hygro-huIL10 A107N, V109T	pSecTag2hygro-huIL10 A107N	GACATCAAGaacCATaccAACTCCCTGGGGGAG	SEQ NO ID:594
		CTCCCCCAGGGAGTTggtATGgttCTTGATGTC	SEQ NO ID:595
pSecTag2hygro-huIL10 H108N	pSecTag2hygro-huIL10	CCCAGACATCAAGGCGaAcGTGAACTCCCTGGGG	SEQ NO ID:596
		CCCCCAGGGAGTTCACgTtCGCCTTGATGTCTGGG	SEQ NO ID:597
pSecTag2hygro-huIL10 H108N, N110T	pSecTag2hygro-huIL10 H108N	CATCAAGGCGaAcGTGAcCTCCCTGGGGGAGAACC	SEQ NO ID:598
		GGTTCTCCCCCAGGGAGgTCACgTtCGCCTTGATG	SEQ NO ID:599
pSecTag2hygro-huIL10 S111N	pSecTag2hygro-huIL10	CAAGGCGCATGTGAACaaCCTGGGGGAGAACCTG	SEQ NO ID:600
		CAGGTTCTCCCCCAGGttGTTACATGCGCCTTG	SEQ NO ID:601
pSecTag2hygro-huIL10 S111N, G113S	pSecTag2hygro-huIL10 S111N	GCATGTGAACaaCCTGaGcGAGAACCTGAAGACCC	SEQ NO ID:602
		GGGTCTTCAGGTTCTCgCtCAGGttGTTACATGC	SEQ NO ID:603
pSecTag2hygro-huIL10 S111N, G113T	pSecTag2hygro-huIL10 S111N	GCATGTGAACaaCCTGaccGAGAACCTGAAGACCC	SEQ NO ID:604
		GGGTCTTCAGGTTCTCggtCAGGttGTTACATGC	SEQ NO ID:605
pSecTag2hygro-huIL10 L112S	pSecTag2hygro-huIL10	CGCATGTGAACTCCtcGGGGGAGAACCTG	SEQ NO ID:606
		CAGGTTCTCCCCCgaGGAGTTCACATGCG	SEQ NO ID:607
pSecTag2hygro-huIL10 L112T	pSecTag2hygro-huIL10	GGCGCATGTGAACTCCaccGGGGAGAACCTGAAG	SEQ NO ID:608
		CTTCAGGTTCTCCCCggtGGAGTTCACATGCGCC	SEQ NO ID:609
pSecTag2hygro-huIL10 G113N	pSecTag2hygro-huIL10	GCATGTGAACTCCCTGaacGAGAACCTGAAGACCC	SEQ NO ID:610
		GGGTCTTCAGGTTCTCgttCAGGGAGTTCACATGC	SEQ NO ID:611
pSecTag2hygro-huIL10 G113N, N115S	pSecTag2hygro-huIL10 G113N	GAACTCCCTGaacGAGAgCCTGAAGACCCTCAGGC	SEQ NO ID:612
		GCCTGAGGGTCTTCAGGcTCTCgttCAGGGAGTTC	SEQ NO ID:613
pSecTag2hygro-huIL10 G113N, N115T	pSecTag2hygro-huIL10 G113N	GAACTCCCTGaacGAGAcCCTGAAGACCCTCAGGC	SEQ NO ID:614
		GCCTGAGGGTCTTCAGGgTCTCgttCAGGGAGTTC	SEQ NO ID:615
pSecTag2hygro	pSecTag2hy	GTGAACTCCCTGGGGaAcAACCTGAAGACCCTCAG	SEQ NO ID:616

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 E114N	gro-huIL10	CTGAGGGTCTTCAGGTTgTtCCCCAGGGAGTTCAC	SEQ NO ID:617
pSecTag2hygro -huIL10 E114N, L116S	pSecTag2hy gro-huIL10 E114N	CTCCCTGGGGaAcAACcagcAAGACCCTCAGGCTG	SEQ NO ID:618
		CAGCCTGAGGGTCTTgctGTTgTtCCCCAGGGAG	SEQ NO ID:619
pSecTag2hygro -huIL10 E114N, L116T	pSecTag2hy gro-huIL10 E114N	CTCCCTGGGGaAcAACcaccAAGACCCTCAGGCTG	SEQ NO ID:620
		CAGCCTGAGGGTCTTggTGTgTtCCCCAGGGAG	SEQ NO ID:621
pSecTag2hygro -huIL10 K117S	pSecTag2hy gro-huIL10	CCTGGGGGAGAACCTGAgcACCCTCAGGCTGAGG C	SEQ NO ID:622
		GCCTCAGCCTGAGGGTgcTCAGGTTCTCCCCCAGG	SEQ NO ID:623
pSecTag2hygro -huIL10 K117T	pSecTag2hy gro-huIL10	CCTGGGGGAGAACCTGAccACCCTCAGGCTGAGG C	SEQ NO ID:624
		GCCTCAGCCTGAGGGTggTCAGGTTCTCCCCCAGG	SEQ NO ID:625
pSecTag2hygro -huIL10 K117N	pSecTag2hy gro-huIL10	CCTGGGGGAGAACCTGAAcACCCTCAGGCTGAGG C	SEQ NO ID:626
		GCCTCAGCCTGAGGGTgTTCAGGTTCTCCCCCAGG	SEQ NO ID:627
pSecTag2hygro -huIL10 K117N, L119S	pSecTag2hy gro-huIL10 K117N	GGAGAACCTGAACACCagCAGGCTGAGGCTACGGC	SEQ NO ID:628
		GCCGTAGCCTCAGCCTGctGGTgTTCAGGTTCTCC	SEQ NO ID:629
pSecTag2hygro -huIL10 K117N, L119T	pSecTag2hy gro-huIL10 K117N	GGAGAACCTGAACACCacCAGGCTGAGGCTACGGC	SEQ NO ID:630
		GCCGTAGCCTCAGCCTGgtGGTgTTCAGGTTCTCC	SEQ NO ID:631
pSecTag2hygro -huIL10 T118N	pSecTag2hy gro-huIL10	GGAGAACCTGAAGAAcCCTCAGGCTGAGGC	SEQ NO ID:632
		GCCTCAGCCTGAGGtTCTTCAGGTTCTCC	SEQ NO ID:633
pSecTag2hygro -huIL10 T118N, R120S	pSecTag2hy gro-huIL10 T118N	CCTGAAGAAcCCTCAGcCTGAGGCTACGGCGCTGTC	SEQ NO ID:634
		GACAGCGCCGTAGCCTCAGgCTGAGGtTCTTCAGG	SEQ NO ID:635
pSecTag2hygro -huIL10 T118N, R120T	pSecTag2hy gro-huIL10 T118N	GAACCTGAAGAAcCCTCAccCTGAGGCTACGGCGC	SEQ NO ID:636
		GCGCCGTAGCCTCAGggTGAGGtTCTTCAGGTTC	SEQ NO ID:637
pSecTag2hygro -huIL10 R120N	pSecTag2hy gro-huIL10	GAACCTGAAGACCCTCAacCTGAGGCTACGGCGC	SEQ NO ID:638
		GCGCCGTAGCCTCAGgtTGAGGGTCTTCAGGTTC	SEQ NO ID:639
pSecTag2hygro -huIL10 R120N, R122S	pSecTag2hy gro-huIL10 R120N	GACCCTCAacCTGAGcCTACGGCGCTGTCATCG	SEQ NO ID:640
		CGATGACAGCGCCGTAGgCTCAGgtTGAGGGTTC	SEQ NO ID:641
pSecTag2hygro -huIL10 R120N, R122T	pSecTag2hy gro-huIL10 R120N	GAAGACCCTCAacCTGAaccCTACGGCGCTGTCATCG	SEQ NO ID:642
		CGATGACAGCGCCGTAGggTCAGgtTGAGGGTCTTC	SEQ NO ID:643
pSecTag2hygro -huIL10 L121N	pSecTag2hy gro-huIL10	CCTGAAGACCCTCAGGaacAGGCTACGGCGCTGTC	SEQ NO ID:644
		GACAGCGCCGTAGCCTgttCCTGAGGGTCTTCAGG	SEQ NO ID:645
pSecTag2hygro -huIL10 L121N, L123S	pSecTag2hy gro-huIL10 L121N	GACCCTCAGGAacAGGagcCGGCGCTGTCATCGAT	SEQ NO ID:646
		ATCGATGACAGCGCCGgctCCTgttCCTGAGGGTC	SEQ NO ID:647
pSecTag2hygro -huIL10 L121N, L123T	pSecTag2hy gro-huIL10 L121N	GACCCTCAGGAacAGGaccCGGCGCTGTCATCG	SEQ NO ID:648
		CGATGACAGCGCCGggtCCTgttCCTGAGGGTC	SEQ NO ID:649
pSecTag2hygro -huIL10 R122N	pSecTag2hy gro-huIL10	GAAGACCCTCAGGCTGAacCTACGGCGCTGTCATC	SEQ NO ID:650
		GATGACAGCGCCGTAGgtTCAGCCTGAGGGTCTTC	SEQ NO ID:651
pSecTag2hygro -huIL10 R122N, R124S	pSecTag2hy gro-huIL10 R122N	CCTCAGGCTGAacCTAagcCGCTGTCATCGATTTC	SEQ NO ID:652
		GAAATCGATGACAGCGgctTAGgtTCAGCCTGAGG	SEQ NO ID:653
pSecTag2hygro	pSecTag2hy	CCTCAGGCTGAacCTAaccCGCTGTCATCGATTTC	SEQ NO ID:654

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 R122N,R124T	gro-huIL10 R122N	GAAATCGATGACAGCGggtTAGgtTCAGCCTGAGG	SEQ NO ID:655
pSecTag2hygro -huIL10 R125N	pSecTag2hy gro-huIL10	CAGGCTGAGGCTACGGaaCTGTTCATCGATTTCTTC	SEQ NO ID:656
		GAAGAAATCGATGACAGttCCGTAGCCTCAGCCTG	SEQ NO ID:657
pSecTag2hygro -huIL10 R125N, H127S	pSecTag2hy gro-huIL10 R125N	GAGGCTACGGaaCTGTtagcCGATTTCTTCCCTGTG	SEQ NO ID:658
		CACAGGGAAGAAATCGgctACAGttCCGTAGCCTC	SEQ NO ID:659
pSecTag2hygro -huIL10 R125N, H127T	pSecTag2hy gro-huIL10 R125N	GAGGCTACGGaaCTGTaccCGATTTCTTCCCTGTG	SEQ NO ID:660
		CACAGGGAAGAAATCGggtACAGttCCGTAGCCTC	SEQ NO ID:661
pSecTag2hygro -huIL10 H127N	pSecTag2hy gro-huIL10	GAGGCTACGGCGCTGTaAcCGATTTCTTCCCTGTG	SEQ NO ID:662
		CACAGGGAAGAAATCGgTtACAGCGCCGTAGCCTC	SEQ NO ID:663
pSecTag2hygro -huIL10 H127N, F129S	pSecTag2hy gro-huIL10 H127N	GGCGCTGTaAcCGAagcCTTCCCTGTGAAAACAAG	SEQ NO ID:664
		CTTGTTTTTCACAGGGAAGgctTCGgTtACAGCGCC	SEQ NO ID:665
pSecTag2hygro -huIL10 H127N, F129T	pSecTag2hy gro-huIL10 H127N	CGGCGCTGTaAcCGAaccCTTCCCTGTGAAAACAAG	SEQ NO ID:666
		CTTGTTTTTCACAGGGAAGggtTCGgTtACAGCGCCG	SEQ NO ID:667
pSecTag2hygro -huIL10 R128N	pSecTag2hy gro-huIL10	GCTACGGCGCTGTTCATaacTTTCTTCCCTGTGAA	SEQ NO ID:668
		TTCACAGGGAAGAAAgttATGACAGCGCCGTAGC	SEQ NO ID:669
pSecTag2hygro -huIL10 R128N, L130S	pSecTag2hy gro-huIL10 R128N	CGCTGTCATaacTTTagcCCCTGTGAAAACAAGAG	SEQ NO ID:670
		CTCTTGTTTTTCACAGGGgctAAAgttATGACAGCG	SEQ NO ID:671
pSecTag2hygro -huIL10 R128N, L130T	pSecTag2hy gro-huIL10 R128N	GGCGCTGTCATaacTTTaccCCCTGTGAAAACAAG	SEQ NO ID:672
		CTTGTTTTTCACAGGGggtAAAgttATGACAGCGCC	SEQ NO ID:673
pSecTag2hygro -huIL10 P131N	pSecTag2hy gro-huIL10	GCTGTCATCGATTTCTTaaCTGTGAAAACAAGAGC	SEQ NO ID:674
		GCTCTTGTTTTTCACAGttAAGAAATCGATGACAGC	SEQ NO ID:675
pSecTag2hygro -huIL10 P131N, E133S	pSecTag2hy gro-huIL10 P131N	CGATTTCTTaaCTGTtagcAACAAGAGCAAGGCCG	SEQ NO ID:676
		CGGCCTTGCTCTTGTTgctACAGttAAGAAATCG	SEQ NO ID:677
pSecTag2hygro -huIL10 P131N, E133T	pSecTag2hy gro-huIL10 P131N	CGATTTCTTaaCTGTaccAACAAGAGCAAGGCCG	SEQ NO ID:678
		CGGCCTTGCTCTTGTTggtACAGttAAGAAATCG	SEQ NO ID:679
pSecTag2hygro -huIL10 E133N	pSecTag2hy gro-huIL10	CGATTTCTTCCCTGTaAcAACAAGAGCAAGGCCG	SEQ NO ID:680
		CGGCCTTGCTCTTGTTgTtACAGGGAAGAAATCG	SEQ NO ID:681
pSecTag2hygro -huIL10 E133N, K135S	pSecTag2hy gro-huIL10 E133N	CTTCCCTGTaAcAACAgcAGCAAGGCCGTGGAGC	SEQ NO ID:682
		GCTCCACGGCCTTGCTgcTGTTgTtACAGGGAAG	SEQ NO ID:683
pSecTag2hygro -huIL10 E133N, K135T	pSecTag2hy gro-huIL10 E133N	CTTCCCTGTaAcAACAccAGCAAGGCCGTGGAGC	SEQ NO ID:684
		GCTCCACGGCCTTGCTggTGTTgTtACAGGGAAG	SEQ NO ID:685
pSecTag2hygro -huIL10 S136T	pSecTag2hy gro-huIL10	CCCTGTGAAAACAAGAcCAAGGCCGTGGAGCAGG	SEQ NO ID:686
		CCTGCTCCACGGCCTTGgTCTTGTttTCACAGGG	SEQ NO ID:687
pSecTag2hygro -huIL10 K135N	pSecTag2hy gro-huIL10	CTTCCCTGTGAAAACAACaAGCAAGGCCGTGGAGC	SEQ NO ID:688
		GCTCCACGGCCTTGCTgTTGTTTTTCACAGGGAAG	SEQ NO ID:689
pSecTag2hygro -huIL10 K135N, K137S	pSecTag2hy gro-huIL10 K135N	GTGAAAACAACaAGCAgcGCCGTGGAGCAGGTGAA G	SEQ NO ID:690
		CTTCACCTGCTCCACGGCgcTGCTgTTGTTTTCAC	SEQ NO ID:691
pSecTag2hygro -huIL10 K135N, K137T	pSecTag2hy gro-huIL10 K135N	GTGAAAACAACaAGCAccGCCGTGGAGCAGGTGAA G	SEQ NO ID:692
		CTTCACCTGCTCCACGGCggTGCTgTTGTTTTCAC	SEQ NO ID:693
pSecTag2hygro	pSecTag2hy	CCCTGTGAAAACAAGAAaCAAGGCCGTGGAGCAGG	SEQ NO ID:694

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
-huIL10 S136N	gro-huIL10	CCTGCTCCACGGCCTTGtTCTTGTTTTTCACAGGG	SEQ NO ID:695
pSecTag2hygro -huIL10 S136N, A138S	pSecTag2hy gro-huIL10 S136N	GTGAAAACAAGAAcCAAGagCGTGGAGCAGGTGAA G	SEQ NO ID:696
		CTTCACCTGCTCCACGctCTTGtTCTTGTTTTTCAC	SEQ NO ID:697
pSecTag2hygro -huIL10 S136N, A138T	pSecTag2hy gro-huIL10 S136N	GTGAAAACAAGAAcCAAGaCCGTGGAGCAGGTGAA G	SEQ NO ID:698
		CTTCACCTGCTCCACGGtCTTGtTCTTGTTTTTCAC	SEQ NO ID:699
pSecTag2hygro -huIL10 K137N	pSecTag2hy gro-huIL10	GTGAAAACAAGAGCAAcGCCGTGGAGCAGGTGAA G	SEQ NO ID:700
		CTTCACCTGCTCCACGGCgTTGCTCTTGTTTTTCAC	SEQ NO ID:701
pSecTag2hygro -huIL10 K137N, V139S	pSecTag2hy gro-huIL10 K137N	AAACAAGAGCAAcGCCagcGAGCAGGTGAAGAAT G	SEQ NO ID:702
		CATTCTTCACCTGCTCgctGGCgTTGCTCTTGTTT	SEQ NO ID:703
pSecTag2hygro -huIL10 K137N, V139T	pSecTag2hy gro-huIL10 K137N	GAAAACAAGAGCAAcGCCaccGAGCAGGTGAAGA ATG	SEQ NO ID:704
		CATTCTTCACCTGCTCggtGGCgTTGCTCTTGTTTTC	SEQ NO ID:705
pSecTag2hygro -huIL10 E140N	pSecTag2hy gro-huIL10	CAAGAGCAAGGCCGTGaAcCAGGTGAAGAATGCC	SEQ NO ID:706
		GGCATTCTTCACCTGgTtCACGGCCTTGCTCTTG	SEQ NO ID:707
pSecTag2hygro -huIL10 E140N, V142S	pSecTag2hy gro-huIL10 E140N	GGCCGTGaAcCAGagcAAGAATGCCTTTAATAAGC	SEQ NO ID:708
		GCTTATTAAAGGCATTCTTgctCTGgTtCACGGCC	SEQ NO ID:709
pSecTag2hygro -huIL10 Q141N	pSecTag2hy gro-huIL10	GAGCAAGGCCGTGGAGaAcGTGAAGAATGCCTTT A	SEQ NO ID:710
		TAAAGGCATTCTTCACgTtCTCCACGGCCTTGCTC	SEQ NO ID:711
pSecTag2hygro -huIL10 Q141N, K143S	pSecTag2hy gro-huIL10 Q141N	GGCCGTGGAGaAcGTGAgcAATGCCTTTAATAAGC	SEQ NO ID:712
		GCTTATTAAAGGCATTgcTCACgTtCTCCACGGCC	SEQ NO ID:713
pSecTag2hygro -huIL10 K143N	pSecTag2hy gro-huIL10	GTGGAGCAGGTGAAcAATGCCTTTAATAAG	SEQ NO ID:714
		CTTATTAAAGGCATTgTTCACCTGCTCCAC	SEQ NO ID:715
pSecTag2hygro -huIL10 K143N, A145S	pSecTag2hy gro-huIL10 K143N	GGAGCAGGTGAAcAATagCTTTAATAAGCTCCAAG	SEQ NO ID:716
		CTTGGAGCTTATTAAAGctATTgTTCACCTGCTCC	SEQ NO ID:717
pSecTag2hygro -huIL10 K143N, A145T	pSecTag2hy gro-huIL10 K143N	GGAGCAGGTGAAcAATaCCTTTAATAAGCTCCAAG	SEQ NO ID:718
		CTTGGAGCTTATTAAAGGtATTgTTCACCTGCTCC	SEQ NO ID:719
pSecTag2hygro -huIL10 F146S	pSecTag2hy gro-huIL10	CAGGTGAAGAATGCCTCTAATAAGCTCCAAGAGA AAGGC	SEQ NO ID:720
		GCCTTTCTCTTGGAGCTTATTAGAGGCATTCTTCA CCTG	SEQ NO ID:721
pSecTag2hygro -huIL10 F146T	pSecTag2hy gro-huIL10	GCAGGTGAAGAATGCCaccAATAAGCTCCAAGAG	SEQ NO ID:722
		CTCTTGGAGCTTATTggtGGCATTCTTCACCTGC	SEQ NO ID:723
pSecTag2hygro -huIL10 K148N	pSecTag2hy gro-huIL10	GAATGCCTTTAATAAcCTCCAAGAGAAAGGCATC	SEQ NO ID:724
		GATGCCTTTCTCTTGGAGgTTATTAAAGGCATTC	SEQ NO ID:725
pSecTag2hygro -huIL10 K148N, Q150S	pSecTag2hy gro-huIL10 K148N	GCCTTTAATAAcCTCagcGAGAAAGGCATCTAC	SEQ NO ID:726
		GTAGATGCCTTTCTCgctGAGgTTATTAAAGGC	SEQ NO ID:727
pSecTag2hygro -huIL10 K148N, Q150T	pSecTag2hy gro-huIL10 K148N	GCCTTTAATAAcCTCaccGAGAAAGGCATCTAC	SEQ NO ID:728
		GTAGATGCCTTTCTCggtGAGgTTATTAAAGGC	SEQ NO ID:729
pSecTag2hygro -huIL10 L149S	pSecTag2hy gro-huIL10	CAGGTGAAGAATGCCTTTAATAAGAGCCAAGAGA AAGGC	SEQ NO ID:730
		GCCTTTCTCTTGGCTCTTATTAAAGGCATTCTTCA CCTG	SEQ NO ID:731

Expression Vector Generated	Template DNA Used for PCR	Primer Set Used for PCR	SEQ ID NO:
pSecTag2hygro-huIL10 L149T	pSecTag2hygro-huIL10	GAATGCCTTTAATAAGacCCAAGAGAAAGGCATC	SEQ NO ID:732
		GATGCCTTTCTCTTGGgtCTTATTAAAGGCATTC	SEQ NO ID:733
pSecTag2hygro-huIL10 Q150N	pSecTag2hygro-huIL10	GCCTTTAATAAGCTCaAcGAGAAAGGCATCTACAA	SEQ NO ID:734
		TTGTAGATGCCTTTCTCgTtGAGCTTATTAAAGGC	SEQ NO ID:735
pSecTag2hygro-huIL10 Q150N, K152S	pSecTag2hygro-huIL10 Q150N	TTAATAAGCTCaAcGAGAgcGGCATCTACAAAGCC	SEQ NO ID:736
		GGCTTTGTAGATGCCgcTCTCgTtGAGCTTATTAA	SEQ NO ID:737
pSecTag2hygro-huIL10 Q150N, K152T	pSecTag2hygro-huIL10 Q150N	TTAATAAGCTCaAcGAGAccGGCATCTACAAAGCC	SEQ NO ID:738
		GGCTTTGTAGATGCCggTCTCgTtGAGCTTATTAA	SEQ NO ID:739
pSecTag2hygro-huIL10 E151N	pSecTag2hygro-huIL10	CTTTAATAAGCTCCAAaAcAAAGGCATCTACAAAG	SEQ NO ID:740
		CTTTGTAGATGCCTTTgTtTTGGAGCTTATTAAAG	SEQ NO ID:741
pSecTag2hygro-huIL10 E151N, G153S	pSecTag2hygro-huIL10 E151N	ATAAGCTCCAAaAcAAAaGCATCTACAAAGCCATG	SEQ NO ID:742
		CATGGCTTTGTAGATGCtTTTgTtTTGGAGCTTAT	SEQ NO ID:743
pSecTag2hygro-huIL10 E151N, G153T	pSecTag2hygro-huIL10 E151N	ATAAGCTCCAAaAcAAAacCATCTACAAAGCCATG	SEQ NO ID:744
		CATGGCTTTGTAGATGgtTTTgTtTTGGAGCTTAT	SEQ NO ID:745
pSecTag2hygro-huIL10 K152N	pSecTag2hygro-huIL10	ATAAGCTCCAAGAGAAcGGCATCTACAAAGCCATG	SEQ NO ID:746
		CATGGCTTTGTAGATGCCgTTCTCTTGGAGCTTAT	SEQ NO ID:747
pSecTag2hygro-huIL10 K152N, I152S	pSecTag2hygro-huIL10 K152N	GCTCCAAGAGAAcGGCAgCTACAAAGCCATGAGT	SEQ NO ID:748
		CACTCATGGCTTTGTAGcTGCCgTTCTCTTGGAGC	SEQ NO ID:749
pSecTag2hygro-huIL10 K152N, I152T	pSecTag2hygro-huIL10 K152N	GCTCCAAGAGAAcGGCAcCTACAAAGCCATGAGT	SEQ NO ID:750
		CACTCATGGCTTTGTAGgTGCCgTTCTCTTGGAGC	SEQ NO ID:751
pSecTag2hygro-huIL10 G153N	pSecTag2hygro-huIL10	ATAAGCTCCAAGAGAAAaaCATCTACAAAGCCATG	SEQ NO ID:752
		CATGGCTTTGTAGATGttTTTCTCTTGGAGCTTAT	SEQ NO ID:753
pSecTag2hygro-huIL10 G153N, Y155S	pSecTag2hygro-huIL10 G153N	CCAAGAGAAAaaCATCagCAAAGCCATGAGTGAG	SEQ NO ID:754
		CTCACTCATGGCTTTGctGATGttTTTCTCTTGG	SEQ NO ID:755
pSecTag2hygro-huIL10 G153N, Y155T	pSecTag2hygro-huIL10 G153N	CCAAGAGAAAaaCATCacCAAAGCCATGAGTGAG	SEQ NO ID:756
		CTCACTCATGGCTTTGgtGATGttTTTCTCTTGG	SEQ NO ID:757
pSecTag2hygro-huIL10 K175N	pSecTag2hygro-huIL10	GCCTACATGACAATGAAcATACGAAACTGAGGGC	SEQ NO ID:758
		GGCCCTCAGTTTCGTATgTTCATTGTCATGTAGGC	SEQ NO ID:759
pSecTag2hygro-huIL10 K175N, R177S	pSecTag2hygro-huIL10 K175N	CATGACAATGAAcATAaGcAACTGAGGGCCCCGAAC	SEQ NO ID:760
		GTTCGGGGCCCTCAGTTgCtTATgTTCATTGTCATG	SEQ NO ID:761
pSecTag2hygro-huIL10 K175N, R177T	pSecTag2hygro-huIL10 K175N	CATGACAATGAAcATAaccAACTGAGGGCCCCGAAC	SEQ NO ID:762
		GTTCGGGGCCCTCAGTTggtTATgTTCATTGTCATG	SEQ NO ID:763

[00314] Transfection Protocol. All human IL-10 expression vectors (wild type and mutein) were transiently expressed in HEK293FT cells (Life Technologies #R700-07). The cells were maintained in 50 mL of DMEM (Life Technologies #11995-073) + 10% characterized fetal bovine serum (Hyclon/Thermo Scientific #SH30071.03) + 1X

Penicillin/Streptomycin (Life Technologies #15140-122) at 37°C at 5% CO₂ in T175 flasks (Greiner One/CellStar #660175). Upon reaching confluence, the cells were detached with 10 mL of PBS + 5 mM EDTA, the cells collected with an additional 10 mL of growth media, pelleted at 1000 RPM in a centrifuge (Beckman Allegra 6R), the media aspirated, the cells resuspended in fresh media, and then split between three T175 flasks each containing 45 mL of growth media.

[00315] All non-cysteine mutein expression vectors were transfected into 6-well plates as follows: Hek293 cells were harvested from a confluent T175 flask, the cells collected as previously described and then resuspended in 20 mL of fresh growth media. Seven hundred (700) µL of the cell suspension was added to each well of a 6-well plate (Falcon #353046) containing 2 mL of fresh media and grown overnight as described. The following day, the cells were transfected using Lipofectamine 2000 (Life Technologies #1388795) using the following protocol: 250 µl of OptiMEMI Reduced Serum Media (Life Technologies #31985-088) was aliquoted to two eppendorf tubes, then 10 µl of Lipofectamine 2000 Transfection Reagent (Life Technologies #1388795) was added to one aliquot and 4 µg of DNA to the other. The two solutions were incubated separately for 5 minutes at room temperature and then the transfection complexes were formed by combining the two solutions and incubating at room temperature for an additional 30 minutes. The complete 500 µL mixture was then added drop-wise to one well of the 6-well plate, and returned to the incubator for 4 hours. The transfection media was then aspirated and replaced with DMEM + Penicillin/Streptomycin and grown for approximately 36 hours. The conditioned media was harvested and stored at 4°C.

[00316] Cysteine muteins were transfected as described above with the following exceptions: Four T175 flasks with 42-45 mL of growth media were grown to 95% confluence prior to transfection, and the transfection complexes were formed by adding 175 µL of Lipofectamine 2000 to 4.4 mL OptiMEM I and 75-100 µL of DNA to a second 4.4 mL of OptiMEM I. Upon aspiration of the transfection complexes, 50 mL of media was added to each flask.

[00317] Mock transfections contained either empty pSecTag2hygro (B) expression vector or no DNA, and were prepared as described for both the cysteine and non-cysteine variants.

[00318] Human IL-10 Detection ELISA. A 96-well plate (Nunc Maxisorp #442404) was coated overnight at 4°C with 100 µL/well PBS + 1 µg/mL anti-human IL-10 antibody 9D7 (Armo Biosciences; Redwood City, CA), washed 6 X 200 µL in DPBS-Tween 20 (Teknova

#P0297), blocked in 200 μ L/well PBS + 5% BSA (Calbiochem #2960) for 2 hours at room temperature on a rocking platform, and washed as previously described. The samples were serially diluted 1:5 down wells A-H in PBS and 100 μ L/well was added to the assay plate. Samples were run in duplicate or triplicate. As a positive control purified human IL-10 (Armo Biosciences) was spiked into growth media to a final concentration of 2 μ g/mL, while conditioned media from the mock transfections was used as a negative control, and both serially diluted as described. The samples were incubated overnight at 4°C on a rocking platform and then washed as previously described. 100 μ L/well of PBS + anti-human-IL-10 antibody 12G8-biotin (Armo Biosciences) was added to each well, incubated for one hour at room temperature on a rocking platform, washed as previously described, and then 100 μ L/well of PBS + streptavidin-HRP (Jackson Immuno Research # 016-030-084, diluted 1:1000) was added and incubated for an additional 1 hour at room temperature on a rocking platform. The plate was then washed as described and developed with 100 μ L/well of 1-Step Ultra TMB-ELISA (Pierce/Thermo #34029) for 1-5 minutes, and then the reaction stopped with 100 μ L/well Stop Solution (Life Technologies #SS04). The plate was read on a Molecular Devices M2 plate reader at 450nm.

[00319] MC/9 Bioactivity Assay. MC/9 cells (ATCC #CRL-8306) were grown in DMEM (Life Technologies) + 10% FBS (Hyclon/Thermo) + 1X Penicillin/Streptomycin (Life Technologies) + 50 μ M β -mercaptoethanol (Fisher #O3446I-100) + 1X rat T-STIM with ConA (BD #354115) at 37°C in 5% CO₂. The cells were suspended in growth media at a density of 0.4E6 cells/mL and passaged when the cell density approached 1.5E6 cells/mL (typically after 3-4 days). To passage the cells, an appropriate volume of cell suspension was pelleted at 1000 RPM, the media aspirated, and the cells resuspended in new growth media. A fresh vial was thawed after about four weeks of culturing.

[00320] Prior to using the cells in the assay, they were washed three times in growth media without rat T-STIM, by pelleting the cells at 1000 RPM, aspirating the media, and then resuspending them in new media (without T-STIM). For the cysteine mutants, purified proteins were used in the MC/9 assay, while conditioned media from transiently transfected cells was used for the non-cysteine mutants. Samples were run in duplicates or triplicates.

[00321] Proteins in conditioned media: A cell suspension of 0.05E6 cells/mL was prepared (without T-STIM), and 50 μ L/well (~5000 cells) was added to each well of an opaque 96-well tissue culture plate (Costar #3917) and returned to the incubator while the test samples

are prepared. Conditioned media from the transient transfection was diluted 1:3 in growth media without T-STIM and serially diluted 1:3 down 12 rows, and 100 μ L/well was added to the cell suspension. Each plate contained conditioned media from a transient transfection with the wild type IL-10 as well as a mock transfection to use as relative reference for gauging activity. The cells were grown for ~40 hours at 37°C and 5% CO₂, allowed to equilibrate to room temperature for 20 minutes, and then 100 μ L/well Cell Titer Glo (Promega #G7571) was added to each well. The plates were rocked at 450 rpm for about 30 minutes and read on a Molecular Devices SpectraMax L plate reader at 395nm with a 1 second integration time.

[00322] Purified proteins: The protocol was the same as the conditioned media with the exception that the final concentration of the IL-10 protein in the assay plate was between 200-800 ng/mL.

[00323] Numerous assays involving the use of MC/9 cells are described in the literature. IL-10 administration to MC/9 cells (murine cell line with characteristics of mast cells available from Cell Signaling Technology; Danvers, MA) causes increased cell proliferation in a dose-dependent manner. An exemplary assay is disclosed by Thompson-Snipes, L. et al. ((1991) J. Exp. Med. 173:507-10), who describe a standard assay protocol in which MC/9 cells are supplemented with IL3 + IL10 and IL3 + IL4 + IL10. Vendors (e.g., R&D Systems, USA; and Cell Signaling Technology, Danvers, MA) use the assay as a lot release assay for rhIL10. Those of ordinary skill in the art will be able to modify the standard assay protocol described in Thompson-Snipes, L. et al, such that cells are only supplemented with IL-10.

[00324] Purification of Wild Type Human IL-10 and Cysteine Muteins. Anti-human-IL-10 antibody 9D7 was coupled to CNBr-activated Sepharose 4 Fast Flow (GE Healthcare #71-5000-15 AF, followed manufacturer's protocol) and equilibrated in PBS. 500 μ L-1mL of 9D7-sepharose was added per 100 mL of conditioned media contained in a glass Econo-Column (Bio-rad, Hercules, CA) and incubated for 1-2 hours at room temperature on a rocking platform. The media was allowed to run through the column via gravity flow, washed 1X with 1X PBS (pH 7.4), eluted with 0.1M glycine (pH 2.9) and neutralized with a 10% volume of 1M Tris buffer (pH 8.0). The protein was concentrated and buffer exchanged into PBS (pH 7.4) using an Amicon Ultra Centrifugal Filter Device (Millipore, Billerica, MA; 10,000 kD molecular weight cutoff). Protein concentration was determined by spectrophotometer at 280nm. SEC Analysis of Cysteine Variants. Using a 1100 series HPLC (Agilent Technologies, Santa Clara, CA), 20-

50 µg of protein was injected on a TSK3000sw column (Tosoh Biosciences, Tokyo, JP), equilibrated with PBS (pH 7.4), and run at a flow rate of 1 mL/min.

Production of Pegylated IL-10

[00325] The present disclosure contemplates the synthesis of pegylated IL-10 by any means known to the skilled artisan. The description hereafter of several alternative synthetic schemes for producing mono-PEG-IL-10 and a mix of mono-/di-PEG-IL-10 is meant to be illustrative only. While both mono-PEG-IL-10 and a mix of mono-/di-PEG-IL-10 have many comparable properties, a mix of selectively pegylated mono- and di-PEG-IL-10 improves the yield of the final pegylated product (see, e.g., US Pat No. U.S. Patent No. 7,052,686 and US Pat. Publn. No. 2011/0250163).

[00326] In addition to leveraging her own skills in the production and use of PEGs (and other drug delivery technologies) suitable in the practice of the present disclosure, the skilled artisan is also familiar with many commercial suppliers of PEG-related technologies (and other drug delivery technologies). By way of example, NOF America Corp (Irvine, CA) supplies mono-functional Linear PEGs, bi-functional PEGs, multi-arm PESs, branched PEGs, heterofunctional PEGs, forked PEGs, and releasable PEGs; and Parchem (New Rochelle, NY) is a global distributor of PEG products and other specialty raw materials.

[00327] Exemplary PEG-IL-10 Synthetic Scheme No. 1. IL-10 may be dialyzed against 10 mM sodium phosphate at pH 7.0, 100 mM NaCl. The dialyzed IL-10 may then be diluted 3.2 times to a concentration of 4 mg/mL using the dialysis buffer. Prior to the addition of the linker, SC-PEG-12K (Delmar Scientific Labs;, Maywood, IL), 1 volume of 100 mM Na-tetraborate at pH 9.1 can be added into 9 volumes of the diluted IL-10 to raise the pH of the IL-10 solution to 8.6. The SC-PEG-12K linker can be dissolved in the dialysis buffer and the appropriate volume of the linker solution (1.8 to 3.6 mole of linker/mole of IL-10) can be added into the diluted IL-10 solution to start the pegylation reaction. The reaction can be carried out at 5°C in order to control the rate of the reaction. The reaction solution can be mildly agitated during the pegylation reaction. When the mono-PEG-IL-10 yield, as determined by size exclusion HPLC (SE-HPLC), is close to 40%, the reaction is stopped by adding 1M glycine solution to a final concentration of 30 mM. The pH of the reaction solution is slowly adjusted to 7.0 using an HCl solution, and the reaction solution is then filtered using a 0.2 micron filter and stored at -80.degree °C.

[00328] Exemplary PEG-IL-10 Synthetic Scheme No. 2. Mono-PEG-IL-10 is prepared using methoxy-PEG-aldehyde (PALD-PEG) as a linker (Inhale Therapeutic Systems Inc., Huntsville, AL; also available from NOF America Corp (Irvine, CA)). PALD-PEG can have molecular weights of 5 KDa, 12 KDa, or 20 KDa. IL-10 is dialyzed and diluted as described above, except the pH of the reaction buffer is between 6.3 and 7.5. Activated PALD-PEG linker is added to reaction buffer at a 1:1 molar ratio. Aqueous cyanoborohydride is added to the reaction mixture to a final concentration of 0.5 to 0.75 mM. The reaction is carried out at room temperature (18-25 °C) for 15-20 hours with mild agitation. The reaction is quenched with 1M glycine. Yields are analyzed by SE-HPLC. Mono-PEG-IL-10 is separated from unreacted IL-10, PEG linker and di-PEG-IL-10 by gel filtration chromatography and characterized by RP-HPLC and bioassay (e.g., stimulation of IL-10 – responsive cells or cell lines).

[00329] Exemplary PEG-IL-10 Synthetic Scheme No. 3. IL-10 (e.g., rodent or primate) is dialyzed against 50 mM sodium phosphate, 100 mM sodium chloride pH ranges 5-7.4. A 1:1-1:7 molar ratio of 5K PEG-propylaldehyde is reacted with IL-10 at a concentration of 1-12 mg/mL in the presence of 0.75-30 mM sodium cyanoborohydride. Alternatively the reaction can be activated with picoline borane in a similar manner. The reaction is incubated at 5-30°C for 3-24 hours.

[00330] The pH of the pegylation reaction is adjusted to 6.3, 7.5 mg/mL of hIL-10 is reacted with PEG to make the ratio of IL-10 to PEG linker 1:3.5. The final concentration of cyanoborohydride is ~25 mM, and the reaction is carried out at 15°C for 12-15 hours. The mono- and di-PEG IL-10 are the largest products of the reaction, with the concentration of each at ~45-50% at termination. The reaction may be quenched using an amino acid such as glycine or lysine or, alternatively, Tris buffers. Multiple purification methods can be employed such as gel filtration, anion and cation exchange chromatographies, and size exclusion HPLC (SE-HPLC) to isolate the desired pegylated IL-10 molecules.

[00331] Exemplary PEG-IL-10 Synthetic Scheme No. 4. IL-10 is dialyzed against 10 mM sodium phosphate pH 7.0, 100 mM NaCl. The dialyzed IL-10 is diluted 3.2 times to a concentration of about 0.5 to 12 mg/mL using the dialysis buffer. Prior to the addition of the linker, SC-PEG-12K (Delmar Scientific Laboratories, Maywood, Ill.), one volume of 100 mM Na-tetraborate at pH 9.1 is added into 9 volumes of the diluted IL-10 to raise the pH of the IL-10 solution to 8.6. The SC-PEG-12K linker is dissolved in the dialysis buffer and the appropriate volume of the linker solution (1.8 to 3.6 mole linker per mole of IL-10) is added into

the diluted IL-10 solution to initiate the pegylation reaction. The reaction is carried out at 5°C in order to control the rate of the reaction, and the reaction solution is mildly agitated. When the mono-PEG-IL-10 yield, as determined by size exclusion HPLC (SE-HPLC), is close to 40%, the reaction is stopped by adding 1M glycine solution to a final concentration of 30 mM. The pH of the reaction solution is slowly adjusted to 7.0 using an HCl solution, and the reaction is 0.2 micron filtered and stored at -80°C.

Assays to Determine the Bioactivity of Modified Forms of IL-10

[00332] The present disclosure contemplates the use of any assays and methodologies known in the art for determining the bioactivity of the IL-10 molecules described herein. The assays described hereafter are representative, and not exclusionary.

[00333] TNF α Inhibition Assay. PMA-stimulation of U937 cells (lymphoblast human cell line from lung available from Sigma-Aldrich (#85011440); St. Louis, MO) causes the cells to secrete TNF α , and subsequent treatment of these TNF α -secreting cells with human IL-10 causes a decrease in TNF α secretion in a dose-dependent manner.

[00334] An exemplary TNF α inhibition assay may be performed using the following protocol. After culturing U937 cells in RPMI containing 10% FBS/FCS and antibiotics, plate 1×10^5 , 90% viable U937 cells in 96-well flat bottom plates (any plasma-treated tissue culture plates (e.g., Nunc; Thermo Scientific, USA) may be used) in triplicate per condition. Plate cells to provide for the following conditions (all in at least triplicate; for 'media alone' the number of wells is doubled because one-half will be used for viability after incubation with 10 nM PMA): 5 ng/ml LPS alone; 5 ng/mL LPS + 0.1 ng/mL rhIL-10; 5 ng/mL LPS + 1 ng/mL rhIL-10; 5 ng/mL LPS + 10 ng/mL rhIL-10; 5 ng/mL LPS + 100 ng/mL rhIL-10; 5 ng/mL LPS + 1000 ng/mL rhIL-10; 5 ng/mL LPS + 0.1ng/mL PEG-rhIL-10; 5 ng/mL LPS + 1 ng/mL PEG-rhIL-10; 5 ng/mL LPS + 10 ng/mL PEG-rhIL-10; 5 ng/mL LPS + 100 ng/mL PEG-rhIL-10; and 5 ng/mL LPS + 1000 ng/mL PEG-rhIL-10.

[00335] Expose each well to 10 nM PMA in 200 μ L for 24 hours, culturing at 37°C in 5% CO₂ incubator, after which time ~90% of cells should be adherent. The three extra wells are re-suspended, and the cells are counted to assess viability (>90% should be viable). Wash gently but thoroughly 3X with fresh, non-PMA – containing media, ensuring that cells are still in the wells. Add 100 μ L per well of media containing the appropriate concentrations (2X as the volume will be diluted by 100%) of rhIL-10 or PEG-rhIL-10, incubate at 37°C in a 5% CO₂

incubator for 30 minutes. Add 100 μ L per well of 10 ng/mL stock LPS to achieve a final concentration of 5 ng/mL LPS in each well, and incubate at 37°C in a 5% CO₂ incubator for 18-24 hours. Remove supernatant and perform TNF α ELISA according to the manufacturer's instructions. Run each conditioned supernatant in duplicate in ELISA.

[00336] CD8+T-cell IFN γ Secretion Assay. Activated primary human CD8+ T-cells secrete IFN γ when treated with PEG-IL-10 and then with an anti-CD3 antibody. The following protocol provides an exemplary CD8+ T-cell IFN γ secretion assay. Human primary peripheral blood mononuclear cells (PBMCs) can be isolated according to any standard protocol (see, e.g., Fuss et al. (2009) Current Protocols in Immunology, Unit 7.1, John Wiley, Inc., NY). 2.5 mL of PBMCs (at a cell density of 10 million cells/mL) can be cultured per well with complete RPMI, containing RPMI (Life Technologies; Carlsbad, CA), 10 mM HEPES (Life Technologies; Carlsbad, CA), 10% Fetal Calf Serum (Hyclone Thermo Fisher Scientific; Waltham, MA) and Penicillin/Streptomycin cocktail (Life Technologies; Carlsbad, CA), in any standard tissue culture treated 6-well plate (BD; Franklin Lakes, NJ). Human pegylated-IL-10 can be added to the wells at a final concentration of 100 ng/mL; a final concentration of 10 μ g/mL of antibodies blocking the function of inhibitory/checkpoint receptors can also be added in combination with pegylated-IL-10. Cells can be incubated in a humidified 37°C incubator with 5% CO₂ for 6-7 days. After this incubation, CD8+ T-cells can be isolated using Miltenyi Biotec's MACS cell separation technology according to the manufacture's protocol (Miltenyi Biotec; Auburn, CA). The isolated CD8+ T-cells can then be cultured with complete RPMI containing 1 μ g/mL anti-CD3 antibody (Affymetrix eBioscience; San Diego, CA) in any standard tissue culture plate for 4 hours. After the 4 hour incubation, the media can be collected and assayed for IFN γ using a commercial ELISA kit and following the manufacture's protocol (Affymetrix Bioscience; San Diego, CA).

Tumor Models and Tumor Analysis

[00337] Any art-accepted tumor model, assay, and the like can be used to evaluate the effect of the IL-10 molecules described herein on various tumors. The tumor models and tumor analyses described hereafter are representative of those that can be utilized.

[00338] Syngeneic mouse tumor cells are injected subcutaneously or intradermally at 10⁴, 10⁵ or 10⁶ cells per tumor inoculation. Ep2 mammary carcinoma, CT26 colon carcinoma, PDV6 squamous carcinoma of the skin and 4T1 breast carcinoma models can be used (see, e.g.,

Langowski et al. (2006) Nature 442:461-465). Immunocompetent Balb/C or B-cell deficient Balb/C mice can be used. PEG-mIL-10 can be administered to the immunocompetent mice, while PEG-hIL-10 treatment can be in the B-cell deficient mice. Tumors are allowed to reach a size of 100-250 mm³ before treatment is started. IL-10, PEG-mIL-10, PEG-hIL-10, or buffer control is administered subcutaneously at a site distant from the tumor implantation. Tumor growth is typically monitored twice weekly using electronic calipers.

[00339] Tumor tissues and lymphatic organs are harvested at various endpoints to measure mRNA expression for a number of inflammatory markers and to perform immunohistochemistry for several inflammatory cell markers. The tissues are snap-frozen in liquid nitrogen and stored at -80°C. Primary tumor growth is typically monitored twice weekly using electronic calipers. Tumor volume may be calculated using the formula (width² x length/2) where length is the longer dimension. Tumors are allowed to reach a size of 90-250 mm³ before treatment is started.

Identifying Mutants Demonstrating Biological Activity

[00340] Using the methodologies described herein, an assessment was conducted to determine which of the 160 amino acid residues of the mature human IL-10 protein will tolerate a substitution with a residue conducive to forming an anchor site for a PEG moiety. Residues identified using this assessment were further analyzed to determine whether a substitution will result in a mutant (mutein) exhibiting bioactivity. The skilled artisan will recognize that not all mutants active in an in vitro assay will have activity in an in vivo setting, and vice versa.

[00341] The results of the assessment are summarized in FIG. 5. The first two rows of FIG. 5 define the boundaries for each of the regions of IL-10 (i.e., a) Pre-helix A, b) Helix A, c) A/B Inter-helix Junction, d) Helix B, e) B/C Inter-helix Junction, f) Helix C, g) C/D Inter-helix Junction h) Helix D, i) D/E Inter-helix Junction, j) Helix E, k) E/F Inter-helix Junction, l) Helix F, and m) and the amino acid residues of each of the regions, as well as the locations of the intrahelical kinks and the amino acid residues of each kink. The next four rows of FIG. 5 relate to the types of mutations that were introduced at each residue: Cysteine, Tyrosine, N-X-S, and N-X-T; N-X-S, and N-X-T are N-glycosylation motifs.

[00342] Referring to the shading in FIG. 5, with the exception of the dark grey boxes with an “x” that are described below, the residues in the dark grey boxes were not mutated or part of the analysis. Based on application of the teachings herein, such residues are not surface-

exposed or are involved in receptor binding. The remaining 78 residues in the light grey boxes represent the residues that are more likely to be surface exposed on the homodimer and less likely to interfere with receptor binding. It is to be understood that a skilled artisan may conclude that one or more residues may be categorized differently (i.e., a residue that is in a dark grey box might be placed in a light gray box).

[00343] The mutants (e.g., cysteine or tyrosine) were generated using the methods described herein and were evaluated in an MC/9 assay to determine biological activity. If a mutant was expressed and exhibited biological activity, a “+” was placed in the applicable box (e.g., referring to amino acid residue 96, a tyrosine mutant exhibited activity whereas a cysteine mutant did not). For purposes of the assessment, the measurement of any biological activity resulted in the assignment of a “+” sign.

[00344] In the columns associated with particular amino acid residues in FIG. 5, some boxes (light grey) contain an “+” while other boxes (dark grey) contain an “x”. In these instances (e.g., 10 (N)), the dark grey “x” boxes could not be mutated for various reasons. Residue 59 (Y) could not be mutated to a tyrosine because human IL-10 already contains a tyrosine at that position. For residues at the 10 (N), and 60 (L), 106 (R), introducing an N-glycosylation site would interfere with cysteine bonding and likely destroyed the bioactivity of the protein. For residue 116 (N), the N-X-S N-glycosylation motif could not be introduced because the protein already contains an N-X-S N-glycosylation motif. For residue 160 (N), because the N-glycosylation motif is three amino acids long (N-X-S or N-X-T), an N-glycosylation site cannot be introduced at the last residue of a protein.

[00345] Mutants in light grey boxes without a “+” (e.g., the cysteine row of column 4 (Q)) indicate that the mutants did not express or were not active in the MC/9 assay. However, it should be noted that only cysteine mutants which formed a large degree of heterodimers were tested for activity. Free cysteines allow the protein to form numerous different isoforms or aggregates as it attempts to pair up the free cysteine, and these aggregates might show some activity in a cell-based assay system even though they are not likely to be a therapeutic candidate; thus, these were not evaluated. In comparison, the other mutations were far less likely to introduce aggregates and therefore they were tested for bioactivity.

[00346] Based on the foregoing description, 78 amino acid residues may initially be considered as sites for the generation of mutants. Of the 78 potential sites to introduce a

mutation, 76 possessed properties that made them viable candidates for anchoring a PEG moiety as two sites did not generate an active protein with any of the tested mutations.

[00347] As previously indicated, the present disclosure contemplates peptides comprising a substitution that would facilitate the attachment of a PEG or other moiety to at least one amino acid residue of i) Pre-helix A other than amino acid residues 12 (C), 15 (F) or 16 (P); ii) Helix A other than amino acid residues 19-24 (LPNMLR (SEQ ID NO:33)), 26-30 (LRDAF (SEQ ID NO:34)), 33-39; (VKTFFQM (SEQ ID NO:35)), or 41 (D); iii) Helix B other than amino acid residues 52 (L), 53 (L), or 56 (F); iv) B/C Inter-helix Junction; v) Helix C other than amino acid residues 62 (C), 64 (A), 65 (L), 68 (M), 69 (I), 71-73 (FYL), 76 (V), 77 (M), or 80 (A); vi) C/D Inter-helix Junction; vii) Helix D other than amino acid residues 87 (I), 91 (V), 94 (L), 98 (L), 101 (L), 105 (L), or 108 (C); viii) D/E Inter-helix Junction other than amino acid residues 111 (F), 112 (L), or 114 (C); ix) Helix E other than amino acid residues 120 (A), 121 (V), 124 (V), 127 (A), 128 (F) or 131 (L); x) E/F Inter-helix Junction; xi) Helix F other than amino acid residues 136-156 (IYKAMSEFDIFINYIEAYMTM (SEQ ID NO:36)), 158 (I) or 159 (R); or xii) Post-helix F.

[00348] Some embodiments of the present disclosure contemplate peptides comprising at least one amino acid substitution in at least one of the following regions: 1-11, 49-51, 57-61, 81-86, 88-90, 102-104, 115-119, or 132-134. In other embodiments, the peptides comprise at least one amino acid substitution at least at one of the following positions: 1-11, 13, 14, 17, 18, 25, 31, 32, 40, 49-51, 54, 55, 57-61, 63, 66, 67, 70, 74, 75, 78, 79, 81-86, 88-90, 92, 93, 96, 97, 99, 100, 102-104, 106, 107, 109, 110, 113, 115-119, 122, 123, 125, 126, 129, 130, 132-134, 157 or 160.

[00349] Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Upon reading the foregoing, description, variations of the disclosed embodiments may become apparent to individuals working in the art, and it is expected that those skilled artisans may employ such variations as appropriate. Accordingly, it is intended that the invention be practiced otherwise than as specifically described herein, and that the invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[00350] All publications, patent applications, accession numbers, and other references cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

CLAIMS

1. A peptide comprising:
 - a) a Pre-helix A, b) a Helix A, c) an A/B Inter-helix Junction, d) a Helix B, e) a B/C Inter-helix Junction, f) a Helix C, g) a C/D Inter-helix Junction h) a Helix D, i) a D/E Inter-helix Junction, j) a Helix E, k) an E/F Inter-helix Junction, l) a Helix F, and m) a Post-helix F; and wherein the peptide further comprises at least one amino acid substitution, addition or deletion to one or more of a) – m).
2. The peptide of Claim 1, comprising:
 - a) a Pre-helix A, b) a Helix A, c) an A/B Inter-helix Junction, d) a Helix B, e) a B/C Inter-helix Junction, f) a Helix C, g) a C/D Inter-helix Junction h) a Helix D, i) a D/E Inter-helix Junction, j) a Helix E, k) an E/F Inter-helix Junction, l) a Helix F, and m) a Post-helix F; and wherein the peptide further comprises at least one amino acid substitution comprising:
 - substitution of at least one amino acid residue of Pre-helix A other than amino acid residues 12 (C), 15 (F) or 16 (P); or
 - substitution of at least one amino acid residue of Helix A other than amino acid residues 19-24 (LPNMLR), 26-30 (LRDAF), 33-39; (VKTFQFM), or 41 (D); or
 - substitution of at least one amino acid residue of Helix B other than amino acid residues 52 (L), 53 (L), or 56 (F); or
 - substitution of the amino acid residue of the B/C Inter-helix Junction; or
 - substitution of at least one amino acid residue of Helix C other than amino acid residues 62 (C), 64 (A), 65 (L), 68 (M), 69 (I), 71-73 (FYL), 76 (V), 77 (M), or 80 (A); or
 - substitution of at least one amino acid residue of the C/D Inter-helix Junction; or
 - substitution of at least one amino acid residue of Helix D other than amino acid residues 87 (I), 91 (V), 94 (L), 98 (L), 101 (L), 105 (L), or 108 (C); or
 - substitution of at least one amino acid residue of the D/E Inter-helix Junction other than amino acid residues 111 (F), 112 (L), or 114 (C); or
 - substitution of at least one amino acid residue of Helix E other than amino acid residues 120 (A), 121 (V), 124 (V), 127 (A), 128 (F) or 131 (L); or

substitution of the amino acid residue of the E/F Inter-helix Junction; or
 substitution of at least one amino acid residue of Helix F other than amino acid
 residues 136-156 (IYKAMSEFDIFINYIEAYMTM), 158 (I) or 159 (R); or
 substitution of the amino acid residue of Post-helix F.

3. The peptide of Claim 2, wherein the at least one amino acid substitution does not disrupt the non-covalent interactions between the two monomer subunits of the peptide.
4. The peptide of Claim 2, wherein the at least one amino acid substitution is a conservative substitution
5. The peptide of Claim 2, wherein the peptide has a bioactivity at least equal to the bioactivity of SEQ ID NO:2, wherein the bioactivity is determined in an in vitro assay or an in vivo assay.
6. The peptide of Claim 5, wherein the in vitro activity is at least one of a TNF α inhibition assay, an MC/9 cell proliferation assay, or a CD8⁺T-cell IFN γ secretion assay.
7. The peptide of Claim 2, wherein the at least one amino acid substitution does not adversely affect immunogenicity.
8. The peptide of Claim 7, wherein the immunogenicity of the peptide is predicted by screening for at least one of T-cell epitopes or B-cell epitopes.
9. The peptide of Claim 8, wherein the screening is at least one of an in silico screening system or an ex vivo assay system.
10. The peptide of Claim 2, wherein the at least one amino acid substitution is in at least one of the following regions: 1-11, 49-51, 57-61, 81-86, 88-90, 102-104, 115-119, or 132-134.
11. The peptide of Claim 2, wherein the at least one amino acid substitution is at least at one of the following positions: 1-11, 13, 14, 17, 18, 25, 31, 32, 40, 49-51, 54, 55, 57-61, 63, 66, 67, 70, 74, 75, 78, 79, 81-86, 88-90, 92, 93, 96, 97, 99, 100, 102-104, 106, 107, 109, 110, 113, 115-119, 122, 123, 125, 126, 129, 130, 132-134, 157 or 160.
12. The peptide of Claim 2, wherein the peptide does not comprise substitution of an amino acid residue involved with receptor binding.
13. The peptide of Claim 2, wherein the peptide comprises at least one modification to form a modified peptide;
 wherein the modification does not alter the amino acid sequence of the peptide, and
 wherein the modification improves at least one property of the peptide.
14. The peptide of Claim 13, wherein the modified peptide is pegylated.

15. The peptide of Claim 14, wherein the modified peptide comprises at least one PEG molecule covalently attached to at least one amino acid residue of at least one monomer of IL-10.
16. The peptide of Claim 15, wherein the modified peptide comprises a mixture of mono-pegylated and di-pegylated IL-10.
17. The peptide of Claim 15, wherein the PEG component of the modified peptide has a molecular mass from 5kDa to 20kDa.
18. The peptide of Claim 15, wherein the PEG component of the modified peptide has a molecular mass greater than 20kDa.
19. The peptide of Claim 15, wherein the PEG component of the modified peptide has a molecular mass of at least 30kD.
20. The peptide of Claim 13, wherein the modified peptide is glycosylated.
21. The peptide of Claim 13, wherein the modified peptide comprises at least one of an Fc fusion molecule, a serum albumin, or an albumin binding domain (ABD).
22. The peptide of Claim 13, wherein the modification is site-specific.
23. The peptide of Claim 13, wherein the modification comprises a linker.
24. The peptide of Claim 13, wherein the modification improves at least one physical property of the peptide.
25. The peptide of Claim 24, wherein the physical property is selected from the group consisting of solubility, bioavailability, serum half-life, and circulation time.
26. The peptide of Claim 13, wherein the modified peptide has activity at least comparable to the activity of mature human IL-10.
27. The peptide of Claim 2, wherein the peptide is produced recombinantly.
28. A peptide comprising the amino acid sequence of SEQ ID NO:2, wherein the peptide comprises at least one amino acid substitution of a surface-exposed amino acid residue;
and wherein the substitution has at least one of the following effects: (a) improves at least one physical property of the peptide, (b) does not adversely affect the immunogenicity of the peptide, or (c) does not adversely affect the bioactivity of the peptide.
29. The peptide of Claim 28, wherein the peptide does not comprise substitution of an amino acid residue involved with receptor binding.

30. The peptide of Claim 28, wherein the substitution does not disrupt the intramolecular disulfide bonds of the peptide.
31. The peptide of Claim 28, wherein the substitution does not disrupt the non-covalent interactions between the two monomer subunits of the peptide.
32. The peptide of Claim 28, wherein the at least one amino acid substitution is a conservative substitution.
33. The peptide of Claim 28, wherein the at least one amino acid substitution is not a substitution at one or more of amino acid residues 12, 62, 108 and 114.
34. A peptide comprising at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2, wherein the peptide has at least one of the following characteristics: (a) is not more immunogenic than the peptide of SEQ ID NO:2, (b) has a bioactivity at least equal to the bioactivity of the peptide of SEQ ID NO:2, (c) has an improvement in at least one physical property of the peptide of SEQ ID NO:2.
35. The peptide of Claim 34, wherein the peptide has at least 95% amino acid sequence identity.
36. The peptide of Claim 34, wherein the peptide has at least 97% amino acid sequence identity.
37. The peptide of Claim 34, wherein the peptide has at least 98% amino acid sequence identity.
38. The peptide of Claim 34, wherein the peptide has at least 99% amino acid sequence identity.
39. The peptide of Claim 34, wherein each monomer of the peptide has at least 125 amino acid residues.
40. The peptide of Claim 34, wherein each monomer of the peptide has at least 150 amino acid residues.
41. The peptide of Claim 34, wherein each monomer of the peptide has at least 155 amino acid residues.
42. The peptide of Claim 34, wherein the peptide comprises at least one amino acid substitution, deletion or addition relative to the amino acid sequence of SEQ ID NO:2.
43. The peptide of Claim 42, wherein the peptide does not comprise substitution of an amino acid residue involved with receptor binding.

44. The peptide of Claim 42, wherein the peptide comprises at least one amino acid substitution of a surface-exposed amino acid residue.
45. The peptide of Claim 42, wherein the at least one addition, deletion, or substitution does not disrupt the intramolecular disulfide bonds of the peptide.
46. The peptide of Claim 42, wherein the at least one addition, deletion, or substitution does not disrupt the non-covalent interactions between the two monomer subunits of the peptide.
47. The peptide of Claim 42, wherein the at least one amino acid substitution is a conservative substitution.
48. The peptide of Claim 42, wherein the at least one amino acid substitution is not a substitution at one or more of amino acid residues 12, 62, 108 and 114.
49. The peptide of Claim 28 or 34, wherein the physical property is selected from the group consisting of solubility, bioavailability, serum half-life, and circulation time.
50. The peptide of Claim 28 or 34, wherein the peptide has a bioactivity at least equal to the bioactivity of SEQ ID NO:2, wherein the bioactivity is determined in an in vitro assay or an in vivo assay.
51. The peptide of Claim 48, wherein the in vitro activity is at least one of a TNF α inhibition assay, an MC/9 cell proliferation assay, or a CD8 $^{+}$ -T-cell IFN γ secretion assay.
52. The peptide of Claim 28 or 34, wherein the immunogenicity of the peptide is predicted by screening for at least one of T-cell epitopes or B-cell epitopes.
53. The peptide of Claim 52, wherein the screening is at least one of an in silico screening system or an ex vivo assay system.
54. The peptide of Claim 28 or 34, wherein the peptide comprises at least one modification to form a modified peptide;
wherein the modification does not alter the amino acid sequence of the modified peptide,
and
wherein the modified peptide has activity at least comparable to the activity of mature human IL-10.
55. The peptide of Claim 54, wherein the modified peptide is pegylated.
56. The peptide of Claim 55, wherein the modified peptide comprises at least one PEG molecule covalently attached to at least one amino acid residue of at least one monomer of IL-10.

57. The peptide of Claim 56, wherein the modified peptide comprises a mixture of mono-pegylated and di-pegylated IL-10.
58. The peptide of Claim 56, wherein the PEG component of the modified peptide has a molecular mass from 5kDa to 20kDa.
59. The peptide of Claim 56, wherein the PEG component of the modified peptide has a molecular mass greater than 20kDa.
60. The peptide of Claim 56, wherein the PEG component of the modified peptide has a molecular mass of at least 30kD.
61. The peptide of Claim 54, wherein the modified peptide is glycosylated.
62. The peptide of Claim 54, wherein the modified peptide comprises at least one of an Fc fusion molecule, a serum albumin, or an albumin binding domain (ABD).
63. The peptide of Claim 54, wherein the modification is site-specific.
64. The peptide of Claim 54, wherein the modification comprises a linker.
65. The peptide of Claim 28 or 34, wherein the peptide is produced recombinantly.
66. A nucleic acid molecule encoding a peptide of Claim 1, 26 or 32.
67. The nucleic acid molecule of Claim 66, wherein the nucleic acid molecule is operably linked to an expression control element that confers expression of the nucleic acid molecule encoding the peptide in vitro, in a cell or in vivo.
68. A vector comprising the nucleic acid molecule of Claim 67.
69. The vector of Claim 68, wherein the vector comprises a viral vector.
70. A transformed or host cell that expresses a peptide of Claim 2, 28 or 34.
71. A pharmaceutical composition, comprising a peptide of Claim 2, 28 or 34, and a pharmaceutically acceptable diluent, carrier or excipient.
72. The pharmaceutical composition of Claim 71, wherein the excipient is an isotonic injection solution.
73. The pharmaceutical composition of Claim 71, wherein the pharmaceutical composition is suitable for human administration.
74. The pharmaceutical composition of Claim 71, further comprising at least one additional prophylactic or therapeutic agent.
75. A sterile container comprising the pharmaceutical composition of Claim 71.
76. The sterile container of Claim 75, wherein the sterile container is a syringe.
77. A kit comprising the sterile container of Claim 75.

78. The kit of Claim 77, further comprising a second sterile container comprising at least one additional prophylactic or therapeutic agent.
79. An antibody that binds specifically to a peptide of Claim 2, 28 or 34.
80. The antibody of Claim 79, wherein the antibody is a monoclonal antibody.
81. The antibody of Claim 79, wherein the antibody comprises a light chain variable region and a heavy chain variable region present in separate polypeptides.
82. The antibody of Claim 79, wherein the antibody comprises a light chain variable region and a heavy chain variable region present in a single polypeptide.
83. The antibody of Claim 79, wherein the antibody comprises a heavy chain constant region, and wherein the heavy chain constant region is of the isotype IgG1, IgG2, IgG3, or IgG4.
84. The antibody of Claim 79, wherein the antibody is detectably labeled.
85. The antibody of Claim 79, wherein the antibody is a Fv, scFv, Fab, F(ab')₂, or Fab'.
86. The antibody of Claim 79, wherein the antibody is a human antibody.
87. The antibody of Claim 79, wherein the antibody binds the peptide with an affinity of from about 10^7 M^{-1} to about 10^{12} M^{-1} .
88. The antibody of Claim 79, wherein the antibody comprises a covalently linked moiety selected from a lipid moiety, a fatty acid moiety, a polysaccharide moiety, and a carbohydrate moiety.
89. The antibody of Claim 79, wherein the antibody comprises an affinity domain.
90. The antibody of Claim 79, wherein the antibody is immobilized on a solid support.
91. The antibody of Claim 79, wherein the antibody is a humanized antibody.
92. The antibody of Claim 79, wherein the antibody is a single chain Fv (scFv) antibody.
93. The antibody of Claim 92, wherein the scFv is multimerized.
94. The antibody of Claim 79, wherein the antibody comprises a covalently linked non-peptide polymer.
95. The antibody of Claim 94, wherein the polymer is a poly(ethylene glycol) polymer.
96. A pharmaceutical composition comprising an antibody of Claim 79, and a pharmaceutically acceptable diluent, carrier, or excipient.
97. The pharmaceutical composition of Claim 96, wherein the excipient is an isotonic injection solution.

98. The pharmaceutical composition of Claim 96, wherein the pharmaceutical composition is suitable for human administration.
99. The pharmaceutical composition of any one of Claim 96, further comprising at least one additional prophylactic or therapeutic agent.
100. A sterile container comprising the pharmaceutical composition of Claim 96.
101. The sterile container of Claim 100, wherein the sterile container is a syringe.
102. A kit comprising the sterile container of Claim 100.
103. The kit of Claim 102, further comprising a second sterile container comprising a second therapeutic agent.
104. A method of treating or preventing a disease, disorder or condition in a subject, comprising administering to the subject a therapeutically effective amount of a peptide of Claim 2, 28 or 34.
105. The method of Claim 104, wherein the disease, disorder or condition is a proliferative disorder.
106. The method of Claim 105, wherein the proliferative disorder is a cancer.
107. The method of Claim 106, wherein the cancer is a solid tumor or a hematological disorder.
108. The method of Claim 104, wherein the disease, disorder or condition is an immune or inflammatory disorder.
109. The method of Claim 108, wherein immune or inflammatory disorder is selected from the group consisting of inflammatory bowel disease, psoriasis, rheumatoid arthritis, multiple sclerosis, and Alzheimer's disease.
110. The method of Claim 104, wherein the disease, disorder or condition is thrombosis or a thrombotic condition.
111. The method of Claim 104, wherein the disease, disorder or condition is a fibrotic disorder.
112. The method of Claim 104, wherein the disease, disorder or condition is a viral disorder.
113. The method of Claim 112, wherein the viral disorder is selected from the group consisting of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and cytomegalovirus.
114. The method of Claim 104, wherein the disease, disorder or condition is a cardiovascular disorder.

- 115. The method of Claim 114, wherein the cardiovascular disorder is atherosclerosis.
- 116. The method of Claim 115, wherein the subject has elevated cholesterol.
- 117. The method of Claim 104, wherein the subject is human.
- 118. The method of Claim 104, wherein the administering is by parenteral injection.
- 119. The method of Claim 118, wherein the parenteral injection is subcutaneous.
- 120. The method of Claim 104, further comprising administering at least one additional prophylactic or therapeutic agent.

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3A

Complete Human IL-10 (NP_000563) (SEQ ID NO:1):

MHSSALLCCLVLLTGVRASPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMK
DQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPPQAENQDPDIKAHVNSLGENLK
TLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKI
RN

FIG. 3B

Mature Human IL-10 (BC104252) (SEQ ID NO:2):

SPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGY
LGCQALSEMIQFYLEEVMPPQAENQDPDIKAHVNSLGENLKTTLRLRLRRCHRFLPCENKS
KAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN

FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5

Pre-Helix A												Helix A												kink	Helix A														
S	P	G	Q	G	T	Q	S	E	N	S	C	T	H	F	P	G	N	L	P	N	M	L	R	D	L	H	D	A	F	S	R	V	N	F	F	Q	M	K	
Cysteine	+	+														+																							
Tyrosine	+	+	+	+	+	+	+	+	+	+		+	+				+						+							+	+							+	
N-X-S	+	+	+	+	+	+	+	+	+	+		+	+				+												+	+							+		
N-X-T	+	+	+	+	+	+	+	+	+	+		+	+				+												+	+							+		
1-11																																							
Loop A/B												Helix B						Helix C						kink	Helix C														
A													B C																										
D	Q	L	D	N	L	L	L	K	E	S	L	L	E	D	F	K	G	Y	L	G	C	Q	A	L	S	E	M	I	Q	F	Y	L	E	E	V	M	P	Q	A
Cysteine									+	+							+		+																			+	
Tyrosine									+	+			+				+		+	+					+				+			+					+		
N-X-S								+	+	+			+				+		+	+																+			
N-X-T								+	+	+			+				+		+	+													+			+			
49-51												57-61																											
Loop C/D												Helix D						Loop D/E						E															
E	N	Q	D	P	D	L	K	A	H	V	N	S	L	G	E	N	L	K	T	L	R	L	R	L	R	R	C	H	R	F	L	P	C	E	N	K	S	K	A
Cysteine	+	+	+	+	+			+	+		+	+				+		+										+	+										
Tyrosine	+	+	+	+	+			+	+		+	+				+		+					+	+				+	+										
N-X-S	+	+	+	+	+			+	+		+					+		+					+	+															
N-X-T	+	+	+	+	+			+	+		+					+		+					+	+															
81-86												88-90						102-104						115-119															
												Helix E						Helix F						kink															
V	E	Q	V	K	N	A	F	N	K	L	Q	E	K	G	I	Y	K	A	M	S	E	F	D	I	F	I	N	Y	I	E	A	Y	M	T	M	K	I	R	N
Cysteine									+																														
Tyrosine	+	+		+					+			+	+																										+
N-X-S									+																														+
N-X-T					+				+																														+
												132-134																											